

JC19 Rec'd PCT/PTO 21 MAY 2001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER UEMURA 6
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/856298
INTERNATIONAL APPLICATION NO. PCT/JP99/06472	INTERNATIONAL FILING DATE 19 November 1999	PRIORITY CLAIMED 20 November 1998
TITLE OF INVENTION NOVEL SERINE PROTEASES BSSP4		
APPLICANT(S) FOR DO/EO/US Hidetoshi UEMURA et al.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ol style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 00/31277). <input checked="" type="checkbox"/> Courtesy copy of the International Preliminary Examination Report (In Japanese). <input checked="" type="checkbox"/> Formal drawings, 7 sheets, Figures 1-7. <input checked="" type="checkbox"/> Courtesy Copy of the International Search Report. <input checked="" type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> The application is (or will be) assigned to: FUSO PHARMACEUTICAL INDUSTRIES, LTD., whose address is 7-10, Doshomachi 1-chome, Chuo-ku, Osaka-shi, Osaka, Japan 		

JC18 Rec'd PCT/PTO 21 MAY 2001

U.S. APPLICATION NO. 09/856298	INTERNATIONAL APPLICATION NO. PCT/JP99/06472	Attorney's Docket No UEMURA 6
---------------------------------------	--	---

17. [x] The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO.....**\$1000.00**

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO.....**\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....**\$710.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4).....**\$690.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4).....**\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$ 860.00
--	------------------

Claims as Originally Presented	Number Filed	Number Extra	Rate	
Total Claims	388 - 20	368	X \$18.00	\$
Independent Claims	56 - 3	53	X \$80.00	\$
Multiple Dependent Claims (if applicable)			+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 860.00

Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate	
Total Claims	- 20		X \$18.00	\$
Independent Claims	- 3		X \$78.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 860.00

Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.

SUBTOTAL =

Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	\$ 860.00
---	------------------

TOTAL NATIONAL FEE =

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +	\$ 860.00
---	------------------

TOTAL FEES ENCLOSED =

	\$ 860.00
Amount to be refunded charged	\$

a. [] A check in the amount of \$_____ to cover the above fees is enclosed.

b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 860.00, is attached.

c. [] Please charge my Deposit Account No. **02-4035** in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

d. [] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **02-4035**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, N.W., SUITE 300
WASHINGTON, D.C. 20001
TEL: (202) 628-5197
FAX: (202) 737-3528
Date of this submission: **May 21, 2001**

SIGNATURE
Roger L. Browdy
NAME
25.618
REGISTRATION NUMBER

PROCT Rec'd 1 OCT 2001**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:)	
H. UEMURA et al.)	Examiner:
Appln. No.: 09/856,298)	Washington, D.C.
Filed: May 21, 2001)	October 1, 2001
For: NOVEL SERINE PROTEASE)	Atty. Docket: UEMURA=6
BSSP4)	

SUPPLEMENTAL PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply and prior to Examination on the merits, please amend as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 22, line 11, with the following rewritten paragraph:

-- The protein having the amino acid sequence represented by SEQ ID NO: 2 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 268th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:2 and Asp-Ser-Gly-Gly-Pro corresponding to the 192nd to 196th amino acid residues of SEQ ID NO:2 and one or more of Asp's are present between the consensus sequences. A

In re Appln. No. 09/856,298

nucleotide sequence encoding this protein is shown in SEQ ID NO:1.--

Please replace the paragraph beginning at the bottom of page 22, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:4 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 270th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys corresponding to residues of the 39th to 42nd amino acids of SEQ ID NO:4 and Asp-Ser-Gly-Gly-Pro corresponding to residues of the represented by the 192nd to 196th amino acids of SEQ ID NO:1 and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO:3. This sequence corresponds to SEQ ID NO:1 from which the 943rd to 1217th bases have been removed, and the amino acid sequence represented by SEQ ID NO:4 corresponds to the amino acid sequence represented by SEQ ID NO:2 in which the 265th amino acid and the subsequent amino acids are different.--

Please replace the paragraph beginning at page 23, line 12, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:6 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 257th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-

In re Appln. No. 09/856,298

Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:6 and Asp-Ser-Gly-Gly-Pro corresponding to the 192nd to 196th amino acid residues of SEQ ID NO:2 and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO:5. This sequence corresponds to SEQ ID NO:1 from which the 895th to 11208th bases have been removed, and the amino acid sequence represented by SEQ ID NO:6 correspond to the amino acid sequence represented by SEQ ID NO:2 in which the 249th amino acids and the subsequent amino acids are different. Further, the nucleotide sequence corresponds to the sequence wherein the 969th to 1036th bases of SEQ ID NO:5 are added to the downstream of the 1282 base of SEQ ID NO:1.--

Please replace the paragraph beginning at the bottom of page 24, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 10 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, this does not have Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:10, but has Asp-Ser-Gly-Gly-Pro corresponding to residues of the 82nd to 86th amino acids of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:9. This sequence corresponds to the nucleotide sequence of SEQ ID NO:1 from which the 233rd to 562nd bases have been removed.--

Please replace the paragraph beginning at page 24,

In re Appln. No. 09/856,298

line 14, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 12 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys corresponding to residues 39th to 42nd amino acids of SEQ ID NO:12 but does not have Asp-Ser-Gly-Gly-Pro corresponding to residues of the 82nd to 86th amino acids of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:11. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO:1 from which the 364th to 562nd amino acids have been removed.--

Please replace the paragraph beginning at page 25, line 7, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:14 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:14 but do not have Asp-Ser-Gly-Gly-Pro corresponding to residues of the 82nd to 86th amino acid of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:13. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO:1 from which the 588th to 1145th bases have been removed. There is a possibility that the nucleotide sequence represented by the 652nd and the subsequent bases of SEQ ID NO: 13 would be "ccc ggg ccc cag cgc ttt tgt gta tat aaa tgt taatgatttt tataggtatt tgaaccctg cccacatatt" SEQ ID NO:49 and the amino acid

In re Appln. No. 09/856,298

sequence represented by the 168th and the subsequent amino acids of SEQ ID NO: 14 would be "Pro Gly Pro Gln Arg Phe Cys Val, Tyr Lys Cys" SEQ ID NO:50.

Please replace the paragraph beginning at the bottom of page 25, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:16 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:16 but does not have Asp-Ser-Gly-Gly-Pro corresponding to the 82nd to 86th amino acid residues of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:15. This sequence corresponds to SEQ ID NO: 1 from which the 285th to 562nd bases have been removed.

Please replace the paragraph beginning at page 26, line 6, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 18 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:18 but does not have Asp-Ser-Gly-Gly-Pro corresponding to the 82nd to 86th amino acid residues of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:17. This sequence corresponds to the sequence wherein the 721st to 948th bases of SEQ ID NO: 17 is added to the downstream of the 720th base of SEQ ID NO: 1, and

In re Appln. No. 09/856,298

corresponds SEQ ID NO:1 from which the 720th and the subsequent bases have been removed.--

Please replace the paragraph beginning at the bottom page 26, with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:20 is a mouse type protein (mBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 253 amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:20 and Asp-Ser-Gly-Gly-Pro corresponding to the 192nd to 196th amino acid residues of SEQ ID NO:20 and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 19.--

Please replace the paragraph beginning at page 35, line 12, with the following rewritten paragraph:

--The vector is not specifically limited in so far as it can express the protein of the present invention. Examples thereof include pBAD/His, pRSETA, pcDNA2.1, pTrcHis2A, pYES2, pBlueBac4.5, pcDNA3.1 and pSecTag2 manufactured by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by Pharmacia, PfastBAC1 manufactured by GIBCO and the like. Preferably, a protein expression vector (described in the

In re Appln. No. 09/856,298

specification of a patent application entitled "Protein expression vector and its use" and filed by the same applicant on the same day) is used. This expression vector is constructed by using pCRII-TOPO vector described in the Examples hereinafter, or a commercially available expression vector, for example pSecTag2A vector or pSecTag2B vector (Invitrogen) and integrating a secretory signal nucleotide sequence suitable for expression of the protein of the present invention, in the 3' downstream side thereof, a Tag nucleotide sequence, a cleavable nucleotide sequence and a cloning site, into which a nucleotide sequence encoding a target protein can be inserted, in this order. More specifically, it is preferred to use trypsin signal as the secretory signal, a nucleotide sequence encoding polyhistidine as the Tag nucleotide sequence, and a nucleotide sequence encoding an amino acid sequence which is susceptible to enzyme-specific cleavage, i.e., a nucleotide sequence encoding the amino acid sequence of Asp-Asp-Asp-Asp-Lys SEQ ID NO:51 (said amino acid sequence is recognized by enterokinase, and the recombinant fusion protein is cleaved at the C-terminus part thereof) as the cleavable nucleotide sequence.--

Please replace the paragraph beginning at page 58, line 3, with the following rewritten paragraph:

--The cloning was carried out by PCR using a human brain cDNA library (Clontech) as a template and nucleotide sequences corresponding to an amino acid sequence common to serine proteases represented by

In re Appln. No. 09/856,298

Primer 1: GTG CTC ACN GCN GCB CAY TG (SEQ ID NO: 30)

Primer 2: CCV CTR WSD CCN CCN GGC GA (SEQ ID NO: 31)

as primers. Namely, 5 μ l of the template, 5 μ l of 10 x ExTaq buffer, 5 μ l of dNTP, 10 pmol of each of the above primers and 0.5 μ l of ExTaq (TAKARA) were added and the total volume was adjusted to 50 μ l with sterilized water. PCR was carried out by repeating a cycle of heating at 94°C for 0.5 minute, at 55°C for 0.5 minute and then at 72°C for 1 minutes, 35 times.

The PCR product was mixed with pCR II-TOPO vector attached to TOPO TA cloning kit (Invitrogen) and the mixture was allowed to stand at room temperature for 5 minutes. Then, according to a conventional manner, *E. coli* Top 10 attached to the kit was transformed and applied to a LB (Amp^r) plate (containing 100 μ g/ml of ampicillin). According to a conventional manner, a plasmid was extracted from each colony obtained and its nucleotide sequence was determined by cycle sequencing method with a fluorescence sequencer (ABI). Homology of the sequence of each clone was examined by means of GenBank. Regarding an unknown sequence, i.e., BSSP4 gene, the full length cDNA was obtained by 5' RACE and 3' RACE and, according to the same manner as described above, the nucleotide sequence was determined. Namely, BSSP4 clone specific primers, GSP1 primers [hBSSP4F1 (SEQ ID NO: 32) or hBSSP4R1 (SEQ ID NO: 36)] and GSP2 primers [hBSSP4F2 (SEQ ID NO: 33) or hBSSP4R2 (SEQ ID NO: 37)] were prepared. PCR was carried out by using human brain Marathon-Ready cDNA (Clontech), AP1 primer attached to this reagent and either of the above GSP1 primers and heating at 94°C for 2 minutes once and repeating a cycle of heating at

In re Appln. No. 09/856,298

94°C for 30 seconds, at 60°C for 30 seconds and then at 72°C for 30 seconds 35 times. Then, 5 µl of the PCR product diluted to 1/100, 5 µl of 10 x buffer, 5 µl of dNTP, 10 pmol of either of 10 µM of the above GSP2 primer, 10 pmol of AP2 primer attached to the above reagent and 0.5 unit of ExTaq were admixed and adjusted to 50 µl with sterilized water. Then, according to the same manner as the above, PCR was carried out. The PCR product was cloned by the above TOPO TA cloning kit and sequenced to obtain the upstream and downstream regions of the above clone. At this time, as for a clone which seemed not to cover the full length of a protein, the specific primers shown hereinafter were prepared based on the newly found nucleotide sequence. Further, based on this sequence, the primers capable of amplifying ORF as shown hereinafter [hBSSP4F6 (SEQ ID NO: 35) and hBSSP4R3/E (SEQ ID NO: 38) or hBSSP4R4/E (SEQ ID NO: 39)] were prepared and PCR carried out using human brain Marathon-ready cDNA as a template to confirm that these clones were identical. This was cloned into pCR II-TOPO vector attached to TOPO TA cloning kit to obtain the plasmid pCR II/hBSSP4 containing the full length cDNA clone. The nucleotide sequence of DNA contained in this plasmid is shown in SEQ ID NO: 1 and the amino acid sequence of hBSSP4 protein deduced from the nucleotide sequence is shown in SEQ ID NO: 2. Further, two different types of clones were obtained. The amino acid sequence of hBSSP4 represented by SEQ ID NO: 2 (the 1st to 268th amino acids) is hBSSP4 mature or active type protein composed of 268 amino acids. In the amino acid sequence represented by SEQ ID

In re Appln. 'No. 09/856,298

NO: 2, the -49th to -1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of hBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys represented by the 39th to 42nd amino acid residues of SEQ ID NO:2 and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acid residues of SEQ ID NO:2 and there are one or more Asp's between these consensus sequences.--

Please replace the paragraph beginning at page 61, line 10, with the following rewritten paragraph:

--According to the same manner, 5' RACE and 3' RACE were carried out by using the primers as described hereinafter and mouse brain Marathon-Ready cDNA (Clontech) as a template, followed by cloning to obtain mouse homologous gene pCRII/mBSSP4. The nucleotide of DNA containing this plasmid is shown by SEQ ID NO:19 and the amino acid sequence of mBSSP4 protein deduced from this nucleotide sequence is shown in SEQ ID NO:20. The amino acid sequence of mBSSP4 represented by SEQ ID NO:20 (the 1st to 259th amino acids) is mBSSP4 mature or active type protein composed of 259 amino acids. In the amino acid sequence represented by SEQ ID NO:20, the -49th to 1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of mBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys (the 39th to 42nd amino acid residues of SEQ ID NO:20) and Asp-Ser-Gly-Gly-Pro (the 192nd to 196th amino acid residues of SEQ ID NO:20) and there

In re Appln. No. 09/856,298

are one or more Asp's between the consensus sequences.

human BSSP4

hBSSP4F1	Forward	AGGTTCTATCATCGACTCG	RACE
			(SEQ ID NO: 32)
hBSSP4F2	Forward	TGAGGACATGCTGTGTGCCGG	RACE
			(SEQ ID NO: 33)
hBSSP4F3	Forward	GTTGTGGGCGGCGAGGACAG	mature
			(SEQ ID NO: 34)
hBSSP4F6	Forward	GCCATGGTGGTTTCTGGAGC	FL*
			(SEQ ID NO: 35)
hBSSP4R1	Reverse	TATGGTTTGTTTCAGGTTGTCC	RACE
			(SEQ ID NO: 36)
hBSSP4R2	Reverse	AGGGCAATGTCTGCACAGGC	RACE
			(SEQ ID NO: 37)
hBSSP4R3/E	Reverse	CTGAATTCCTAGGAGCGCGCGGCC	FL*
			(SEQ ID NO: 38)
hBSSP4R4/E	Reverse	GAGAATTCGATATGTGGGCAGGGTTACA	FL*
			(SEQ ID NO: 39)

mouse BSSR4

mBSSP4.1	Forward	ACAAACCATCTCTGTTCTCAG	RACE
			(SEQ ID NO: 40)
mBSSP4F2	Forward	GTCCCAGAAAGTAGGCATTG	RACE
			(SEQ ID NO: 41)
mBSSP4F3	Forward	CTCCACCCATACCGCAATG	FL*
			(SEQ ID NO: 42)
mBSSP4F4	Forward	ATTGTGGGAGGTGAGGACAG	mature
			(SEQ ID NO: 43)
mBSSP4.2	Reverse	TGCAGAGTTCGGAGTCGATG	RACE

In re Appln. No. 09/856,298

(SEQ ID NO: 44)

mBSSP4R2 Reverse ATCCAGCAGTCGGTCTTGGG RACE

(SEQ ID NO: 45)

mBSSP4R3/P Reverse ATTCTGCAGTTCCTTGTCTCTCGCTCAGG FL*

(SEQ ID NO: 46)

*: for full length

Please replace the paragraph beginning at the bottom of page 68, line 19, with the following rewritten paragraph:

--Amplification was carried out by using the primers having the sequences represented by SEQ ID NOS: 25 and 26 so that the peptide of Leu-Val-His-Gly SEQ ID NO:52 was present at the C-terminus of the part from trypsin signal to the enterokinase recognition site of pSecTrypHis/neurosin. This was inserted between NheI and HindIII sites of pSecTag2A to construct the plasmid pTrypSig.--

IN THE CLAIMS

Please cancel claims 1 and 2 without prejudice and add new claims 76-86 as follows:

--76(New). A protein selected from the group consisting of:

(a) a protein having the amino acid sequence composed of 268 amino acids represented by the 1st to 268th amino acids of SEQ ID NO:2;

(b) a protein having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:2 by

In re Appln. No. 09/856,298

deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO:2;

(c) a protein having the amino acid sequence composed of 270 amino acids represented by the 1st to 270th amino acids of SEQ ID NO:4;

(d) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO:4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO:4;

(e) a protein having the amino acid sequence composed of 257 amino acids represented by the 1st to 257th amino acids of SEQ ID NO:6;

(f) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO:6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO:6;

(g) a protein having the amino acid sequence composed of 97 amino acids represented by the 1st to 97th amino acids of SEQ ID NO:8;

(h) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO:8 by deletion, substitution or

In re Appln. No. 09/856,298

addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO:8;

(i) a protein having the amino acid sequence composed of 158 amino acids represented by the 1st to 158th amino acids of SEQ ID NO:10;

(j) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO:10 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO:10;

(k) a protein having the amino acid sequence composed of 82 amino acids represented by the 1st to 82nd amino acids of SEQ ID NO:12;

(l) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO:12 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO:12;

(m) a protein having the amino acid sequence composed of 185 amino acids represented by the 1st to 185th amino acids of SEQ ID NO:14;

(n) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO:14 by deletion, substitution or addition of one to several amino acids and having the same

In re Appln. No. 09/856,298

property as that of the protein having the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO:14;

(o) a protein having the amino acid sequence composed of 80 amino acids represented by the 1st to 80th amino acids of SEQ ID NO:16;

(p) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO:16 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO:16;

(q) a protein having the amino acid sequence composed of 253 amino acids represented by the 1st to 253rd amino acids of SEQ ID NO:18;

(r) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO:18 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO:18;

(s) a protein having the amino acid sequence composed of 34 amino acids represented by the -49th to -16th amino acids of SEQ ID NO:2;

(t) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence

In re Appln. No. 09/856,298

represented by the -49th to -16th amino acids of SEQ ID NO:2;

(u) a protein having the amino acid sequence composed of 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO:2;

(v) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:2;

(w) a protein having the amino acid sequence composed of 259 amino acids represented by the 1st to 259th amino acids of SEQ ID NO:20;

(x) a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO:20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO:20;

(y) a protein having the amino acid sequence composed of 34 amino acids represented by the -49th to -16th amino acids of SEQ ID NO:20;

(z) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:20;

In re Appln. No. 09/856,298

(aa) a protein having the amino acid sequence composed of 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO:20;

(bb) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:20;

(cc) a protein having the amino acid sequence composed of 317 amino acids represented by the -49th to 268th amino acids of SEQ ID NO:2;

(dd) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO:2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO:2;

(ee) a protein having the amino acid sequence composed of 283 amino acids represented by the -15th to 268th amino acids of SEQ ID NO:2;

(ff) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO:2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO:2;

(gg) a protein having the amino acid sequence

In re Appln. No. 09/856,298

composed of 319 amino acids represented by the -49th to 270th amino acids of SEQ ID NO:4;

(hh) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO:4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO:4;

(ii) a protein having the amino acid sequence composed of 285 amino acids represented by the -15th to 270th amino acids of SEQ ID NO:4;

(jj) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO:4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO:4;

(kk) a protein having the amino acid sequence composed of 306 amino acids represented by the -49th to 257th amino acids of SEQ ID NO:6;

(ll) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO:6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO:6;

(mm) a protein having the amino acid sequence composed of 272 amino acids represented by the -15th to 257th

In re Appln. No. 09/856,298

amino acids of SEQ ID NO:6;

(nn) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO:6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO:6;

(oo) a protein having the amino acid sequence composed of 308 amino acids represented by the -49th to 259th amino acids of SEQ ID NO:20;

(pp) a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO:20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO:20;

(qq) a protein having the amino acid sequence composed of 274 amino acids represented by the -15th to 259th amino acids of SEQ ID NO:20;

(rr) a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO:20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO:20;
and

(ss) a modified derivative or fragment of these proteins (a) to (rr).--

In re Appln. No. 09/856,298

--77(New). A nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence represented by the 151st to 954th nucleotides of SEQ ID NO:1;

(ii) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO:2;

(iii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (i) or (ii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO:2;

(iv) a nucleotide sequence represented by the 151st to 960th nucleotides of SEQ ID NO:3;

(v) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO:4;

(vi) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (iv) or (v) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO:4;

(vii) a nucleotide sequence represented by the 151st to 921st nucleotides of SEQ ID NO:5;

(viii) a nucleotide sequence encoding the amino

In re Appln. No. 09/856,298

acid sequence represented by the 1st to 257th amino acids of SEQ ID NO:6;

(ix) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (vii) or (viii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO:6;

(x) a nucleotide sequence represented by the 151st to 441st nucleotides of SEQ ID NO:7;

(xi) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO:8;

(xii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (x) or (xi) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO:8;

(xiii) a nucleotide sequence represented by the 151st to 624th nucleotides of SEQ ID NO:9;

(xiv) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO:10;

(xv) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xiii) or (xiv) under stringent conditions and encoding a protein having the same property as that of the

In re Appln. No. 09/856,298

protein having the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO: 10;

(xvi) a nucleotide sequence represented by the 151st to 396th nucleotides of SEQ ID NO:11;

(xvii) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO:12;

(xviii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xvi) or (xvii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 82th amino acids of SEQ ID NO:12;

(xix) a nucleotide sequence represented by the 151st to 705th nucleotides of SEQ ID NO:13;

(xx) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO:14;

(xxi) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xiv) or (xx) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO:14;

(xxii) a nucleotide sequence represented by the 151st to 390th nucleotides of SEQ ID NO:15;

(xxiii) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 80th amino acids of

In re Appln. No. 09/856,298

SEQ ID NO:16;

(xxiv) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxii) or (xxiii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO:16;

(xxv) a nucleotide sequence represented by the 151st to 909th nucleotides of SEQ ID NO:17;

(xxvi) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO:18;

(xxvii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxv) or (xxvi) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO:18;

(xxviii) a nucleotide sequence represented by the 4th to 105th nucleotides of SEQ ID NO:1;

(xxix) a nucleotide sequence encoding the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:2;

(xxx) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxviii) or (xxix) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented

In re Appln. No. 09/856,298

by the -49th to -16th amino acids of SEQ ID NO:2;

(xxxi) a nucleotide sequence represented by the 106th to 150th nucleotides of SEQ ID NO:1;

(xxxii) a nucleotide sequence encoding the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:2;

(xxxiii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxxi) or (xxxii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:2;

(xxxiv) a nucleotide sequence represented by the 227th to 1003rd nucleotides of SEQ ID NO:19;

(xxxv) a nucleotide sequence encoding the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO:20;

(xxxvi) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxxiv) or (xxxv) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO:20;

(xxxvii) a nucleotide sequence represented by the 80th to 181st nucleotides of SEQ ID NO:19;

(xxxviii) a nucleotide sequence encoding the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:20;

In re Appln. No. 09/856,298

(xxxix) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xxxvii) or (xxxviii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO:20;

(xl) a nucleotide sequence represented by the 182th to 226th nucleotides of SEQ ID NO:19;

(xli) a nucleotide sequence encoding the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:20;

(xlii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xl) or (xli) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO:20;

(xliii) a nucleotide sequence represented by the 4th to 954th nucleotides of SEQ ID NO:1;

(xliv) a nucleotide sequence encoding the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO:2;

(xlv) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xliii) or (xliv) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO:2;

In re Appln. No. 09/856,298

(xlvi) a nucleotide sequence represented by the 106th to 954th nucleotides of SEQ ID NO:1;

(xlvii) a nucleotide sequence encoding the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO:2;

(xlviii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xlvi) or (xlvii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO:2;

(xlix) a nucleotide sequence represented by the 4th to 960th nucleotides of SEQ ID NO:3;

(l) a nucleotide sequence encoding the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO:4;

(li) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (xlix) or (l) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO:4;

(lii) a nucleotide sequence represented by the 106th to 960th nucleotides of SEQ ID NO:3;

(liii) a nucleotide sequence encoding the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO:4;

(liv) a nucleotide sequence hybridizable with a

In re Appln. No. 09/856,298

nucleotide sequence which is complementary to the above nucleotide sequence (lii) or (liv) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO:4;

(lv) a nucleotide sequence represented by the 4th to 921th nucleotides of SEQ ID NO:5;

(lvi) a nucleotide sequence encoding the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO:6;

(lvii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lv) or (lvi) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO:6;

(lviii) a nucleotide sequence represented by the 106th to 921th nucleotides of SEQ ID NO:5;

(lix) a nucleotide sequence encoding the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO:6;

(lx) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lviii) or (lix) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO:6;

(lxi) a nucleotide sequence represented by the 80th

In re Appln. No. 09/856,298

to 1003rd nucleotides of SEQ ID NO:19;

(lxii) a nucleotide sequence encoding the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO:20;

(lxiii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxi) or (lxii) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO:20;

(lxiv) a nucleotide sequence represented by the 182nd to 1003rd nucleotides of SEQ ID NO:19;

(lxv) a nucleotide sequence encoding the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO:20;

(lxvi) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxiv) or (lxv) under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO:20;

(lxvii) a nucleotide sequence represented by SEQ ID NO:1;

(lxviii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxvii) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ

In re Appln. No. 09/856,298

ID NO:1;

(lxiv) a nucleotide sequence represented by SEQ ID NO:3;

(lxx) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxix) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:3;

(lxxi) a nucleotide sequence represented by SEQ ID NO:5;

(lxxii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxi) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:5;

(lxxiii) a nucleotide sequence represented by SEQ ID NO:7;

(lxxiv) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxiii) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:7;

(lxxv) a nucleotide sequence represented by SEQ ID NO:9;

(lxxvi) a nucleotide sequence hybridizable with a

In re Appln. No. 09/856,298

nucleotide sequence which is complementary to the above nucleotide sequence (lxxv) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:9;

(lxxvii) a nucleotide sequence represented by SEQ ID NO:11;

(lxxviii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxvii) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:11;

(lxxix) a nucleotide sequence represented by SEQ ID NO:13;

(lxxx) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxix) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:13;

(lxxxii) a nucleotide sequence represented by SEQ ID NO:15;

(lxxxiii) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxxii) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ

In re Appln. No. 09/856,298

ID NO:15;

(lxxxiii) a nucleotide sequence represented by SEQ

ID NO:17;

(lxxxiv) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxxiii) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:17;

(lxxxv) a nucleotide sequence represented by SEQ ID NO:19;

(lxxxvi) a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence (lxxxv) under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO:19; and

(lxxxvii) a fragment of these nucleotide sequences
(i) to (lxxxvi).--

--78(New). A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence (xxxiv) to (xlii), (lxi) to (lxvi), (lxxxv) or (lxxxvi) of claim 77 or a fragment thereof, and collecting mBSSP4 produced.--

--79(New). The process according to claim 78, wherein the cells are *E. coli* cells, animal cells or insect

In re Appln. No. 09/856,298

cells.--

--80(New). The method according to claim 68,
wherein the specimen is a body fluid.--

--81(New). The method according to claim 69,
wherein the specimen is a body fluid.

--82(New). A method for screening for an inhibitor
of serine protease comprising comparing the enzyme activity of
the protein according to claim 76 upon bringing it into
contact with a candidate compound with the enzyme activity of
the protein without contact with the candidate compound.--

--83(New). A pharmaceutical composition comprising
the protein according to claim 76.--

--84(New). A method for detecting a diagnostic
marker for diseases in tissues comprising the protein
according to claim 76, which comprises using the antibody
against the protein according to claim 76.--

--85(New). The method according to claim 83,
wherein the marker is used for diagnosis of a cancer.--

Please replace claims 55-57, 64, 66-69, and 71 with
new amended claims 55-57, 64, 66-69, and 71 as follows below.
A marked up version of the amended claims to show the changes
made is attached hereto.

In re Appln. No. 09/856,298

55(Twice-Amended). A vector comprising the nucleotide sequence according to claim 77.

56(Twice-Amended). Transformed cells having the nucleotide sequence according to 77 in an expressible state.

57(Twice-Amended). A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to (i) to (xxxiii), (xliii) to (lx) or (lxiv) to (lxxxvi) of claim 77 or a fragment thereof, and collecting hBSSP4 produced.

64(Twice-Amended). An antibody against the protein according to claim 76 or a fragment thereof.

66(Twice-Amended). A process for producing a monoclonal antibody against the protein according to claim 76 or a fragment thereof which comprises administering the protein according to claim 76 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

67(Twice-Amended). A method for determining the protein according to claim 76 or a fragment thereof in a specimen which is based on immunological binding of an

In re Appln. No. 09/856,298

antibody against the protein or a fragment thereof to the protein or a fragment thereof.

68(Twice-Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein (a) to (v) or (cc) to (nn) of claim 76 or a modified derivative or fragment thereof and a labeled antibody with hBSSP4 or a fragment thereof in the specimen to detect a sandwich complex produced.

69(Twice-Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein (a) to (v) or (cc) to (nn) of claim 76 or a modified derivative or fragment thereof or a fragment thereof with labeled hBSSP4 and hBSSP4 or a fragment thereof in the specimen competitively to detect an amount of hBSSP4 or a fragment thereof in the specimen based on an amount of the labeled hBSSP4 reacted with the antibody.

71(Twice-Amended). A diagnostic marker for diseases in tissues comprising the protein according to claim 76.

IN THE SEQUENCE LISTING

Please substitute the paper copy Sequence Listing attached hereto for the Sequence Listing originally filed.

In re Appln. No. 09/856,298

REMARKS

Applicants have added into the present specification a substitute paper copy Sequence Listing section according to 37 C.F.R. §1.821(c). Furthermore, attached hereto is a 3 1/2" disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

Applicants have amended the specification to insert SEQ ID Nos, as supported in the present specification.

The following statement is provided to meet the requirements of 37 C.F.R. §1.825(a) and 1.825(b).

I hereby state, in accordance with 37 C.F.R. §1.825(a), that the amendments included in the substitute sheets of the sequence listing are believed to be supported in the application as filed and that the substitute sheets of the sequence listing are not believed to include new matter.

I hereby further state, in accordance with 37 C.F.R. §1.825(b), that the attached copy of the computer readable form is the same as the attached substitute paper copy of the sequence listing.

Under U.S. rules, each sequence must be classified in <213> as an "Artificial Sequence", a sequence of "Unknown" origin, or a sequence originating in a particular organism, identified by its scientific name.

Neither the rules nor the MPEP clarify the nature of the relationship which must exist between a listed sequence and an organism for that organism to be identified as the origin of the sequence under <213>.

In re Appln. No. 09/856,298

Hence, counsel may choose to identify a listed sequence as associated with a particular organism even though that sequence does not occur in nature by itself in that organism (it may be, e.g., an epitopic fragment of a naturally occurring protein, or a cDNA of a naturally occurring mRNA, or even a substitution mutant of a naturally occurring sequence). Hence, the identification of an organism in <213> should not be construed as an admission that the sequence *per se* occurs in nature in said organism.

Similarly, designation of a sequence as "artificial" should not be construed as a representation that the sequence has no association with any organism. For example, a primer or probe may be designated as "artificial" even though it is necessarily complementary to some target sequence, which may occur in nature. Or an "artificial" sequence may be a substitution mutant of a natural sequence, or a chimera of two or more natural sequences, or a cDNA (i.e., intron-free sequence) corresponding to an intron-containing gene, or otherwise a fragment of a natural sequence.

The examiner should be able to judge the relationship of the enumerated sequences to natural sequences by giving full consideration to the specification, the art cited therein, any further art cited in an IDS, and the results of his or her sequence search against a database containing known natural sequences.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current

In re Appln. No. 09/856,298

amendment. The attached version is captioned "Version with markings to show changes made".

Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.


The amendments to the claims are made to place the application in better condition for examination.

Favorable consideration is respectfully solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Allen C. Yun
Registration No. 37,971

ACY:pr
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\A\Aoyb\Demura 4\PTO\supplemental Preliminary Amendment.doc

In re Appln. No. 09/856,298

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

The paragraph beginning at page 22, line 11, is replaced with the following rewritten paragraph:

-- The protein having the amino acid sequence represented by SEQ ID NO: 2 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 268th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:2 and Asp-Ser-Gly-Gly-Pro ~~represented by the~~ corresponding to the 192nd to 196th amino acids residues of SEQ ID NO:2 and one or more of Asp's are present between the concensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO:1.--

The paragraph beginning at the bottom of page 22, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:4 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 270th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to residues of the 39th to 42nd amino acids of SEQ ID NO:4 and Asp-Ser-Gly-Gly-Pro corresponding to residues of the represented by the 192nd to 196th amino acids of SEQ ID NO:1 and one or more of Asp's are present between the concensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO:3. This

In re Appln. No. 09/856,298

sequence corresponds to SEQ ID NO:1 from which the 943rd to 1217th bases have been removed, and the amino acid sequence ~~represent~~represented by SEQ ID NO:4 corresponds to the amino acid sequence represented by SEQ ID NO:2 in which the 265th amino acid and the subsequent amino acids are different.--

The paragraph beginning at page 23, line 12, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:6 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 257th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:6 and Asp-Ser-Gly-Gly-Pro ~~represented by the~~corresponding to the 192nd to 196th amino acids residues of SEQ ID NO:2 and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO:5. This sequence corresponds to SEQ ID NO:1 from which the 895th to 11208th bases have been removed, and the amino acid sequence represented by SEQ ID NO:6 correspond to the amino acid sequence represented by SEQ ID NO:2 in which the 249th amino acids and the subsequent amino acids are different. Further, the nucleotide sequence corresponds to the sequence wherein the 969th to 1036th bases of SEQ ID NO:5 are added to the downstream of the 1282 base of SEQ ID NO:1.--

In re Appln. No. 09/856,298

The paragraph beginning at the bottom of page 24, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 10 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, this does not have Ala-Ala-His-Cys-~~represented~~ corresponding to the 39th to 42nd amino acid residues of SEQ ID NO:10, but has Asp-Ser-Gly-Gly-Pro ~~represented by the~~ corresponding to residues of the 82nd to 86th amino acids of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:9. This sequence corresponds to the nucleotide sequence of SEQ ID NO:1 from which the 233rd to 562nd bases have been removed.--

The paragraph beginning at page 24, line 14, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 12 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to residues 39th to 42nd amino acids of SEQ ID NO:12 but does not have Asp-Ser-Gly-Gly-Pro corresponding to residues of the 82nd to 86th amino acids of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:11. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO:1 from which the 364th to 562nd amino acids have been removed.--

The paragraph beginning at page 25, line 7, is replaced with the following rewritten paragraph:

In re Appln. No. 09/856,298

--The protein having the amino acid sequence represented by SEQ ID NO:14 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:14 but do not have Asp-Ser-Gly-Gly-Pro corresponding to residues of the 82nd to 86th amino acid of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:13. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO:1 from which the 588th to 1145th bases have been removed. There is a possibility that the nucleotide sequence represented by the 652nd and the subsequent bases of SEQ ID NO: 13 would be "ccc ggg ccc cag cgc ttt tgt gta tat aaa tgt taatgatttt tataggtatt tgtaaccctg ccacatatc" SEQ ID NO:49 and the amino acid sequence represented by the 168th and the subsequent amino acids of SEQ ID NO: 14 would be "Pro Gly Pro Gln Arg Phe Cys Val, Tyr Lys Cys" SEQ ID NO:50.

The paragraph beginning at the bottom of page 25, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:16 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:16 but does not have Asp-Ser-Gly-Gly-Pro corresponding to the 82nd to 86th amino acid residues of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:15. This sequence corresponds

In re Appln. No. 09/856,298

to SEQ ID NO: 1 from which the 285th to 562nd bases have been removed.

The paragraph beginning at page 26, line 6, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO: 18 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:18 but does not have Asp-Ser-Gly-Gly-Pro corresponding to the 82nd to 86th amino acid residues of SEQ ID NO:10. A nucleotide sequence encoding this protein is shown in SEQ ID NO:17. This sequence corresponds to the sequence wherein the 721st to 948th bases of SEQ ID NO: 17 is added to the downstream of the 720th base of SEQ ID NO: 1, and corresponds SEQ ID NO:1 from which the 720th and the subsequent bases have been removed.--

The paragraph beginning at the bottom page 26, is replaced with the following rewritten paragraph:

--The protein having the amino acid sequence represented by SEQ ID NO:20 is a mouse type protein (mBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 253 amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys ~~represented by the~~ corresponding to the 39th to 42nd amino acids residues of SEQ ID NO:20 and Asp-Ser-Gly-Gly-Pro ~~represented by the~~ corresponding to the 192nd to 196th amino acids residues of SEQ ID NO:20 and one or more of Asp's are

In re Appln. No. 09/856,298

present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 19.--

The paragraph beginning at page 35, line 12, is replaced with the following rewritten paragraph:

--The vector is not specifically limited in so far as it can express the protein of the present invention. Examples thereof include pBAD/His, pRSETA, pcDNA2.1, pTrcHis2A, pYES2, pBlueBac4.5, pcDNA3.1 and pSecTag2 manufactured by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by Pharmacia, PfastBAC1 manufactured by GIBCO and the like. Preferably, a protein expression vector (described in the specification of a patent application entitled "Protein expression vector and its use" and filed by the same applicant on the same day) is used. This expression vector is constructed by using pCRII-TOPO vector described in the Examples hereinafter, or a commercially available expression vector, for example pSecTag2A vector or pSecTag2B vector (Invitrogen) and integrating a secretory signal nucleotide sequence suitable for expression of the protein of the present invention, in the 3' downstream side thereof, a Tag nucleotide sequence, a cleavable nucleotide sequence and a cloning site, into which a nucleotide sequence encoding a target protein can be inserted, in this order. More specifically, it is preferred to use trypsin signal as the secretory signal, a nucleotide sequence encoding polyhistidine as the Tag

In re Appln. No. 09/856,298

nucleotide sequence, and a nucleotide sequence encoding an amino acid sequence which is susceptible to enzyme-specific cleavage, i.e., a nucleotide sequence encoding the amino acid sequence of Asp-Asp-Asp-Asp-Lys SEQ ID NO:51 (said amino acid sequence is recognized by enterokinase, and the recombinant fusion protein is cleaved at the C-terminus part thereof) as the cleavable nucleotide sequence.--

The paragraph beginning at page 58, line 3, is replaced with the following rewritten paragraph:

--The cloning was carried out by PCR using a human brain cDNA library (Clontech) as a template and nucleotide sequences corresponding to an amino acid sequence common to serine proteases represented by

Primer 1: GTG CTC ACN GCN GCB CAY TG (SEQ ID NO: 30)

Primer 2: CCV CTR WSD CCN CCN GGC GA (SEQ ID NO: 31)

as primers. Namely, 5 µl of the template, 5 µl of 10 x ExTaq buffer, 5 µl of dNTP, 10 pmol of each of the above primers and 0.5 µl of ExTaq (TAKARA) were added and the total volume was adjusted to 50 µl with sterilized water. PCR was carried out by repeating a cycle of heating at 94°C for 0.5 minute, at 55°C for 0.5 minute and then at 72°C for 1 minutes, 35 times.

The PCR product was mixed with pCR II-TOPO vector attached to TOPO TA cloning kit (Invitrogen) and the mixture was allowed to stand at room temperature for 5 minutes. Then, according to a conventional manner, *E. coli* Top 10 attached to the kit was transformed and applied to a LB (Amp^r) plate (containing 100 µg/ml of ampicillin). According to a conventional manner,

In re Appln. No. 09/856,298

a plasmid was extracted from each colony obtained and its nucleotide sequence was determined by cycle sequencing method with a fluorescence sequencer (ABI). Homology of the sequence of each clone was examined by means of GenBank. Regarding an unknown sequence, i.e., BSSP4 gene, the full length cDNA was obtained by 5' RACE and 3' RACE and, according to the same manner as described above, the nucleotide sequence was determined. Namely, BSSP4 clone specific primers, GSP1 primers [hBSSP4F1 (SEQ ID NO: 32) or hBSSP4R1 (SEQ ID NO: 36)] and GSP2 primers [hBSSP4F2 (SEQ ID NO: 33) or hBSSP4R2 (SEQ ID NO: 37)] were prepared. PCR was carried out by using human brain Marathon-Ready cDNA (Clontech), AP1 primer attached to this reagent and either of the above GSP1 primers and heating at 94°C for 2 minutes once and repeating a cycle of heating at 94°C for 30 seconds, at 60°C for 30 seconds and then at 72°C for 30 seconds 35 times. Then, 5 µl of the PCR product diluted to 1/100, 5 µl of 10 x buffer, 5 µl of dNTP, 10 pmol of either of 10 µM of the above GSP2 primer, 10 pmol of AP2 primer attached to the above reagent and 0.5 unit of ExTaq were admixed and adjusted to 50 µl with sterilized water. Then, according to the same manner as the above, PCR was carried out. The PCR product was cloned by the above TOPO TA cloning kit and sequenced to obtain the upstream and downstream regions of the above clone. At this time, as for a clone which seemed not to cover the full length of a protein, the specific primers shown hereinafter were prepared based on the newly found nucleotide sequence. Further, based on this sequence, the primers capable of amplifying ORF as shown

In re Appln. No. 09/856,298

hereinafter [hBSSP4F6 (SEQ ID NO: 35) and hBSSP4R3/E (SEQ ID NO: 38) or hBSSP4R4/E (SEQ ID NO: 39)] were prepared and PCR carried out using human brain Marathon-ready cDNA as a template to confirm that these clones were identical. This was cloned into pCR II-TOPO vector attached to TOPO TA cloning kit to obtain the plasmid pCR II/hBSSP4 containing the full length cDNA clone. The nucleotide sequence of DNA contained in this plasmid is shown in SEQ ID NO: 1 and the amino acid sequence of hBSSP4 protein deduced from the nucleotide sequence is shown in SEQ ID NO: 2. Further, two different types of clones were obtained. The amino acid sequence of hBSSP4 represented by SEQ ID NO: 2 (the 1st to 268th amino acids) is hBSSP4 mature or active type protein composed of 268 amino acids. In the amino acid sequence represented by SEQ ID NO: 2, the -49th to -1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of hBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys represented by the 39th to 42nd amino acids residues of SEQ ID NO:2 and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids residues of SEQ ID NO:2 and there are one or more Asp's between these consensus sequences.--

The paragraph beginning at page 61, line 10, is replaced with the following rewritten paragraph:

--According to the same manner, 5' RACE and 3' RACE were carried out by using the primers as described hereinafter and mouse brain Marathon-Ready cDNA (Clontech) as a template,

In re Appln. No. 09/856,298

followed by cloning to obtain mouse homologous gene pCRII/mBSSP4. The nucleotide of DNA containing this plasmid is shown by SEQ ID NO:19 and the amino acid sequence of mBSSP4 protein deduced from this nucleotide sequence is shown in SEQ ID NO:20. The amino acid sequence of mBSSP4 represented by SEQ ID NO:20 (the 1st to 259th amino acids) is mBSSP4 mature or active type protein composed of 259 amino acids. In the amino acid sequence represented by SEQ ID NO:20, the -49th to 1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of mBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys (the 39th to 42nd amino acids residues of SEQ ID NO:20) and Asp-Ser-Gly-Gly-Pro (the 192nd to 196th amino acids residues of SEQ ID NO:20) and there are one or more Asp's between the consensus sequences.

human BSSP4

hBSSP4F1	Forward	AGGTTCCCTATCATCGACTCG	RACE
			(SEQ ID NO: 32)
hBSSP4F2	Forward	TGAGGACATGCTGTGTGCCGG	RACE
			(SEQ ID NO: 33)
hBSSP4F3	Forward	GTTGTGGGCGGCGAGGACAG	mature
			(SEQ ID NO: 34)
hBSSP4F6	Forward	GCCATGGTGGTTTCTGGAGC	FL*
			(SEQ ID NO: 35)
hBSSP4R1	Reverse	TATGGTTTGTTCAGGTTGTCC	RACE
			(SEQ ID NO: 36)
hBSSP4R2	Reverse	AGGGCAATGTCTGCACAGGC	RACE
			(SEQ ID NO: 37)

In re Appln. No. 09/856,298

hBSSP4R3/E Reverse	CTGAATTCCTAGGAGCGCGCGCGGCC	FL*
		(SEQ ID NO: 38)
hBSSP4R4/E Reverse	GAGAAATCGATATGTGGGCAGGGTTACA	FL*
		(SEQ ID NO: 39)
mouse BSSR4		
mBSSP4.1 Forward	ACAAACCATCTCTGTTCTCAG	RACE
		(SEQ ID NO: 40)
mBSSP4F2 Forward	GTCCAGAAAGTAGGCATTG	RACE
		(SEQ ID NO: 41)
mBSSP4F3 Forward	CTCCACCCATACCAGCAATG	FL*
		(SEQ ID NO: 42)
mBSSP4F4 Forward	ATTGTGGGAGGTGAGGACAG	mature
		(SEQ ID NO: 43)
mBSSP4.2 Reverse	TGCAGAGTTCGGAGTCGATG	RACE
		(SEQ ID NO: 44)
mBSSP4R2 Reverse	ATCCAGCAGTCGGTCTTGGG	RACE
		(SEQ ID NO: 45)
mBSSP4R3/P Reverse	ATTCTGCAGTTCCTTGTCTCTCGCTCAGG	FL*
		(SEQ ID NO: 46)

*: for full length

The paragraph beginning at the bottom of page 68, line 19, is replaced with the following rewritten paragraph:

--Amplification was carried out by using the primers having the sequences represented by SEQ ID NOS: 25 and 26 so that the peptide of Leu-Val-His-Gly SEQ ID NO:52 was present at the C-terminus of the part from trypsin signal to the enterokinase recognition site of pSecTrypHis/neurosin. This

In re Appln. No. 09/856,298

was inserted between NheI and HindIII sites of pSecTag2A to construct the plasmid pTrypSig.--

In the Claims:

Claims 55-57, 66-69, and 71 have been amended as follows below:

55(Twice-Amended). A vector comprising the nucleotide sequence according to claim 2 77.

56(Twice-Amended). Transformed cells having the nucleotide sequence according to 2 77 in an expressible state.

57(Twice-Amended). A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to (i) to (xxxi), (xliii) to (lx) or (lxiv) to (lxxxvi) of claim 2 77 or a fragment thereof, and collecting hBSP4 produced.

64(Twice-Amended). An antibody against the protein according to claim ±76 or a fragment thereof.

66(Twice-Amended). A process for producing a monoclonal antibody against the protein according to claim ±76 or a fragment thereof which comprises administering the protein according to claim ±76 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells

In re Appln. No. 09/856,298

contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

67(Twice-Amended). A method for determining the protein according to claim ~~176~~ or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

68(Twice-Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein (a) to (v) or (cc) to (nn) of claim ~~176~~ or a modified derivative or fragment thereof and a labeled antibody with hBSSP4 or a fragment thereof in the specimen to detect a sandwich complex produced.

69(Twice-Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein (a) to (v) or (cc) to (nn) of claim ~~176~~ or a modified derivative or fragment thereof or a fragment thereof with labeled hBSSP4 and hBSSP4 or a fragment thereof in the specimen competitively to detect an amount of hBSSP4 or a fragment thereof in the specimen based on an amount of the labeled hBSSP4 reacted with the antibody.

71(Twice-Amended). A diagnostic marker for diseases

In re Appln. No. 09/856,298

in tissues comprising the protein according to claim 476.

SEQUENCE LISTING

<110> UEMURA, Hidetoshi
 OKUI, Akira
 KOMINAMI, Katsuya
 YAMAGUCHI, Nozomi
 MITSUI, Shinichi

<120> NOVEL SERINE PROTEASE BSSP4

<130> UEMURA=6

<140> 09/856,298
 <141> 2001-05-21

<150> JP 10/347813
 <151> 1998-11-20

<150> PCT/JP99/06472
 <151> 1999-11-19

<160> 52

<170> PatentIn version 3.1

<210> 1
 <211> 1282
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(954)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 1
 gcc atg gtg gtt tct gga ggc ccc cca gcc ctg ggt ggg ggc tgt ctc 48
 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
 -45 -40 -35

ggc acc ttc acc tcc ctg ctg ctg ctg ggc tgc aca gcc atc ctc aat 96
 Gly Thr Phe Thr Ser Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
 -30 -25 -20

gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg 144
 Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
 -15 -10 -5

aac cgg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg 192
 Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
 -1 1 5 10

atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg 240
 Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu

15	20	25	30	
ctc acc agc cgc tgg	gtg atc act gct gcc	cac tgt ttc aag gac aac		288
Leu Thr Ser Arg Trp	Val Ile Thr Ala His	Cys Phe Lys Asp Asn		
	35	40	45	
ctg aac aaa cca tac	ctg ttc tct gtg ctg	ctg ggg gcc tgg cag ctg		336
Leu Asn Lys Pro Tyr	Leu Phe Ser Val Leu	Leu Gly Ala Trp Gln Leu		
	50	55	60	
ggg aac cct ggc tct	cgg tcc cag aag gtg	ggt gtt gcc tgg gtg gag		384
Gly Asn Pro Gly Ser	Arg Ser Gln Lys Val	Gly Val Ala Trp Val Glu		
	65	70	75	
ccc cac cct gtg tat	tcc tgg aag gaa ggt	gcc tgt gca gac att gcc		432
Pro His Pro Val Tyr	Ser Trp Lys Glu Gly	Ala Cys Ala Asp Ile Ala		
	80	85	90	
ctg gtg cgt ctc gag	cgc tcc ata cag ttc	tca gag cgg gtc ctg ccc		480
Leu Val Arg Leu Glu	Arg Ser Ile Gln Phe	Ser Glu Arg Val Leu Pro		
	95	100	105	
atc tgc cta cct gat	gcc tct atc cac ctc	cct cca aac acc cac tgc		528
Ile Cys Leu Pro Asp	Ala Ser Ile His Leu	Pro Pro Asn Thr His Cys		
	115	120	125	
tgg atc tca ggc tgg	ggg agc atc caa gat	gga gtt ccc ttg ccc cac		576
Trp Ile Ser Gly Trp	Gly Ser Ile Gln Asp	Gly Val Pro Leu Pro His		
	130	135	140	
cct cag acc ctg cag	aag ctg aag gtt cct	atc atc gac tgg gaa gtc		624
Pro Gln Thr Leu Gln	Lys Leu Lys Val Pro	Ile Ile Asp Ser Glu Val		
	145	150	155	
tgc agc cat ctg tac	tgg cgg gga gca gga	cag gga ccc atc act gag		672
Cys Ser His Leu Tyr	Trp Arg Gly Ala Gly	Gln Gly Pro Ile Thr Glu		
	160	165	170	
gac atg ctg tgt gcc	ggc tac ttg gag ggg	gag cgg gat gct tgt ctg		720
Asp Met Leu Cys Ala	Gly Tyr Leu Glu Gly	Gln Arg Asp Ala Cys Leu		
	175	180	185	
ggc gac tcc ggg ggc	ccc ctc atg tgc cag	gtg gac ggc gcc tgg ctg		768
Gly Asp Ser Gly Gly	Pro Leu Met Cys Gln	Val Asp Gly Ala Trp Leu		
	195	200	205	
ctg gcc ggc atc atc	agc tgg ggc gag ggc	tgt gcc gag cgc aac agg		816
Leu Ala Gly Ile Ile	Ser Trp Gly Glu Gly	Cys Ala Glu Arg Asn Arg		
	210	215	220	
ccc ggg gtc tac atc	agc ctc tct gcg cac	cgc tcc tgg gtg gag aag		864
Pro Gly Val Tyr Ile	Ser Leu Ser Ala His	Arg Ser Trp Val Glu Lys		
	225	230	235	
atc gtg caa ggg gtg	cag ctc cgc ggg cgc	gct cag ggg ggt ggg gcc		912
Ile Val Gln Gly Val	Gln Leu Arg Gly Arg	Ala Gln Gly Gly Gly Ala		
	240	245	250	
ctc agg gca ccg agc	cag ggc tct ggg gcc	gcc gcg cgc tcc		954
Leu Arg Ala Pro Ser	Gln Gly Ser Gly Ala	Ala Ala Arg Ser		
	255	260	265	

```

tagggcgag cggaagcgg ggcctggatc tgaaggcgg ccagatccac atctggatct 1014
ggatctcgg cggcctcgg cggtttcccc cgcctgaaat aggtctatct acctctacct 1074
ctggggggccc ggacggctgc tgcggaaagg aaacccccct cccgaccgcg ccgacggcct 1134
cagggccccg cctccaaggc atcaggcccc gcccaacggc ctcatgtccc cgcctccacg 1194
acttccggcc cgcctccgg gccccagcgc ttttgtgtat ataaatgtta atgattttta 1254
taggtatttg taacctgccc cacatatc 1282

```

```

<210> 2
<211> 317
<212> PRT
<213> Homo sapiens

```

```
<400> 2
```

```

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
      -45                -40                -35

```

```

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
      -30                -25                -20

```

```

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
      -15                -10                -5

```

```

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
-1  1                5                10                15

```

```

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu
      20                25                30

```

```

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
      35                40                45

```

```

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
      50                55                60

```

```

Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu Pro
      65                70                75

```

```

His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala Leu
      80                85                90                95

```

```

Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro Ile
      100                105                110

```


Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys Trp
 115 120 125

Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
 130 135 140

Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys
 145 150 155

Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp
 160 165 170 175

Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly
 180 185 190

Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp Leu Leu
 195 200 205

Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg Pro
 210 215 220

Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile
 225 230 235

Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu
 240 245 250 255

Arg Ala Pro Ser Gln Gly Ser Gly Ala Ala Ala Arg Ser
 260 265

<210> 3
 <211> 1007
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(960)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 3
 gcc atg atg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc
 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
 -45 -40 -35

ggc acc ttc acc tcc ctg ctg ctg ctg gcg tcg aca gcc atc ctc aat Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn -30 -25 -20	96
gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu -15 -10 -5	144
aac cgg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp -1 1 5 10	192
atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu 15 20 25 30	240
ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gac aac Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn 35 40 45	288
ctg aac aaa cca tac ctg ttc tct gtg ctg ctg ggg gcc tgg cag ctg Leu Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu 50 55 60	336
ggg aac cct gcc tct cgg tcc cag aag gtg ggt gtt gcc tgg gtg gag Gly Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu 65 70 75	384
ccc cac cct gtg tat tcc tgg aag gaa ggt gcc tgt gca gac att gcc Pro His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala 80 85 90	432
ctg gtg cgt ctc gag cgc tcc ata cag ttc tca gag cgg gtc ctg ccc Leu Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro 95 100 105 110	480
atc tgc cta cct gat gcc tct atc cac ctc cct cca aac acc cac tgc Ile Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys 115 120 125	528
tgg atc tca gcc tgg ggg agc atc caa gat gga gtt ccc ttg ccc cac Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His 130 135 140	576
cct cag acc ctg cag aag ctg aag gtt cct atc atc gac tgc gaa gtc Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val 145 150 155	624
tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc atc act gag Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu 160 165 170	672
gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct tgt ctg Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu 175 180 185 190	720
ggc gac tcc ggg ggc ccc ctc atg tgc cag gtg gac ggc gcc tgg ctg Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp Leu 195 200 205	768

ctg gcc ggc atc atc agc tgg ggc gag ggc tgt gcc gag cgc aac agg 816
 Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg
 210 215 220

ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg gtg gag aag 864
 Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys
 225 230 235

atc gtg caa ggg gtg cag ctc cgc ggg cgc gct cag ggg ggt ggg gcc 912
 Ile Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala
 240 245 250

ctc agg gca cgc agc cag ggc tct ggg gcc cca gcg ctt ttg tgt ata 960
 Leu Arg Ala Pro Ser Gln Gly Ser Gly Ala Pro Ala Leu Leu Cys Ile
 255 260 265 270

taaattgttaa tgatttttat aggtatttgt aaccctgccc acatatc 1007

<210> 4
 <211> 319
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
 -30 -25 -20

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
 -15 -10 -5

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
 -1 1 5 10 15

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu
 20 25 30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
 35 40 45

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
 50 55 60

Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu Pro
 65 70 75

His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala Leu
 80 85 90 95

Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro Ile
 100 105 110

Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys Trp
 115 120 125

Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
 130 135 140

Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys
 145 150 155

Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp
 160 165 170 175

Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly
 180 185 190

Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp Leu Leu
 195 200 205

Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg Pro
 210 215 220

Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile
 225 230 235

Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu
 240 245 250 255

Arg Ala Pro Ser Gln Gly Ser Gly Ala Pro Ala Leu Leu Cys Ile
 260 265 270

<210> 5
 <211> 1036
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(921)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 5
gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc 48
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
-45 -40 -35

ggc acc ttc acc tcc ctg ctg ctg ctg gcg tgc aca gcc atc ctc aat 96
Gly Thr Phe Thr Ser Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
-30 -25 -20

gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg 144
Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
-15 -10 -5

aac egg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg 192
Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
-1 1 5 10

atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg 240
Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu
15 20 25 30

ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gac aac 288
Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn
35 40 45

ctg aac aaa cca tac ctg ttc tct gtg ctg ctg ggg gcc tgg cag ctg 336
Leu Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu
50 55 60

ggg aac cct ggc tct cgg tcc cag aag gtg ggt gtt gcc tgg gtg gag 384
Gly Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu
65 70 75

ccc cac cct gtg tat tcc tgg aag gaa ggt gcc tgt gca gac att gcc 432
Pro His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala
80 85 90

ctg gtg cgt ctc gag cgc tcc ata cag ttc tca gag cgg gtc ctg ccc 480
Leu Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro
95 100 105 110

atc tgc cta cct gat gcc tct atc cac ctc cct cca aac acc cac tgc 528
Ile Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys
115 120 125

tgg atc tca ggc tgg ggg agc atc caa gat gga gtt ccc ttg ccc cac 576
Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His
130 135 140

cct cag acc ctg cag aag ctg aag gtt cct atc atc gac tgc gaa gtc 624
Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val
145 150 155

tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc atc act gag 672
Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu
160 165 170

gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct tgt ctg 720
Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Arg Asp Ala Cys Leu
175 180 185 190

ggc gac tcc ggg ggc ccc ctc atg tgc cag gtg gac ggc gcc tgg ctg 768
 Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp Leu
 195 200 205

ctg gcc ggc atc atc agc tgg ggc gag ggc tgt gcc gag cgc aac agg 816
 Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg
 210 215 220

ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg gtg gag aag 864
 Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys
 225 230 235

atc gtg caa ggg gtg cag ctc cgc ggg cgc ccc cgg gcc cca gcg ctt 912
 Ile Val Gln Gly Val Gln Leu Arg Gly Arg Pro Arg Ala Pro Ala Leu
 240 245 250

ttg tgt ata taaatgttaa tgatttttat aggtatttgt aacctgtccc 961
 Leu Cys Ile
 255

acatatctta ttatttcctc caatttcaat aaattattta ttctccagaa aaaaaaaaaa 1021
 aaaaaaaaaa aaaaa 1036

<210> 6
 <211> 306
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
 -30 -25 -20

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
 -15 -10 -5

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
 -1 1 5 10 15

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu
 20 25 30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
 35 40 45

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
 50 55 60

Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu Pro
 65 70 75
 His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala Leu
 80 85 90 95
 Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro Ile
 100 105 110
 Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys Trp
 115 120 125
 Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
 130 135 140
 Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys
 145 150 155
 Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp
 160 165 170 175
 Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly
 180 185 190
 Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp Leu Leu
 195 200 205
 Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg Pro
 210 215 220
 Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile
 225 230 235
 Val Gln Gly Val Gln Leu Arg Gly Arg Pro Arg Ala Pro Ala Leu Leu
 240 245 250 255
 Cys Ile

<210> 7
 <211> 1231
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (4)..(441)
 <223>

```

<220>
<221> mat_peptide
<222> (151)..()
<223>

<400> 7
gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc      48
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
-45 -40 -35

ggc acc ttc acc tcc ctg ctg ctg gcg tgc aca gcc atc ctc aat      96
Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
-30 -25 -20

gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg      144
Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
-15 -10 -5

aac cgg gtt gtg ggc gcc gag gac agc act gac agc gag tgg ccc tgg      192
Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
-1 1 5 10

atc gtg agc atc cag aag aat ggg acc cac cac tgc gca gga caa cct      240
Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Gln Pro
15 20 25 30

gaa caa acc ata cct gtt ctc tgt gct gct ggg ggc ctg gca gct ggg      288
Glu Gln Thr Ile Pro Val Leu Cys Ala Ala Gly Gly Leu Ala Ala Gly
35 40 45

gaa ccc tgg ctc tgc gtc cca gaa ggt ggg tgt tgc ctg ggt gga gcc      336
Glu Pro Trp Leu Ser Val Pro Glu Gly Gly Cys Cys Leu Gly Gly Ala
50 55 60

cca ccc tgt gta ttc ctg gaa gga agg tgc ctg tgc aga cat tgc cct      384
Pro Pro Cys Val Phe Leu Glu Gly Arg Cys Leu Cys Arg His Cys Pro
65 70 75

ggt gcg tct cga gcg ctc cat aca gtt ctc aga gcg ggt cct gcc cat      432
Gly Ala Ser Arg Ala Leu His Thr Val Leu Arg Ala Gly Pro Ala His
80 85 90

ctg cct acc tga tgcctct tccacctccc tccaaacacc cactgctgga      481
Leu Pro Thr
95

tctcaggctg ggggagcacc caagatggag ttccttgcc ccacctccag accctgcaga      541

agctgaagggt tcctatcacc gactcggaag tctgcagcca tctgtactgg cggggagcag      601

gacaggggacc catcactgag gacatgctgt gtgcgggcta ctggaggggg gagcgggatg      661

cttgtctggg cgactccggg ggcctcccca tgtgccaggt ggacggcgcc ttgctgctgg      721

ccggcatcat cagctggggc gagggctgtg ccgagcgcaa caggcccggg gtctacatca      781

gcctctctgc gcaccgctcc tgggtggaga agatcgtgca aggggtgcag ctccgcgggc      841

```



```

gcgcctcaggg ggggtggggcc ctcagggcac cgagccaggg ctctggggcc gccgcgcgct 901
cctagggcgc agcgggacgc ggggctcgga tetgaaagc gccagatcc acatctggat 961
ctggatctgc ggcggcctcg ggcggtttcc ccgcgcgtaa ataggtcat ctacctctac 1021
ctctgggggc ccggacggct gctgcggaaa ggaaccccc tccccagcc gcccgacggc 1081
ctcagggccc gccctccaag gcatcaggcc ccgccaacg gctcatgtc ccgcgcccc 1141
cgacttcgg ccccgcccc gggcccccag gcttttgtgt atataaatgt taatgatttt 1201
tatagggtatt tgtaaccctg cccacatatc 1231

```

```

<210> 8
<211> 146
<212> PRT
<213> Homo sapiens

```

```
<400> 8
```

```

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
               -45                      -40                      -35

```

```

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
               -30                      -25                      -20

```

```

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
               -15                      -10                      -5

```

```

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
-1 1          5          10          15

```

```

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Gln Pro Glu
                20          25          30

```

```

Gln Thr Ile Pro Val Leu Cys Ala Ala Gly Gly Leu Ala Ala Gly Glu
                35          40          45

```

```

Pro Trp Leu Ser Val Pro Glu Gly Gly Cys Cys Leu Gly Gly Ala Pro
                50          55          60

```

```

Pro Cys Val Phe Leu Glu Gly Arg Cys Leu Cys Arg His Cys Pro Gly
                65          70          75

```

```

Ala Ser Arg Ala Leu His Thr Val Leu Arg Ala Gly Pro Ala His Leu
80          85          90          95

```

```
Pro Thr
```

<210> 9
 <211> 952
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(624)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 9
 gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc 48
 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
 -45 -40 -35
 ggc acc ttc acc tcc ctg ctg ctg ctg gcg tgc aca gcc atc ctc aat 96
 Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
 -30 -25 -20
 gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg 144
 Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
 -15 -10 -5
 aac cgg gtt gtg ggc gcc gag gac agc act gac agc gag tgg ccc tgg 192
 Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
 -1 1 5 10
 atc gtg agc atc cag aag aat ggg acc cac cac tgc gca gtt ccc ttg 240
 Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Val Pro Leu
 15 20 25 30
 ccc cac cct cag acc ctg cag aag ctg aag gtt cct atc atc gac tgc 288
 Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser
 35 40 45
 gaa gtc tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc atc 336
 Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile
 50 55 60
 act gag gac atg ctg tgt gcc gcc tac ttg gag ggg gag cgg gat gct 384
 Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala
 65 70 75
 tgt ctg ggc gac tcc ggg gcc ccc ctc atg tgc cag gtg gac ggc gcc 432
 Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala
 80 85 90
 tgg ctg ctg gcc gcc atc atc agc tgg gcc gag gcc tgt gcc gag cgc 480
 Trp Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg
 95 100 105 110
 aac agg ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg gtg 528
 Asn Arg Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val

115	120	125	
gag aag atc gtg caa ggg gtg cag ctc cgc ggg cgc gct cag ggg ggt			576
Glu Lys Ile Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly			
130	135	140	
ggg gcc ctc agg gca cgg agc cag ggc tct ggg gcc gcc gcg cgc tcc			624
Gly Ala Leu Arg Ala Pro Ser Gln Gly Ser Gly Ala Ala Ala Arg Ser			
145	150	155	
tagggcgccag cgggacgcgg ggctcggatc tgaaggcgg ccagatccac atctggatct			684
ggatctgcgg cggcctcggg cggtttcccc cgcgtaaat aggcctcatct acctctacct			744
ctggggggccc ggacggctgc tgcggaaagg aaacccccctc cccgaccgc cgcacggcct			804
caggccccgc cctccaaggc atcaggcccc gcccaacggc ctcattgtccc cgccccacg			864
acttcgggcc ccgccccggg gccccagcgc ttttgtgtat ataaatgtta atgattttta			924
taggtatttg taacctgcc cacatata			952
<210> 10			
<211> 207			
<212> PRT			
<213> Homo sapiens			
<400> 10			
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly			
-45	-40	-35	
Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala			
-30	-25	-20	
Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn			
-15	-10	-5	
Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile			
-1 1	5	10	15
Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Val Pro Leu Pro			
20	25	30	
His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu			
35	40	45	
Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr			
50	55	60	
Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys			
65	70	75	

Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp
80 85 90 95

Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn
100 105 110

Arg Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu
115 120 125

Lys Ile Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly
130 135 140

Ala Leu Arg Ala Pro Ser Gln Gly Ser Gly Ala Ala Arg Ser
145 150 155

<210> 11
<211> 1083
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (4)..(396)
<223>

<220>
<221> mat_peptide
<222> (151)..()
<223>

<400> 11
gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc 48
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
-45 -40 -35
ggc acc ttc acc tcc ctg ctg ctg gcg tcg aca gcc atc ctc aat 96
Gly Thr Phe Thr Ser Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
-30 -25 -20
gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg 144
Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
-15 -10 -5
aac cgg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg 192
Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
-1 1 5 10
atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg 240
Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu
15 20 25 30
ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gac aac 288
Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn

35	40	45	
ctg aac aaa cca tac ctg ttc tct gtg ctg ctg ggg gcc tgg cag ctg			336
Leu Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu			
50	55	60	
ggg aac cct ggc tct cgg tcc cag aag ttc cct tgc ccc acc ctg aga			384
Gly Asn Pro Gly Ser Arg Ser Gln Lys Phe Pro Cys Pro Thr Leu Arg			
65	70	75	
ccc tgc aga agc tgaaggttcc tatcatcgac tcggaagtct gcagccatct			436
Pro Cys Arg Ser			
80			
gtactggcgg ggagcaggac agggacccat cactgaggac atgctgtgtg ccggtacttt			496
ggagggggag cgggatgctt gtctgggcga ctccgggggc cccctcatgt gccaggtgga			556
cggcgccctgg ctgtggccgg gcatcatcag ctggggcgag ggctgtgccg agcgcaacag			616
gccccggggtc tacatcagcc tctctgcgca ccgctcctgg gtggagaaga tctgtcaagg			676
ggtgcagetc cgcggggcgg ctcagggggg tggggccctc agggcaccca gccagggtc			736
tggggccgcc gcgcgtcct agggcgcgag gggacgcggg gctcggtatct gaaaggcgcc			796
cagatccaca tctggatctg gatctgcggc ggccctcggc ggtttccccc gccgtaata			856
ggctcatcta cctctacctc tgggggcccc gacggctgct gcggaaagga aaccccctcc			916
ccgacccgcc cgacggcctc agggccccgc ctccaaggca tcaggccccg cccaacggcc			976
tcattgcccc gccccacga ctcccgcccc cgccccggg cccacgcgt tttgtgtata			1036
taaatgttaa tgattttttt aggtattttgt aacctgccc acatatc			1083
<210> 12			
<211> 131			
<212> PRT			
<213> Homo sapiens			
<400> 12			
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly			
-45	-40	-35	
Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala			
-30	-25	-20	
Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn			
-15	-10	-5	
Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile			
-1 1	5	10	15
Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu			

20

25

30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
 35 40 45

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
 50 55 60

Asn Pro Gly Ser Arg Ser Gln Lys Phe Pro Cys Pro Thr Leu Arg Pro
 65 70 75

Cys Arg Ser
 80

<210> 13
 <211> 723
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(705)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 13
 gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc 48
 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
 -45 -40 -35
 ggc acc ttc acc tcc ctg ctg ctg gcg tcg aca gcc atc ctc aat 96
 Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
 -30 -25 -20
 gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg 144
 Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
 -15 -10 -5
 aac cgg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg 192
 Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
 -1 1 5 10
 atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg 240
 Ile Val Ser Ile Gln Lys Asn Gly Thr His Cys Ala Gly Ser Leu
 15 20 25 30
 ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gac aac 288
 Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn
 35 40 45

ctg aac aaa cca tac ctg ttc tct gtg ctg ctg ggg gcc tgg cag ctg 336
 Leu Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu
 50 55 60

ggg aac cct ggc tct cgg tcc cag aag gtg ggt gtt gcc tgg gtg gag 384
 Gly Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu
 65 70 75

ccc cac cct gtg tat tcc tgg aag gaa ggt gcc tgt gca gac att gcc 432
 Pro His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala
 80 85 90

ctg gtg cgt ctc gag cgc tcc ata cag ttc tca gag cgg gtc ctg ccc 480
 Leu Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro
 95 100 105 110

atc tgc cta cct gat gcc tct atc cac ctc cct cca aac acc cac tgc 528
 Ile Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys
 115 120 125

tgg atc tca ggc tgg ggg agc atc caa gat gga gtt ccc ttg ccc cac 576
 Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His
 130 135 140

cct cag acc ctc tcc aag gca tca ggc ccc gcc caa cgg cct cat gtc 624
 Pro Gln Thr Leu Ser Lys Ala Ser Gly Pro Ala Gln Arg Pro His Val
 145 150 155

ccc gcc ccc acg act tcc ggc ccc gcc cgg gcc ccc agc gct ttt gtg 672
 Pro Ala Pro Thr Thr Ser Gly Pro Ala Pro Gly Pro Ser Ala Phe Val
 160 165 170

tat ata aat gtt aat gat ttt tat agg tat ttg taaccctgcc cacatatc 723
 Tyr Ile Asn Val Asn Asp Phe Tyr Arg Tyr Leu
 175 180 185

<210> 14

<211> 234

<212> PRT

<213> Homo sapiens

<400> 14

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
 -30 -25 -20

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
 -15 -10 -5

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
 -1 1 5 10 15

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu

20

25

30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
 35 40 45

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
 50 55 60

Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu Pro
 65 70 75

His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala Leu
 80 85 90 95

Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro Ile
 100 105 110

Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys Trp
 115 120 125

Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
 130 135 140

Gln Thr Leu Ser Lys Ala Ser Gly Pro Ala Gln Arg Pro His Val Pro
 145 150 155

Ala Pro Thr Thr Ser Gly Pro Ala Pro Gly Pro Ser Ala Phe Val Tyr
 160 165 170 175

Ile Asn Val Asn Asp Phe Tyr Arg Tyr Leu
 180 185

<210> 15
 <211> 1004
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(390)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 15


```

gcc atg gtg gtt tct gga gcg ccc cca gcc etg ggt ggg ggc tgt ctc      48
Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
                    -45                      -40                      -35

ggc acc ttc acc tcc ctg ctg ctg ctg gcg tgg aca gcc atc ctc aat      96
Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn
                    -30                      -25                      -20

gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg      144
Ala Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu
                    -15                      -10                      -5

aac cgg gtt gtg ggc gcc gag gac agc act gac agc gag tgg ccc tgg      192
Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp
-1 1                      5                      10

atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg      240
Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu
15                      20                      25                      30

ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gat tcc      288
Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Ser
                    35                      40                      45

ctt gcc cca ccc tca gac cct gca gaa gct gaa ggt tcc tat cat cga      336
Leu Ala Pro Pro Ser Asp Pro Ala Glu Ala Glu Gly Ser Tyr His Arg
                    50                      55                      60

ctc gga agt ctg cag cca tct gta ctg gcg ggg agc agg aca ggg acc      384
Leu Gly Ser Leu Gln Pro Ser Val Leu Ala Gly Ser Arg Thr Gly Thr
65                      70                      75

cat cac tgaggacatg ctgtgtgccg gctacttgga gggggagcgg gatgcttgtc      440
His His
80

tgggcgactc cgggggcccc ctcatgtgcc aggtggacgg cgcttgctg ctggccgcca      500

tcacagctg gggcgagggc tgtgccgagc gcaacaggcc cggggtctac atcagcctct      560

ctgcgcaccg ctctctgggtg gagaagatcg tgcaaggggg cgagctccgc gggcgcgctc      620

aggggggttg ggcctcagg gcaccgagcc agggctctgg ggccgcgcgg cgctcctagg      680

gcgcagcggg acgcggggct cggatctgaa aggcggccag atccacatct ggatctggat      740

ctgcggcggc ctgcggcggt ttcccccgcc gtaaataggc tcactctacct ctacctctgg      800

gggcccggac ggctgctgcg gaaaggaaac cccctccccg acccgcccca cggcctcagg      860

ccccgccctc caaggcatca ggccccgcc aacggcctca tgtccccgcc ccacgactt      920

ccgccccgcg ccccgggccc cagcgctttt gtgtatataa atgttaataa tttttatagg      980

tatttgtaac cctgccca tate      1004

```

<210> 16
 <211> 129
 <212> PRT
 <213> Homo sapiens

<400> 16

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
 -30 -25 -20

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
 -15 -10 -5

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
 -1 1 5 10 15

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu
 20 25 30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Ser Leu
 35 40 45

Ala Pro Pro Ser Asp Pro Ala Glu Ala Glu Gly Ser Tyr His Arg Leu
 50 55 60

Gly Ser Leu Gln Pro Ser Val Leu Ala Gly Ser Arg Thr Gly Thr His
 65 70 75

His
 80

<210> 17
 <211> 948
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (4)..(909)
 <223>

<220>
 <221> mat_peptide
 <222> (151)..()
 <223>

<400> 17
 gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc
 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu
 -45 -40 -35

48

ggc acc ttc acc tcc ctg ctg ctg ctg ggc tgc aca gcc atc ctc aat Gly Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn -30 -25 -20	96
gcg gcc agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg Ala Ala Arg Ile Pro Val Pro Ala Cys Gly Lys Pro Gln Gln Leu -15 -10 -5	144
aac cgg gtt gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg Asn Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp -1 1 5 10	192
atc gtg agc atc cag aag aat ggg acc cac cac tgc gca ggt tct ctg Ile Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu 15 20 25 30	240
ctc acc agc cgc tgg gtg atc act gct gcc cac tgt ttc aag gac aac Leu Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn 35 40 45	288
ctg aac aaa cca tac ctg ttc tct gtg ctg ctg ggg gcc tgg cag ctg Leu Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu 50 55 60	336
ggg aac cct gcc tct cgg tcc cag aaa gtg ggt gtt gcc tgg gtg gag Gly Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu 65 70 75	384
ccc cac cct gtg tat tcc tgg aag gaa ggt gcc tgt gca gac att gcc Pro His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala 80 85 90	432
ctg gtg cgt ctc gag cgc tcc ata cag ttc tca gag cgg gtc ctg ccc Leu Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro 95 100 105 110	480
atc tgc cta cct gat gcc tct atc cac ctc cct cca aac acc cac tgc Ile Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys 115 120 125	528
tgg atc tca ggc tgg ggg agc atc caa gat gga gtt ccc ttg ccc cac Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His 130 135 140	576
cct cag acc ctg cag aag ctg aag gtt cct atc atc gac tgc gaa gtc Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val 145 150 155	624
tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc atc act gag Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu 160 165 170	672
gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct tgt ctg Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu 175 180 185 190	720
gtg agc tcc ctc gag ccc ccc acc cct ggc cag gag ggc ctc ggg aag Val Ser Ser Leu Glu Pro Pro Thr Pro Gly Gln Glu Gly Leu Gly Lys 195 200 205	768
gag cca gcg tca gtc ctg tcc cca ctg agc ccc aca acc tct ccc tgg	816

Glu Pro Ala Ser Val Leu Ser Pro Leu Ser Pro Thr Thr Ser Pro Trp
 210 215 220

cct cct ccc cag aac tgg ctg tgc ctg aca gtc ccg ggt ccc cat aga 864
 Pro Pro Pro Gln Asn Trp Leu Cys Leu Thr Val Pro Gly Pro His Arg
 225 230 235

acc agc ctc agc ctg gct cag cca ctc act tat ttg ttc aga cat 909
 Thr Ser Leu Ser Leu Ala Gln Pro Leu Thr Tyr Leu Phe Arg His
 240 245 250

taaactgggc atcccagctg caaaaaaaaa aaaaaaaaa 948

<210> 18
 <211> 302
 <212> PRT
 <213> Homo sapiens

<400> 18

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala
 -30 -25 -20

Ala Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn
 -15 -10 -5

Arg Val Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile
 -1 1 5 10 15

Val Ser Ile Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu
 20 25 30

Thr Ser Arg Trp Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu
 35 40 45

Asn Lys Pro Tyr Leu Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly
 50 55 60

Asn Pro Gly Ser Arg Ser Gln Lys Val Gly Val Ala Trp Val Glu Pro
 65 70 75

His Pro Val Tyr Ser Trp Lys Glu Gly Ala Cys Ala Asp Ile Ala Leu
 80 85 90 95

Val Arg Leu Glu Arg Ser Ile Gln Phe Ser Glu Arg Val Leu Pro Ile
 100 105 110

Cys Leu Pro Asp Ala Ser Ile His Leu Pro Pro Asn Thr His Cys Trp
115 120 125

Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
130 135 140

Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys
145 150 155

Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp
160 165 170 175

Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Val
180 185 190

Ser Ser Leu Glu Pro Pro Thr Pro Gly Gln Glu Gly Leu Gly Lys Glu
195 200 205

Pro Ala Ser Val Leu Ser Pro Leu Ser Pro Thr Thr Ser Pro Trp Pro
210 215 220

Pro Pro Gln Asn Trp Leu Cys Leu Thr Val Pro Gly Pro His Arg Thr
225 230 235

Ser Leu Ser Leu Ala Gln Pro Leu Thr Tyr Leu Phe Arg His
240 245 250

<210> 19
<211> 1322
<212> DNA
<213> Mus. Sp.

<220>
<221> CDS
<222> (80)..(1003)
<223>

<220>
<221> mat_peptide
<222> (227)..()
<223>

<400> 19
cctgccagtc tcaagcaaca cagcccttag gtcctttgag ccggccagca gccttgcctg 60
gtctccaccc ataccagca atg atg atc tcc aga cct ccc cca gca ctg ggt 112
Met Met Ile Ser Arg Pro Pro Pro Ala Leu Gly
-45 -40
ggg gac cag ttc agc atc tta atc ctt ctg gtg ctg ctg act tcc aca 160

Gly Asp Gln Phe Ser Ile Leu Ile Leu Leu Val Leu Leu Thr Ser Thr	
-35 -30 -25	
gct ccc atc agt gct gcc acc atc cga gtg tcc cca gac tgt ggg aag	208
Ala Pro Ile Ser Ala Ala Thr Ile Arg Val Ser Pro Asp Cys Gly Lys	
-20 -15 -10	
cct cag cag ctg aac cgg att gtg gga ggt gag gac agc atg gat gcc	256
Pro Gln Gln Leu Asn Arg Ile Val Gly Gly Glu Asp Ser Met Asp Ala	
-5 -1 1 5 10	
cag tgg ccc tgg att gtt agc atc ctc aag aat ggc tcc cac cac tgt	304
Gln Trp Pro Trp Ile Val Ser Ile Leu Lys Asn Gly Ser His His Cys	
15 20 25	
gca ggc tcc ctg ctc acc aac cgc tgg gtg gtc aca gcc gcg cac tgc	352
Ala Gly Ser Leu Leu Thr Asn Arg Trp Val Val Thr Ala Ala His Cys	
30 35 40	
ttt aag agc aat atg gac aaa cca tct ctg ttc tca gta ttg ttg ggg	400
Phe Lys Ser Asn Met Asp Lys Pro Ser Leu Phe Ser Val Leu Leu Gly	
45 50 55	
gcc tgg aag ctg ggg agc cca gcc cca agg tcc cag aaa gta gcc att	448
Ala Trp Lys Leu Gly Ser Pro Gly Pro Arg Ser Gln Lys Val Gly Ile	
60 65 70	
gct tgg gtg ctg cct cac ccc agg tat tct tgg aag gag gga acc cat	496
Ala Trp Val Leu Pro His Pro Arg Tyr Ser Trp Lys Glu Gly Thr His	
75 80 85 90	
gca gac att gcc ctg gtg cgc ctg gaa cac tcc atc cag ttc tct gag	544
Ala Asp Ile Ala Leu Val Arg Leu Glu His Ser Ile Gln Phe Ser Glu	
95 100 105	
cgg atc ctg ccc atc tgc cta cct gac tcc tct gtc cgt ctc cct ccc	592
Arg Ile Leu Pro Ile Cys Leu Pro Asp Ser Ser Val Arg Leu Pro Pro	
110 115 120	
aag acc gac tgc tgg att gcc ggc tgg gga agc atc cag gat gga gtg	640
Lys Thr Asp Cys Trp Ile Ala Gly Trp Gly Ser Ile Gln Asp Gly Val	
125 130 135	
ccc ctg ccc cac cct cag acc ctt cag aag ctg aag gtg ccc atc atc	688
Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile	
140 145 150	
gac tcc gaa ctc tgc aaa agc ttg tac tgg cgg gga gcc ggt cag gaa	736
Asp Ser Glu Leu Cys Lys Ser Leu Tyr Trp Arg Gly Ala Gly Gln Glu	
155 160 165 170	
gcc atc acg gag ggc atg ctg tgt gct ggt tac ctg gaa ggg gag cgg	784
Ala Ile Thr Glu Gly Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg	
175 180 185	
gat gct tgt ctg ggc gac tct ggg ggt ccc ctg atg tgc cag gtg gat	832
Asp Ala Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp	
190 195 200	
gac cac tgg cta ctg act ggc ata atc agc tgg gga gag gcc tgc gga	880
Asp His Trp Leu Leu Thr Gly Ile Ile Ser Trp Gly Glu Gly Cys Gly	

205	210	215	
gcg caa ccg gcc cgg tgt gta cac cag cct cct agc tca ccg ctc ctg			928
Ala Gln Pro Ala Arg Cys Val His Gln Pro Pro Ser Ser Pro Leu Leu			
220	225	230	
ggg gca aag gat cgt tca agg ggt gca gct gcg cgg gta ctt ggc gga			976
Gly Ala Lys Asp Arg Ser Arg Gly Ala Ala Arg Val Leu Gly Gly			
235	240	245	250
cag tgg gga cac agg aag ctc cta atc taggatctga agatgagcag			1023
Gln Trp Gly His Arg Lys Leu Leu Ile			
255			
ctctctgcaa ttctctctgc tgtaaatatg tcttctacct ccggggggcg ccgcgggcct			1083
gagcgagaga acaaggaagt tctggaaccg cccacataga ggatccgccc ctcaatcgag			1143
gactctgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgcct ctgtgtgcgt gtgtatgcgc			1203
gcgcacgtgc gcgcgagagc aatgattttt ttttttacag ttatacgtaa ccattgccac			1263
atattttattc cagtttcaat aaattattta ttcttaaaaa aaaaaaaaaa aaaaaaaaaa			1322
<210> 20			
<211> 308			
<212> PRT			
<213> Mus. Sp.			
<400> 20			
Met Met Ile Ser Arg Pro Pro Ala Leu Gly Gly Asp Gln Phe Ser			
-45	-40	-35	
Ile Leu Ile Leu Leu Val Leu Leu Thr Ser Thr Ala Pro Ile Ser Ala			
-30	-25	-20	
Ala Thr Ile Arg Val Ser Pro Asp Cys Gly Lys Pro Gln Gln Leu Asn			
-15	-10	-5	
Arg Ile Val Gly Gly Glu Asp Ser Met Asp Ala Gln Trp Pro Trp Ile			
-1 1	5	10	15
Val Ser Ile Leu Lys Asn Gly Ser His His Cys Ala Gly Ser Leu Leu			
20	25	30	
Thr Asn Arg Trp Val Val Thr Ala Ala His Cys Phe Lys Ser Asn Met			
35	40	45	
Asp Lys Pro Ser Leu Phe Ser Val Leu Leu Gly Ala Trp Lys Leu Gly			
50	55	60	
Ser Pro Gly Pro Arg Ser Gln Lys Val Gly Ile Ala Trp Val Leu Pro			

65

70

75

His Pro Arg Tyr Ser Trp Lys Glu Gly Thr His Ala Asp Ile Ala Leu
80 85 90 95

Val Arg Leu Glu His Ser Ile Gln Phe Ser Glu Arg Ile Leu Pro Ile
100 105 110

Cys Leu Pro Asp Ser Ser Val Arg Leu Pro Pro Lys Thr Asp Cys Trp
115 120 125

Ile Ala Gly Trp Gly Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro
130 135 140

Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Leu Cys
145 150 155

Lys Ser Leu Tyr Trp Arg Gly Ala Gly Gln Glu Ala Ile Thr Glu Gly
160 165 170 175

Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly
180 185 190

Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Asp His Trp Leu Leu
195 200 205

Thr Gly Ile Ile Ser Trp Gly Glu Gly Cys Gly Ala Gln Pro Ala Arg
210 215 220

Cys Val His Gln Pro Pro Ser Ser Pro Leu Leu Gly Ala Lys Asp Arg
225 230 235

Ser Arg Gly Ala Ala Ala Arg Val Leu Gly Gly Gln Trp Gly His Arg
240 245 250 255

Lys Leu Leu Ile

<210> 21

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide to construct plasmid pSecTrypHis

<400> 21

aaagcttggct agcaacacca tgaatctact cctgatacctt acctttgttg ctgctgctgt

60

tgctgcccc ttgacgacg atgacaagga tccgaattc

99

<210> 22
 <211> 99
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Designed oligonucleotide to construct plasmid pSecTrypHis

<400> 22
 gaattcggat ccttgatc gtcgtcaaag ggggcagcaa cagcagcagc aacaaaggtg 60
 aggatcagga gtagattcat ggtgttgcta gccaaagctt 99

<210> 23
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Designed oligonucleotide primer to amplify neurosin-encoding sequence

<400> 23
 ttggtgcatg gcgga 15

<210> 24
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Designed oligonucleotide primer to amplify neurosin-encoding sequence

<400> 24
 tcctcgagac ttggcctgaa tggtttt 27

<210> 25
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Designed oligonucleotide primer to amplify a portion of plasmid pSecTrypHis/Neurosin

<400> 25
 gcgctagcag atctccatga atctactcct gatcc 35

<210> 26
 <211> 29
 <212> DNA
 <213> Artificial Sequence

```

<220>
<223>  Designed oligonucleotide primer to amplify a portion of plasmid p
        SecTrypHis/Neurosin

<400>  26
tgaagcttgc catggaccaa cttgtcatc                                29

<210>  27
<211>  26
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Designed oligonucleotide primer to amplify a portion of plasmid p
        TrypHis

<400>  27
ccaagcttca ccataccat caccat                                    26

<210>  28
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Designed oligonucleotide primer to amplify a portion of plasmid p
        TrypSigTag

<400>  28
gcacagtcga ggctgat                                            17

<210>  29
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Designed oligonucleotide primer to amplify a portion of plasmid p
        FBTrypSigTag

<400>  29
caaatgtggt atggctg                                           17

<210>  30
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Designed oligonucleotide primer to amplify conserved region of se
        rin proteases-encoding sequence

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  n is a, c, g or t.

```

```

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g or t.

<400> 30
gtggtcacng cngcbcaytg                                20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer to amplify conserved region of se
rin proteases-encoding sequence

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is a, c, g or t.

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is a, c, g or t.

<400> 31
ccvctrwsdc cncngggcga                                20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as hBSSP4F1 for RACE f
or human BSSP4 (forward)

<400> 32
aggttcctat catcgactcg                                20

<210> 33
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as hBSSP4F2 for RACE f
or human BSSP4 (forward)

<400> 33
tgaggacatg ctgtgtgccg g                                21

```

<210> 34
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Designed oligonucleotide primer designated as hBSSP4F3 to amplify mature human BSSP4-encoding region (forward)

 <400> 34
 gttgtgggcg gcgaggacag 20

 <210> 35
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Designed oligonucleotide primer designated as hBSSP4F6 to amplify full-length human BSSP4-encoding mRNA (forward)

 <400> 35
 gccatggtgg ttctggagc 20

 <210> 36
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Designed oligonucleotide primer designated as hBSSP4R1 for RACE for human BSSP4 (reverse)

 <400> 36
 tatggtttgt tcaggttgtc c 21

 <210> 37
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Designed oligonucleotide primer designated as hBSSP4R2 for RACE for human BSSP4 (reverse)

 <400> 37
 agggcaatgt ctgcacaggc 20

 <210> 38
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Designed oligonucleotide primer designated as hBSSP4R3/E to amplify

fy full-length human BSSP4-encoding mRNA (reverse)

```

<400> 38
ctgaattcct aggagcgcgc gccggcc                                27

<210> 39
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as hBSSP4R4/E to ampli
fy full-length human BSSP4-encoding mRNA (reverse)

<400> 39
gagaattcga tatgtgggca gggttaca                                28

<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4.1 for RACE f
or mouse BSSP4 (forward)

<400> 40
acaaaccatc tctgtttcga g                                21

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4F2 for RACE f
or mouse BSSP4 (forward)

<400> 41
gtcccagaaa gtaggcattg                                20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4F3 to amplify
full-length mouse BSSP4-encoding mRNA (forward)

<400> 42
ctccacccat accagcaatg                                20

<210> 43
<211> 20
<212> DNA

```

```

<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4F4 to amplify
        mature mouse BSSP4-encoding region (forward)

<400> 43
attgtgggag gtgaggacag                                20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4.2 for RACE f
        or mouse BSSP4 (reverse)

<400> 44
tgcagagttc ggagtcgatg                                20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4R2 for RACE f
        or mouse BSSP4 (reverse)

<400> 45
atccagcagt cggctcttggg                                20

<210> 46
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer designated as mBSSP4R3/P to ampli
        fy full-length mouse BSSP4-encoding mRNA (reverse)

<400> 46
attctgcagt tccttggttct ctgcgtcagg                    30

<210> 47
<211> 117
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide to construct plasmid pTrypHis

<400> 47
aagcttggct agcaacacca tgaatctact cctgatcctt acctttgttg ctgctgctgt    60
tgctgcccc ttccaccatc accatcacca tgacgacgat gacaaggatc cgaattc      117

```

<210> 48
<211> 117
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed oligonucleotide to construct plasmid pTrypHis

<400> 48
gaattcgat ccttgcacg gtcgtcatgg tgatggatgat ggtgaaaggg ggcagcaaca 60
gcagcagcaa caaaggtaag gatcaggagt agattcatgg tgttgctagc caagctt 117

<210> 49
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 49
ccttgcacg agcgccttttg tgcataataa tgcataatgat tttatataggt atttgtaacc 60
<211> 11
<212> PRT 73
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 50

Pro Gly Pro Gln Arg Phe Cys Val Tyr Lys Cys
1 5 10

<210> 51
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 51

Asp Asp Asp Asp Lys
1 5

<210> 52
<211> 4
<212> PRT

PROCT Rec'd 1 OCT 2001**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:)	Box Sequence
H. UEMURA et al.)	Examiner:
Appln. No.: 09/856,298)	Washington, D.C.
Filed: May 21, 2001)	October 1, 2001
For: NOVEL SERINE PROTEASE)	Atty. Docket: UEMURA=6
BSSP4)	

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the calculation of the filing fee including additional claims, please amend the present application as follows:

IN THE CLAIMS

Please cancel claims 3-54 and 58 without prejudice.

Please replace claims 55-57, 59, 64, and 66-71, with new amended claims 55-57, 59, 64, and 66-71 to eliminate multiple dependencies as follows below:

55(Amended). A vector comprising the nucleotide sequence according to claim 2.

56(Amended). Transformed cells having the nucleotide sequence according to claim 2 in an expressible state.

57(Amended). A process for producing a protein

<213> Artificial Sequence

<220>

<223> Synthetic

<400> 52

Leu Val His Gly

1

In re Appln. No. 09/856,298

which comprises culturing cells transformed with the nucleotide sequence according to claim 2, and collecting hBSSP4 produced.

59(Amended). The process according to claim 57, wherein the cells are *E. coli* cells, animal cells or insect cells.

64(Amended). An antibody against the protein according to claim 1 or a fragment thereof.

66(Amended). A process for producing a monoclonal antibody against the protein according to claim 1 or a fragment thereof which comprises administering the protein according to claim 1 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

67(Amended). A method for determining the protein according to claim 1 or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

68(Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to claim 1 or a fragment thereof and a labeled antibody with hBSSP4 or a fragment thereof in the specimen to detect a sandwich complex produced.

In re Appln. No. 09/856,298

69(Amended). A method for determining hBSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to claim 1 or a fragment thereof with labeled hBSP4 and hBSP4 or a fragment thereof in the specimen competitively to detect an amount of hBSP4 or a fragment thereof in the specimen based on an amount of the labeled hBSP4 reacted with the antibody.

70(Amended). The method according to claim 67, wherein the specimen is a body fluid.

71(Amended). A diagnostic marker for diseases in tissues comprising the protein according to claim 1.

In re Appln. No. 09/856,298

REMARKS


The amendments to the claims are being made to eliminate multiple dependencies and to reduce the additional claim fees.

Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached version is captioned "version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Allen C. Yun
Registration No. 37,971

ACY:pr
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\A\Aoyb\Demura 4\PRO\Freliminary Amendment.doc

In re Appln. No. 09/856,298

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 55-57, 59, 64, and 66-71 have been amended as follows below:

55(Amended). A vector comprising the nucleotide sequence according to ~~any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 44-54~~ claim 2.

56(Amended). Transformed cells having the nucleotide sequence according to ~~any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 44-54~~ claim 2 in an expressible state.

57(Amended). A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to ~~any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36, 38, 40 and 45-53~~ claim 2, and collecting hBSSP4 produced.

59(Amended). The process according to claim 57 ~~or 58~~, wherein the cells are *E. coli* cells, animal cells or insect cells.

64(Amended). An antibody against the protein according to ~~any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43~~ claim 1 or a fragment thereof.

66(Amended). A process for producing a monoclonal antibody against the protein according to ~~any one of claims 1,~~

In re Appln. No. 09/856,298

~~3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43~~ claim 1 or a fragment thereof which comprises administering the protein according to ~~any one of~~ claims ~~1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43~~ claim 1 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

67(Amended). A method for determining the protein according to ~~any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43~~ claim 1 or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

68(Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to ~~any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35, 37 and 39~~ claim 1 or a fragment thereof and a labeled antibody with hBSSP4 or a fragment thereof in the specimen to detect a sandwich complex produced.

69(Amended). A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to ~~any one of claims 1, 3, 5, 7, 9, 11, 13,~~

In re Appln. No. 09/856,298

~~15, 17, 19, 21, 29, 31, 33, 35, 37 and 39~~ claim 1 or a fragment thereof with labeled hBBSP4 and hBSSP4 or a fragment thereof in the specimen competitively to detect an amount of hBSSP4 or a fragment thereof in the specimen based on an amount of the labeled hBBSP4 reacted with the antibody.

70(Amended). The method according to ~~any one of claims 67-69~~ claim 67, wherein the specimen is a body fluid.

71(Amended). A diagnostic marker for diseases in tissues comprising the protein according to ~~any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43~~ claim 1.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit:
Hidetoshi UEMURA et al.)	
)	
IA No.: PCT/JP99/06472)	
)	Washington, D.C.
IA Filed: 19 November 1999)	
)	
U.S. App. No.:)	
(Not Yet Assigned))	
)	May 21, 2001
National Filing Date:)	
(Not Yet Received))	
)	
For: NOVEL SERINE PROTEASES...)	Docket No.: UEMURA 6

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and prior to calculation of the filing fee, kindly amend as follows:

IN THE SPECIFICATION

After the title please insert the following paragraph:

REFERENCE TO RELATED APPLICATIONS

--The present application is the national stage under 35 U.S.C. §371 of international application PCT/JP99/06472, filed 19 November 1999 which designated the United States, and which application was not published in the English language.--

In re of: Hidetoshi UEMURA et al. (UEMURA 6)

REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Roger L. Browdy
Registration No. 25,618

RLB:wrđ
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

7/PRTS

NOVEL SERINE PROTEASE BSSP4

5

FIELD OF THE INVENTION

The present invention relates to isolated polynucleotides of human and mouse serine proteases (hereinafter referred to as "hBSSP4" and "mBSSP4", respectively, and, in case no differentiation thereof from each other is needed, simply referred to as "BSSP4"), and their homologous forms, mature forms, precursors and polymorphic variants as well as a method for detecting thereof. Further, it relates to hBSSP4 and mBSSP4 proteins, compositions containing hBSSP4 and mBSSP4 polynucleotides and proteins, as well as their production and use.

10
15

BACKGROUND OF THE INVENTION

In general, proteases are biosynthesized as inactive precursors. They undergo limited hydrolysis in molecules to convert into activated type proteases. In so far as enzymes are proteases, they have an activity for hydrolyzing a peptide bond, while their action modes are varied according to kinds of proteases. According to a particular kind of catalytic site, proteases are divided into serine proteases, cysteine proteases, aspartate

20
25

proteases, metal proteases and the like. Proteases of each kind have a variety of properties, ranging from a protease having general digestive properties to a protease having various regulatory domains and strict substrate specificity, thereby specifically hydrolyzing only characteristic proteins.

Further, proteins undergo various processing even after translation to produce active proteins. In many secretory proteins, a protein are first synthesized on the ribosome in cytoplasm as an inactive precursor (pro-form) which comprises an active protein bearing at the N-terminus thereof a peptide of about 15 to 60 amino acids responsible for secretion (secretory signal). This peptide region is concerned with the mechanism for passing through the cell membrane and is removed upon cleavage by a specific protease during the passage through the membrane, in almost all the cases, to produce a mature protein. A secretory signal has a broad hydrophobic region comprising hydrophobic amino acids in the middle of the sequence, and basic amino acid residues at a site close to the N-terminus. A secretory signal is a synonym of a signal peptide. In addition, in some proteins, a peptide moiety which functions as a secretory signal is further attached to the N-terminus of the inactive precursor (pro-form). Such a protein is called a prepro-protein (prepro-form).

For example, trypsin is present as a prepro-form immediately after translation into amino acids. After being secreted from cells, it is present as a pro-form and is converted into active trypsin in duodenum upon limited
5 hydrolysis by enteropeptidase or by trypsin itself.

The optimal pH range of serine proteases is neutral to weak alkaline and, in general, many of them have a molecular weight of about 30,000 or lower. All proteases of blood coagulation, fibrinolysis and complement systems
10 having a large molecular weight belong to trypsin-like serine proteases. They have many regulator domains and form a protease cascade which is of very importance to reactions in a living body.

Recently, cDNAs and amino acid sequences of many
15 novel proteases have been determined by PCR for consensus sequences of serine proteases using oligonucleotide primers. According to this method, novel proteases have been found by various researchers such as Yamamura et al. (Yamamura, Y et al., Biochem. Biophys. Res. Commun., 239, 386, 1997),
20 Gschwend, et al. (Gschwend, T. P. et al., Mol. Cell. Neurosci., 9, 207, 1997), Chen et al. (Chen, Z-L, et al., J. Neurosci., 15, 5088, 1995) and others.

SEQ ID NO: 3 of JP 9-149790 A discloses neurosin as a novel serine protease. Neurosin has also been
25 reported in Biochimica et Biophysica Acta, 1350, 11-14,

1997. By this, there is provided a method for mass production of neurosin using the serine protease gene and a method for screening specific inhibitors using the enzyme. In addition, the screening method has been shown to be
5 useful for screening medicines for treating various diseases.

Serine proteases expressed in a brain-nerve system such as neurosin are considered to play various roles in the brain-nerve system. Therefore, there is a
10 possibility that isolation of a gene encoding a novel protease expressed in a brain-nerve system and production of a protein using the gene would be useful for diagnosis or treatment of various diseases related to the brain-nerve system.

15 Nowadays, in general, clinical diagnosis of Alzheimer's disease is conducted based on the diagnosis standard of DSM-IIIR and NINCDS-ADRDA (Mckhann, G. et al., Neurology, 34. 939, 1994) or the diagnosis standard of DSM-IV (American Psychiatric Association; Diagnostic and
20 statistical manuals of mental disorders, 4th ed., Washington DC, American Psychiatric Association, 1994). However, these standards are conditioned by decline of recognition functions which causes a severe disability in a daily life or a social life. Then, it is pointed out that
25 the diagnosis is less scientific objectivity because the

diagnosis may be influenced by the level of an individual's social life and further the specialty and experience of a physician who diagnoses particular conditions. In addition, definite diagnosis of Alzheimer's disease is conducted by pathohistological analyses and, in this respect, substantial inconsistency between clinical diagnosis and autopsy diagnosis is pointed out.

At present, image diagnosis is employed as a supplemental means in clinical diagnosis of Alzheimer's diagnosis and it is possible to analyze brain functions, for example, decline of metabolism and atrophy in specific sites such as hippocampus, parietal lobe of cerebral cortex and the like which are specific for Alzheimer's disease by PET and SPECT. However, to define Alzheimer's disease based on lowering of a blood flow from parietal lobe to temporal lobe is very dangerous. In addition, there is few report showing that MRS testicle useful for patients with dementia including those of Alzheimer's disease. Further, although CT-MRI image diagnosis is used, a lesion of white matter such as atrophy of brain, PVL or the like is not specific for Alzheimer type dementia. Since it has been reported that atrophy of brain proceeds as getting older, the above observation is not necessarily found in Alzheimer type dementia. Furthermore, since an image obtained by MRI varies according to strength of a magnetic field,

performance of an apparatus and imaging conditions, numerical data obtain in different facilities cannot be compared with each other except atrophic change. In addition, there is a limit to image measurement. Further, enlargement of ventricle can be recognized in vascular dementia cases and there are cases wherein atrophy of hippocampus is observed after ischemia of basilar artery.

Under these circumstances, many researchers have requested to develop biological diagnosis markers as a means for providing better precision and objectivity for clinical diagnosis of Alzheimer's disease. At the same time, the following important roles in the future will be expected.

1) Objective judgment system of effect of medicaments for treating Alzheimer's disease.

2) Detection of Alzheimer's disease before a diagnosis standard is met, or disease conditions are manifested.

Further, data obtained in different facilities can be compared with each other by using the same diagnosis marker. Therefore, development of biological diagnosis markers is recognized to be a most important field among fields of Alzheimer's disease studies and its future prospects will be expected. Approaches to development of biological diagnosis markers up to now are divided into

that based on constitute components of characteristic pathological changes of Alzheimer's disease such as senile plaque and neurofibril change, and an approach based on other measures. Examples of the former include

5 cerebrospinal fluid tau protein, A β and its precursor, β APP. Examples of the latter include mydriasis test with cholinergic drug, Apo E and other genes relating to Alzheimer's disease. However, no good results are obtained.

Serine proteases are also considered to play

10 important role in cancer cells. The reason why extermination of cancer by surgical treatment or topical irradiation of radioactive ray is difficult is metastasis capability of cancer. For spread of solid tumor cells in a body, they should loosen their adhesion to original

15 adjacent cells, followed by separating from an original tissue, passing through other tissues to reach blood vessel or lymph node, entering into the circulatory system through stratum basal and endothelial layer of the vessel, leave from the circulatory system at somewhere in the body, and

20 surviving and proliferating in a new environment. While adhesion to adjacent epidermal cells is lost when expression of cadherin which is an intercellular adhesive molecule of epithelium is stopped, to break through tissues is considered to depend on proteolytic enzymes which

25 decompose an extracellular matrix.

As enzymes which decompose the matrix, mainly, metal proteases (Rha, S. Y. et al., Breast Cancer Research Treatment, 43, 175, 1997) and serine proteases are known. They cooperate to decompose matrix protein such as collagen, laminin and fibronectin. Among serine proteases known to be concerned in decomposition of the matrix, in particular, there is urokinase type plasminogen activator (U-PA). U-PA has a role as a trigger specific for a protein decomposition chain reaction. Its direct target is plasminogen. It is present in blood abundantly and is a precursor of an inactive serine protease which accumulates in reconstructed sites of tissues such as injured sites and tumors as well as inflammatory sites. In addition, as proteases which are concerned in metastasis and infiltration of cancers, for example, a tissue factor, lysosomal type hydrolase and collagenase have been known.

At present, cancer is the top cause of death in Japan and more than 200,000 people are died per year. Then, specific substances which can be used as markers for diagnosis and therapy or prophylaxis of cancer are studied intensively. Such specific substances are referred to as tumor markers or tumor marker relating biomarkers. They are utilized in aid of diagnosis before treatment of cancer, for presuming carcinogenic organ and pathological tissue type, for monitoring effect of treatment, for finding

recurrence early, for presuming prognosis, and the like. At present, tumor markers are essential in clinical analyses. Among them, alpha fetoprotein (AFP) which has high specificity to hepatocellular carcinoma and yolk sac tumor (Taketa K. et al., Tumour Biol., 9, 110, 1988), and carcinoembryonic antigen (CEA) are used worldwide. In the future, tumor markers will be required more and more, and it is desired to develop, for example, organ specific markers and tumor cell specific markers which are highly reliable serologic diagnosis of cancer. Up to now, humunglandular kallikrein (hK2) which is a serine protease expressed at human prostatic epithelial cells has been reported as a marker for prostatic cancer. And, hK2 has 78% homology with the sequence of prostatic specific antigen (PSA) and PSA is also used widely as a biochemical marker of prostatic cancer (Mikolajczyk, S. d. et al., Prostate, 34, 44, 1998; Pannek, J. et al., Oncology, 11, 1273, 1997; Chu, T. M. et al., Tumour Biology, 18, 123, 1997; Hsieh, M. et al., Cancer Res., 57, 2651, 1997). Further, hK2 is reported to be useful as a marker for not only prostatic cancer but also stomach cancer (Cho, J. Y. et al.. Cancer, 79, 878, 1997). Moreover, CYFRA (CYFRA 21-1) for measuring cytokeratin 19 fragment in serum is reported to be useful for lung cancer (Sugiyama, Y. et al., Japan J. Cancer Res., 85, 1178, 1994). Gastrin release

peptide precursor (ProGRP) is reported to be useful as a tumor marker (Yamaguchi, K. et al., Japan, J. Cancer Res., 86, 698, 1995).

5

OBJECTS OF THE INVENTION

Thus, the main object of the present invention is to provide a novel serine protease which can be used for treating or diagnosing various diseases such as Alzheimer's disease (AD), epilepsy, cancer, inflammation, sterility, prostate hypertrophy and the like in various tissues such as brain, lung, prostate, testicle, skeletal muscle, liver and the like, and can be used as an excellent marker instead of that presently used.

15

SUMMARY OF THE INVENTION

Under these circumstances, the present inventors have succeeded in cloning of cDNA encoding novel human and mouse serine proteases.

20

In summary, one feature of the present invention is amino acid sequences of biological active mature serine proteases hBSSP4 and mBSSP4 as well as nucleotide sequences encoding the amino acid sequences.

25

That is, they are the amino acid sequence composed of 268 amino acids represented by the 1st to 268th amino acids of SEQ ID NO: 2 and a nucleotide sequence

encoding the amino acid sequence (the 151st to 954th bases of SEQ ID NO: 1). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid
5 sequences. Further, they include modified derivatives of proteins having these amino acid sequences. An amino acid sequence substantially similar to a given amino acid sequence used herein means an amino acid sequence derived from the given amino acid sequence by modification such as
10 substitution, deletion, addition and/or insertion of one to several amino acids with maintaining the same property as that of the protein having the given amino acid sequence. The modified derivative of the proteins includes, for example, phosphate adduct, sugar chain adduct, metal adduct
15 (e.g., calcium adduct), the protein fused to another protein such as albumin etc., dimer of the protein, and the like.

Further, they are the amino acid sequence composed of 270 amino acids represened by the 1st to 270th
20 amino acids of SEQ ID NO: 4 and a nucleotide sequence encoding the amino acid sequence (the 15th to 960th bases of SEQ ID NO: 3). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid
25 sequences. Further, they include modified derivatives of

proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 257 amino acids represented by the 1st to 257th amino acids of SEQ ID NO: 6 and a nucleotide sequence
5 encoding the amino acid sequence (the 151st to 921st bases of SEQ ID NO: 5). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of
10 proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 97 amino acids represented by the 1st to 97th amino acids of SEQ ID NO: 8 and a nucleotide sequence encoding the amino acid sequence (the 151st to 441st bases
15 of SEQ ID NO: 7). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of
proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 158 amino acids represented by the 1st to 158th amino acids of SEQ ID NO: 10 and a nucleotide sequence encoding the amino acid sequence (the 151st to 624th bases
20 of SEQ ID NO: 9). In addition, they include amino acid sequences substantially similar to the amino acid sequence
25

and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of proteins having these amino acid sequences.

Further, they are the amino acid sequence
5 composed of 82 amino acids represented by the 1st to 82nd
amino acids of SEQ ID NO: 12 and a nucleotide sequence
encoding the amino acid sequence (the 151st to 396th bases
of SEQ ID NO: 11). In addition, they include amino acid
sequences substantially similar to the amino acid sequence
10 and nucleotide sequences encoding such similar amino acid
sequences. Further, they include modified derivatives of
proteins having these amino acid sequences.

Further, they are the amino acid sequence
composed of 185 amino acids represented by the 1st to 185th
15 amino acids of SEQ ID NO: 14 and a nucleotide sequence
encoding the amino acid sequence (the 151st to 705th bases
of SEQ ID NO: 13). In addition, they include amino acid
sequences substantially similar to the amino acid sequence
and nucleotide sequences encoding such similar amino acid
20 sequences. Further, they include modified derivatives of
proteins having these amino acid sequences.

Further, they are the amino acid sequence
composed of 80 amino acids represented by the 1st to 80th
amino acids of SEQ ID NO: 16 and a nucleotide sequence
25 encoding the amino acid sequence (the 151st to 390th bases

of SEQ ID NO: 15). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 253 amino acids represented by the 1st to 253th amino acids of SEQ ID NO: 18 and a nucleotide sequence encoding the amino acid sequence (the 151st to 909th bases of SEQ ID NO: 17). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 34 amino acids represented by the -49th to -16th amino acids of SEQ ID NO: 2 and a nucleotide sequence encoding the amino acid sequence (the 4th to 105th bases of SEQ ID NO: 1). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives and fragments of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 15 amino acids represented by the -15th to -1st

amino acids of SEQ ID NO: 2 and a nucleotide sequence encoding the amino acid sequence (the 106th to 150th bases of SEQ ID NO: 1). In addition, they include amino acid sequences substantially similar to the amino acid sequence
5 and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives and fragments of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 259 amino acids represented by the 1st to 259th
10 amino acids of SEQ ID NO: 20 and a nucleotide sequence encoding the amino acid sequence (the 227th to 1003rd bases of SEQ ID NO: 19). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid
15 sequences. Further, they include modified derivatives of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 34 amino acids represented by the -49th to -16th
20 amino acids of SEQ ID NO: 20 and a nucleotide sequence encoding the amino acid sequence (the 80th to 181st bases of SEQ ID NO: 19). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives and
25 fragments of proteins having these amino acid sequences.

Further, they are the amino acid sequence composed of 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 20 and a nucleotide sequence encoding the amino acid sequence (the 182nd to 226th bases of SEQ ID NO: 19). In addition, they include amino acid sequences substantially similar to the amino acid sequence and nucleotide sequences encoding such similar amino acid sequences. Further, they include modified derivatives and fragments of proteins having these amino acid sequences.

Another feature of the present invention is an amino acid sequence composed of 317 or 283 amino acids wherein 49 amino acids represented by the -49th to -1st amino acids or 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 2 are added to the N-terminus side of the mature hBSSP4 amino acid sequence represented by SEQ ID NO: 2 (the 1st to 268th amino acids) and a nucleotide sequence encoding the amino acid sequence (the 4th to 954th or 106th to 954th bases of SEQ ID NO: 1). In addition, this feature includes amino acid sequences substantially similar to the above amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

Another feature of the present invention is an

amino acid sequence composed of 319 or 285 amino acids wherein 49 amino acids represented by the -49th to -1st amino acids or 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 4 are added to the N-terminus side of the mature hBSSP4 amino acid sequence represented by SEQ ID NO: 4 (the 1st to 270th amino acids) and a nucleotide sequence encoding the amino acid sequence (the 4th to 960th or 106th to 960th bases of SEQ ID NO: 3). In addition, this feature includes amino acid sequences substantially similar to the above amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

Another feature of the present invention is an amino acid sequence composed of 306 or 272 amino acids wherein 49 amino acids represented by the -49th to -1st amino acids or 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 6 are added to the N-terminus side of the mature hBSSP4 amino acid sequence represented by SEQ ID NO: 6 (the 1st to 257th amino acids) and a nucleotide sequence encoding the amino acid sequence (the 4th to 921st or 106th to 921st bases of SEQ ID NO: 5). In addition, this feature includes amino acid sequences substantially similar to the above amino acid sequence and

nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

5 Another feature of the present invention is an amino acid sequence composed of 308 or 274 amino acids wherein 49 amino acids represented by the -49th to -1st amino acids or 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 20 are added to the N-terminus side of the mature mBSP4 amino acid sequence
10 represented by SEQ ID NO: 20 (the 1st to 259th amino acids) and a nucleotide sequence encoding the amino acid sequence (the 8th to 1003rd or 182nd to 1003rd bases of SEQ ID NO: 19). In addition, this feature includes amino acid
15 sequences substantially similar to the above amino acid sequence and nucleotide sequences encoding these substantially similar amino acid sequences. Further, this feature includes modified derivatives of proteins having these amino acid sequences.

20 The present invention also relates to the nucleotide sequences represented by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19 as well as nucleotide sequences similar to them.

 Hereinafter, unless otherwise stated, the
25 nucleotide sequence represented by each SEQ ID NO: includes

the above-described various fragments thereof, and similar nucleotide sequences and their fragments. Likewise, the amino acid sequence represented by each SEQ ID NO: includes the above-described various fragments thereof, similar
5 nucleotide sequences and their fragments, and modified derivatives thereof. In addition, unless otherwise stated, BSSP4, hBSSP4, and mBSSP4 include proteins having the above-described respective amino acid sequences.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the results of northern blotting using human multiple tissue blot membrane.

Fig. 2 illustrates the results of northern blotting using human multiple tissue blot II membrane.

15 Fig. 3 illustrates the results of northern blotting using human multiple tissue blot II membrane.

Fig. 4 illustrates the results of northern blotting using mRNA prepared in Example 2 hereinafter.

20 Fig. 5 illustrates the results of northern blotting using mRNA prepared in Example 2 hereinafter.

Fig. 6 illustrates the plasmid constructed by the method of Example 4 hereinafter.

Fig. 7 illustrates the construction of the plasmid by the method of Example 4 hereinafter.

DETAILED DESCRIPTION OF THE INVENTION

The nucleotide sequences encoding hBSSP4 or mBSSP4 of the present invention can be obtained by preparing mRNAs from cells expressing the protein and converting it into double stranded DNAs according to a conventional manner. For preparing mRNA, guanidine isothiocyanate-calcium chloride method (Chirwin, et al., Biochemistry, 18, 5294, 1979) or the like can be used. For preparing poly (A) + RNA from total RNAs, there can be used affinity chromatography using a carrier, for example, Sepharose, latex particles, etc., to which oligo (dT) is attached, and the like. The above-obtained RNA can be used as a template and treated with reverse transcriptase by using, as a primer, oligo (dT) which is complementary to the poly (A) strand at the 3'-terminus, or a random primer, or a synthesized oligonucleotide corresponding to a part of the amino acid sequence of hBSSP4 or mBSSP4 to obtain a hybrid mRNA strand comprising DNA complementary to the mRNA or cDNA. The double stranded DNA can be obtained by treating the above-obtained hybrid mRNA strand with *E. coli* RNase, *E. coli* DNA polymerase and *E. coli* DNA ligase to convert into a DNA strand.

It is also possible to carry out cloning by RT-PCR method using primers synthesized on the basis of the nucleotide sequence of hBSSP4 or mBSSP4 gene and using

hBSSP4 or mBSSP4 expressing cell poly (A) + RNA as a template. Alternatively, the desired cDNA can be obtained without using PCR by preparing or synthesizing a probe on the basis of the nucleotide sequence of hBSSP4 or mBSSP4 gene and screening a cDNA library directly. Among genes obtained by these methods, the gene of the present invention can be selected by confirming a nucleotide sequence thereof. The gene of the present invention can also be prepared according to a conventional method using chemical syntheses of nucleic acids, for example, phosphoamidite method (Mattencci, M. D. et al., J. Am. Chem. Soc., 130, 3185, 1981) and the like.

By using the thus-obtained hBSSP4 or mBSSP4 gene, their expression in various tissues can be examined.

In case of northern blotting analysis, the expression of hBSSP4 is observed in cerebellum and prostate, and the expression of mBSSP4 is observed in prostate and skeletal muscle. In case of RT-PCR analysis, the expression of hBSSP4 is observed in brain, placenta and prostate of human fetuses and adults and the expression of mBSSP4 is observed in brain and placenta of 12-day-old mice. Then, the novel proteases of the present invention are presumed to play various roles in brain, prostate, placenta and skeletal muscle. For example, in brain, there is a possibility that they can be used for treatment and

diagnosis of brain diseases such as Alzheimer's disease (AD), epilepsy, brain tumor and the like. Further, in other tissues, there is a possibility that they can be used for treatment and diagnosis of various diseases such as cancer, inflammation, sterility, prostate hypertrophy and the like. Further, it is presumed they may have a certain influence on blood coagulation, fibrinolysis and complement systems.

The human novel serine protease (hBSSP4) is composed of 9 proteins due to alternative splicing of mRNA.

The protein having the amino acid sequence represented by SEQ ID NO: 2 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 268th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 1.

The protein having the amino acid sequence represented by SEQ ID NO: 4 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 270th amino acids. As consensus sequences of serine proteases,

it has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 3. This sequence corresponds to SEQ ID NO: 1 from which the 943rd to 1217th bases have been removed, and the amino acid sequence represented by SEQ ID NO: 4 corresponds to the amino acid sequence represented by SEQ ID NO: 2 in which the 265th amino acid and the subsequent amino acids are different.

The protein having the amino acid sequence represented by SEQ ID NO: 6 is a human type protein (hBSSP4) and the mature type having serine protease activity is the polypeptide represented by the 1st to 257th amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids and one or more of Asp's are present between the consensus sequences. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 5. This sequence corresponds to SEQ ID NO: 1 from which the 895th to 11208th bases have been removed, and the amino acid sequence represented by SEQ ID NO: 6 corresponds to the amino acid sequence represented by SEQ ID NO: 2 in which the

249th amino acids and the subsequent amino acids are different. Further, the nucleotide sequence corresponds to the sequence wherein the 969th to 1036th bases of SEQ ID NO: 5 are added to the downstream of the 1282 base of SEQ ID NO: 1.

The protein having the amino acid sequence represented by SEQ ID NO: 8 is a human type protein (hBSSP4). However, it does not have a consensus sequence of serine proteases. Since its expression by mRNA has been confirmed, this sequence is considered to have a certain role. The nucleotide sequence corresponds to the nucleotide sequence of SEQ ID NO: 1 from which the 233rd to 282nd bases have been removed.

The protein having the amino acid sequence represented by SEQ ID NO: 10 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, this does not have Ala-Ala-His-Cys represented, but has Asp-Ser-Gly-Gly-Pro represented by the 82nd to 86h amino acids. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 9. This sequence corresponds to the nucleotide sequence of SEQ ID NO: 1 from which the 233rd to 562nd bases have been removed.

The protein having the amino acid sequence represented by SEQ ID NO: 12 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it

has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids but does not have Asp-Ser-Gly-Gly-Pro. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 11. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO: 1 from which the 364th to 562nd amino acids have been removed.

The protein having the amino acid sequence represented by SEQ ID NO: 14 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids but do not have Asp-Ser-Gly-Gly-Pro. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 13. This nucleotide sequence corresponds to the nucleotide sequence represented by SEQ ID NO: 1 from which the 588th to 1145th bases have been removed. There is a possibility that the nucleotide sequence represented by the 652nd and the subsequent bases of SEQ ID NO: 13 would be "ccc ggg ccc cag cgc ttt tgt gta tat aaa tgt taatgatttt tataggtatt tgaaccctg cccacatc" and the amino acid sequence represented by the 168th and the subsequent amino acids of SEQ ID NO: 14 would be "Pro Gly Pro Gln Arg Phe Cys Val, Tyr Lys Cys".

The protein having the amino acid sequence represented by SEQ ID NO: 16 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it

has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids but does not have Asp-Ser-Gly-Gly-Pro. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 15. This sequence corresponds to SEQ ID NO: 1 from which the
5 285th to 562nd bases have been removed.

The protein having the amino acid sequence represented by SEQ ID NO: 18 is a human type protein (hBSSP4). As a consensus sequence of serine proteases, it has Ala-Ala-His-Cys represented by the 39th to 42nd amino
10 acids but does not have Asp-Ser-Gly-Gly-Pro. A nucleotide sequence encoding this protein is shown in SEQ ID NO: 17. This sequence corresponds to the sequence wherein the 721st to 948th bases of SEQ ID NO: 17 is added to the downstream of the 720th base of SEQ ID NO: 1, and corresponds SEQ ID
15 NO: 1 from which the 720th and the subsequent bases have been removed.

The protein having the amino acid sequence represented by SEQ ID NO: 20 is a mouse type protein (mBSSP4) and the mature type having serine protease
20 activity is the polypeptide represented by the 1st to 253 amino acids. As consensus sequences of serine proteases, it has Ala-Ala-His-Cys represented by the 39th to 42nd amino acids and Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids and one or more of Asp's are
25 present between the consensus sequences. A nucleotide

sequence encoding this protein is shown in SEQ ID NO: 19.

The term "pro part" used herein means a part of a pro-form, i.e., the pro-form from which the corresponding active type protein part is removed. The term "pre part" used herein means a part of a prepro-form, i.e., the prepro-form from which the corresponding pro-form is removed. The term "prepro part" used herein means a part of a prepro-form, i.e., the prepro-form from which the corresponding active type protein part is removed.

The amino acid sequence of mature hBSSP4 (the 1st to 268th amino acids) represented by SEQ ID NO: 2 is hBSSP4 mature or active type protein composed of 268 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 804 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus of the mature type protein of the present invention is deleted or added, while the preferred sequence is this amino acid sequence. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of mature hBSSP4 (the 1st to 270th amino acids) represented by SEQ ID NO: 4 is hBSSP4 mature or active type protein composed of 270 amino acids,

and the nucleotide sequence encoding the amino acid sequence is composed of 810 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus of the mature type protein of the present invention is deleted or added, while the preferred sequence is this amino acid sequence. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of mature hBSSP4 (the 1st to 257th amino acids) represented by SEQ ID NO: 6 is hBSSP4 mature or active type protein composed of 257 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 771 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus of the mature type protein of the present invention is deleted or added, while the preferred sequence is this amino acid sequence. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 97th amino acids) represented by SEQ ID NO: 8 is a protein

composed of 97 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 291 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 158th amino acids) represented by SEQ ID NO: 10 is a protein composed of 158 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 474 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 82nd amino acids) represented by SEQ ID NO: 12 is a protein composed of 82 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 246 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 185th amino acids) represented by SEQ ID NO: 14 is a protein composed of 185 amino acids, and the nucleotide

sequence encoding the amino acid sequence is composed of 555 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 80th amino acids) represented by SEQ ID NO: 16 is a protein composed of 80 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 240 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of hBSSP4 (the 1st to 253th amino acids) represented by SEQ ID NO: 18 is a protein composed of 253 amino acids, and the nucleotide sequence encoding the amino acid sequence is composed of 759 bases. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of hBSSP4 protein.

The amino acid sequence of mature mBSSP4 (the 1st to 259th amino acids) represented by SEQ ID NO: 20 is hBSSP4 mature or active type protein composed of 259 amino acids, and the nucleotide sequence encoding the amino acid

sequence is composed of 777 bases. The present inventors have shown that the serine protease activity is maintained even when one to several amino acids of the N-terminus of the mature type protein of the present invention is deleted or added, while the preferred sequence is this amino acid
5 sequence. The sequence of the -49th to -1st amino acids is the prepro or pro part and the amino acid sequence of the -15th to -1st amino acids is the pro part and is considered to be a precursor of mBSSP4 protein.

10 In general, many genes of eucaryote exhibit polymorphism and, sometimes, one or more amino acids are substituted by this phenomenon. Further, even in such case, sometimes, a protein maintains its activity. Then, the present invention includes a gene encoding a protein
15 obtained by modifying a gene encoding any one of the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20, artificially, in so far as the protein has the characteristic function of the gene of the present invention. Further, the present invention includes
20 a protein which is a modification of any one of amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 in so far as the protein has the characteristics of the present invention. Modification is understood to include substitution, deletion, addition
25 and/or insertion. In particular, the present inventors

have shown that, even when several amino acids are added to or deleted from the N-terminus amino acid of the hBSP4 or mBSP4 mature protein represented by SEQ ID NO: 2, 4, 6 or 20, the resultant sequence maintains its activity.

5 That is, the present invention includes a protein comprising any one of amino acid sequences described in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; an amino acid sequence encoded by any one of nucleotide sequences represented by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17
10 and 19; or one of these amino acid sequences wherein one to several amino acids have been substituted, deleted, added and/or inserted, and being belonging to serine protease family.

 Each codon for the desired amino acid itself has
15 been known and it can be selected freely. For example, codons can be determined according to a conventional manner by taking into consideration of frequency of use of codons in a host to be utilized (Grantham, R. et al., Nucleic Acids Res., 9, r43, 1989). Therefore, the present
20 invention also includes a nucleotide sequence appropriately modified by taking into consideration of degeneracy of a codon. Further, these nucleotide sequences can be modified by a site directed mutagenesis using a primer composed of a synthetic oligonucleotide encoding the desired modification
25 (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA., 81, 5662,

1984), or the like.

Furthermore, the DNA of the present invention includes DNA which is hybridizable to any one of nucleotide sequences described in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 5 15, 17 and 19 or nucleotide sequences complementary to these nucleotide sequences in so far as the protein encoded by the nucleotide sequence has the same properties as those of hBSSP4 or mBSSP4 of the present invention. It is considered that many of sequences which are hybridizable to 10 a given sequence under stringent conditions have a similar activity to that of a protein encoded by the given sequence. The stringent conditions according to the present invention includes, for example, incubation in a solution containing 5 x SSC, 5% Denhardt's solution (0.1% BSA, 0.1% Ficoll 1400, 15 0.1% PVP), 0.5% SDS and 20 µg/ml denatured salmon sperm DNA at 37°C overnight, followed by washing with 2 x SSC containing 0.1% SDS at room temperature. Instead of SSC, SSPE can be appropriately used.

Probes for detecting a hBSSP4 or mBSSP4 gene can 20 be designed based on any one of nucleotide sequences described in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19. Or, primers can be designed for amplifying DNA or RNA containing the nucleotide sequence. To design probes or primers is carried out routinely by a person skilled in the 25 art. An oligonucleotide having a designed nucleotide

sequence can be synthesized chemically. And, when a suitable label is added to the oligonucleotide, the resultant oligonucleotide can be utilized in various hybridization assay. Or, it can be utilized in nucleic acid synthesis reactions such as PCR. An oligonucleotide to be utilized as a primer has, preferably, at least 10 bases, more preferably 15 to 50 bases in length. An oligonucleotide to be utilized as a probe has, preferably, 100 bases to full length.

Moreover, it is possible to obtain a promoter region and an enhancer region of a hBSSP4 or mBSSP4 gene present in the genome based on the cDNA nucleotide sequence of hBSSP4 or mBSSP4 provided by the present invention. Specifically, these control regions can be obtained according to the same manner as described in JP 6-181767 A; J. Immunol., 155, 2477, 1995; Proc. Natl. Acad. Sci., USA, 92, 3561, 1995 and the like. The promoter region used herein means a DNA region which is present upstream from a transcription initiation site and controls expression of a gene. The enhancer region used herein means a DNA region which is present in an intron, a 5'-non-translated region or a 3'-non-translated region and enhances expression of a gene.

The present invention also relates to a vector comprising the nucleotide sequence represented by SEQ ID

NO: 1, 3, 5, 7, 9, 11, 13, 15, 17 or 19, or a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20, or a nucleotide sequence similar to these sequences. A
5 nucleotide sequence similar to a given nucleotide sequence used herein means a nucleotide sequence which is hybridizable to the given nucleotide sequence or its complementary nucleotide sequence under the above-described stringent conditions and encodes a protein having the same
10 properties as those of the protein encoded by the nucleotide sequence.

The vector is not specifically limited in so far as it can express the protein of the present invention. Examples thereof include pBAD/His, pRSETA, pcDNA2.1,
15 pTrcHis2A, pYES2, pBlueBac4.5, pcDNA3.1 and pSecTag2 manufactured by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by Pharmacia, pFastBAC1 manufactured by GIBCO and the like.
20 Preferably, a protein expression vector (described in the specification of a patent application entitled "Protein expression vector and its use" and filed by the same applicant on the same day) is used. This expression vector is constructed by using pCRII-TOPO vector described in the
25 Examples hereinafter, or a commercially available

expression vector, for example pSecTag2A vector or pSecTag2B vector (Invitrogen) and integrating a secretory signal nucleotide sequence suitable for expression of the protein of the present invention, in the 3' downstream side thereof, a Tag nucleotide sequence, a cleavable nucleotide sequence and a cloning site, into which a nucleotide sequence encoding a target protein can be inserted, in this order. More specifically, it is preferred to use trypsin signal as the secretory signal, a nucleotide sequence encoding polyhistidine as the Tag nucleotide sequence, and a nucleotide sequence encoding an amino acid sequence which is susceptible to enzyme-specific cleavage, i.e., a nucleotide sequence encoding the amino acid sequence of Asp-Asp-Asp-Asp-Lys (said amino acid sequence is recognized by enterokinase, and the recombinant fusion protein is cleaved at the C-terminus part thereof) as the cleavable nucleotide sequence.

Furthermore, the present invention provides transformed cells having the nucleotide sequence of the present invention in an expressible state by means of the above vector. Preferably, host cells to be used for the transformed cells of the present invention are animal cells and insect cells. However, host cells include any cells (including those of microorganisms) which can express a nucleotide sequence encoding the desired protein in the

expression vector of the present invention and can secrete extracellularly.

The animal cells and insect cells used herein include cells derived from human being and cells derived from fly or silk worm. For example, there are CHO cell, COS cell, BHK cell, Vero cell, myeloma cell, HEK293 cell, HeLa cell, Jurkat cell, mouse L cell, mouse C127 cell, mouse FM3A cell, mouse fibroblast, osteoblast, cartilage cell, S2, Sf9, Sf21, High Five™ (registered trade mark) cell and the like. The microorganisms used herein include *E. coli* and yeast.

The protein of the present invention as such can be expressed as a recombinant fused protein so as to facilitate isolation, purification and recognition. The recombinant fused protein used herein means a protein expressed as an adduct wherein a suitable peptide chain are added to the N-terminus and/or C-terminus of the desired protein expressed by a nucleotide sequence encoding the desired protein. The recombinant protein used herein means that obtained by integrating a nucleotide sequence encoding the desired protein in the expression vector of the present invention and cut off an amino acid sequence which derived from nucleic acids other than those encoding the desired protein from the expressed recombinant fused protein, and is substantially the same as the protein of the present

invention.

Introduction of the above vector into host cells can be carried out by, for example, transfection according to lipopolyamine method, DEAE-dextran method, Hanahan
5 method, lipofectin method or calcium phosphate method, microinjection, eletroporation and the like.

As described above, the present invention also relates to a process for producing hBSSP4 of mBSSP4 comprising culturing cells transformed with the above
10 nucleotide sequence of the present invention and collecting the produced hBSSP4 of mBSSP4. The culture of cells and separation and purification of the protein can be carried out by a per se known method.

The present invention also relates to an
15 inhibitor of the novel serine protease of the present invention. Screening of the inhibitor can be carried out according to a per se known method such as comparing the enzyme activity upon bringing into contact with a candidate compound with that without contact with the candidate
20 compound, or the like

The present invention relates to a non-human transgenic animal whose expression level of hBSSP4 or mBSSP4 gene has been altered. The hBSSP4 or mBSSP4 gene
used herein includes cDNA, genomic DNA or synthetic DNA
25 encoding hBSSP4 or mBSSP4. In addition, expression of a

gene includes any steps of transcription and translation. The non-human transgenic animal of the present invention is useful for studies of functions or expression control of hBSSP4 or mBSSP4, elucidation of mechanisms of diseases in
5 which hBSSP4 or mBSSP4 is presumed to be involved, and development of disease model animals for screening and safety test of medicine.

In the present invention, expression of a gene can be modified artificially by mutagenizing at a part of
10 several important sites which control normal gene expression (enhancer, promoter, intron, etc.) such as deletion, substitution, addition and/or insertion to increase or decrease an expression level of the gene in comparison with its inherent expression level. This
15 mutagenesis can be carried out according to a known method to obtain the transgenic animal.

In a narrow sense, the transgenic animal means an animal wherein a foreign gene is artificially introduced into reproductive cells by gene recombinant techniques. In
20 a broad sense, the transgenic animal includes an antisense transgenic animal the function of whose specific gene is inhibited by using antisense RNA, an animal whose specific gene is knocked out by using embryonic stem cells (ES cells), and an animal into which point mutation DNA is
25 introduced, and the transgenic animal means an animal into

which a foreign gene is stably introduced into a chromosome at an initial stage of ontogeny and the genetic character can be transmitted to the progeny.

5 The transgenic animal used herein should be understood in a broad sense and includes any vertebrates other than a human being. The transgenic animal of the present invention is useful for studies of functions or expression control of hBSSP4 or mBSSP4, elucidation of mechanisms of diseases associated with cells expressing in
10 a human being, and development of disease model animals for screening and safety test of medicine.

 As a technique for creating the transgenic animal, a gene is introduced into a nucleus in a pronucleus stage of egg cells with a micropipette directly under a phase-
15 contrast microscope (microinjection, U.S. Patent 4,873,191). Further, there are a method using embryonic stem cell (ES cell), and the like. In addition, there are newly developed methods such as a method wherein a gene is introduced into a retroviral vector or adenoviral vector to
20 infect egg cells, a sperm vector method wherein a gene is introduced into egg cells through sperms, and the like.

 A sperm vector method is a gene recombinant technique wherein a foreign gene is incorporated into sperm cells by adhesion, electroporation, etc., followed by
25 fertilization of egg cells to introduce the foreign gene

into the egg cells (M. Lavitrano et al., Cell, 57, 717, 1989). Alternatively, an in vivo site specific gene recombinant technique such as that using cre/loxP recombinase system of bacteriophage P1, FLP recombinase system of *Saccharomyces cerevisiae*, etc. can be used. Furthermore, introduction of a transgene of the desired protein into a non-human animal using a retroviral vector has been reported.

For example, a method for creating a transgenic animal by microinjection can be carried out as follows.

First, a transgene primarily composed of a promoter responsible for expression control, a gene encoding a specific protein and a poly A signal is required. It is necessary to confirm expression modes and amounts between respective systems because an expression mode and amount of a specific molecule is influenced by a promoter activity, and transgenic animals differ from each other according to a particular system due to the difference in a copy number of an introduced transgene and a introduction site on a chromosome. An intron sequence which is spliced may be previously introduced before the poly A signal because it has been found that an expression amount varies due to a non-translation region and splicing. Purity of a gene to be used for introduction into fertilized egg cells should be as high as possible. This is of importance.

Animals to be used include a mouse for collecting fertilized eggs (5 to 6 week old), a male mouse for mating, a false pregnancy female mouse, a seminiferous tubule-ligated mouse, and the like.

5 For obtaining fertilized egg cells efficiently, ovulation may be induced with gonadotropin or the like. Fertilized egg cells are recovered and a gene in an injection pipette is injected into male pronucleus of the egg cells by microinjection. For returning the injected
10 egg cells to a fallopian tube, an animal (false pregnancy female mouse, etc.) is provided and about 10 to 15 eggs/mouse are transplanted. Then, genomic DNA is extracted from the end part of the tail to confirm whether the transgene is introduced into newborn mouse or not.
15 This confirmation can be carried out by detection of the transgene with southern blot technique or PCR technique, or by positive cloning wherein a marker gene, which is activated only when homologous recombination is caused, has been introduced. Further, transcribed products derived
20 from the transgene are detected by northern blot technique or RT-PCR technique to confirm expression of the transgene. Or, western blotting can be carried out with a specific antibody to a protein.

 The knockout mouse of the present invention is
25 treated so that the function of mBSP4 gene is lost. A

knockout mouse means a transgenic mouse any of whose gene is destroyed by homologous recombination technique so that its function is deficient. A knockout mouse can be created by carrying out homologous recombination with ES cells and
5 selecting embryonic stem cells wherein either of allele genes are modified or destroyed. For example, embryonic stem cells whose genes are manipulated at blastocyte or morula stage of fertilized eggs are injected to obtain a chimera mouse wherein cells derived from the embryonic stem
10 cells are mixed with those derived from the embryo. The chimera mouse (chimera means a single individual formed by somatic cells based on two or more fertilized eggs) can be mated with a normal mouse to create a heterozygote mouse wherein all of either of the allele genes have been
15 modified or destroyed. Further, a homozygote mouse can be created by mating heterozygote mice.

Homologous recombination means recombination between two genes whose nucleotide sequences are the same or very similar to each other in terms of gene
20 recombination mechanism. PCR can be employed to select homologous recombinant cells. A PCR reaction can be carried out by using a part of a gene to be inserted and a part of a region where the insertion is expected as primers to find out occurrence of homologous recombination in cells
25 which give an amplification product. Further, for causing

homologous recombination in a gene expressed in embryonic stem cells, homologous recombinant cells can readily be selected by using a known method or its modification. For example, cells can be selected by joining a neomycin resistant gene to a gene to be introduced to impart neomycin resistance to cells after introduction.

The present invention also provide an antibody recognizing hBSSP4 or mBSSP4 or a fragment thereof. The antibody of the present invention includes an antibody against a protein having the amino acid sequence described in any of SEQ ID NOS: 2, 4, 6, 18 and 20 or its fragment. An antibody against hBSSP4 or mBSSP4 or a fragment thereof (e.g., polyclonal antibody, monoclonal antibody, peptide antibody) or an antiserum can be produced by using hBSSP4 or mBSSP4 or a fragment thereof, etc. as an antigen according to a per se known process for producing an antibody or an antiserum.

The hBSSP4 or mBSSP4 or a fragment thereof is administered to a site of a warm-blooded animal where an antibody can be produced by administration thereof as such or together with a diluent or carrier. For enhancing the antibody production, upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant may be administered. Normally, the administration is carried out once every 1 to 6 weeks, 2 to 10 times in all. Examples of

the warm-blooded to be used include monkey, rabbit, dog, guinea pig, mouse, rat, sheep, goat, chicken and the like with mouse and rat being preferred. As rats, for example, Wistar and SD rats are preferred. As mice, for example,
5 BALB/c, C57BL/6 and ICR mice are preferred.

For producing monoclonal antibody producer cells, individuals whose antibody titer have been recognized are selected from warm-blooded animals, e.g., a mouse immunized with an antigen. Two to 5 days after the last immunization,
10 the spleen or lymph node of the immunized animal is collected and antibody producer cells contained therein are subjected to cell fusion with myeloma cells to prepare a monoclonal antibody producer hybridoma. The antibody titer in an antiserum can be determined by, for example, reacting
15 the antiserum with a labeled hBSSP4 or mBSSP4 as described hereinafter, followed by measurement of the activity bound to the antibody. The cell fusion can be carried out according to a known method, for example, that described by Koehler and Milstein (Nature, 256, 495, 1975) or its
20 modifications (J. Immunol. Method, 39, 285, 1980; Eur. J. biochem, 118, 437, 1981; Nature, 285, 446, 1980). As a fusion promoting agent, there are polyethylene glycol (PEG), Sendai virus and the like. Preferably, PEG is used. Further, for improving fusion efficiency, lectin, poly-L-
25 lysine or DMSO can be appropriately added.

Examples of myeloma cells include X-63Ag8, NS-1, P3U1, SP2/0, AP-1 and the like with SP2/0 being preferred. The preferred ratio of the number of the antibody producer cells (spleen cells) : the number of spleen cells are 1 : 20 to 20 : 1. PEG (preferably PEG 1000 to PEG 6000) is added at a concentration of about 10 to 80% and the mixture is incubated at 20 to 40°C, preferably 30 to 37°C for 1 to 10 minutes to carry out the cell fusion efficiently. Screening of anti-hBSSP4 or mBSSP4 antibody producer hybridomas can be carried out by various methods. For example, a supernatant of a hybridoma culture is added to a solid phase to which hBSSP4 or mBSSP4 antigen is adsorbed directly or together with a carrier (e.g., microplate), followed by addition of an anti-immunoglobulin antibody (in case that the cells used in cell fusion is those of a mouse, anti-mouse immunoglobulin antibody is used) or protein A to detect the anti-hBSSP4 or mBSSP4 monoclonal antibody attached to the solid phase. Or, a supernatant of a hybridoma culture is added to a solid phase to which an anti-immunoglobulin antibody or protein A is adsorbed, followed by addition of hBSSP4 or mBSSP4 labeled with a radioactive substance, an enzyme, etc., to detect the anti-hBSSP4 or mBSSP4 monoclonal antibody attached to the solid phase.

Selection and cloning of the anti-hBSSP or mBSSP

monoclonal antibody can be carried out according to a per se known method or its modification. Normally, a HAT (hypoxanthine, aminopterin, thymidine)-added medium for culturing animal cells is used. Any culture medium can be used for selection, cloning and growing up in so far as the hybridoma can grow. For example, there can be used RPMI culture medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, or a serum-free medium for culturing hybridomas. Preferably, the culture is carried out at a temperature of about 37°C. Normally, the culture time is 5 days to 3 weeks, preferably 1 weeks to 2 weeks. Normally, the culture is carried out under 5% CO₂. The antibody titer of a supernatant of a hybridoma culture can be measured according to the same manner as that of the above-described measurement of anti-BSSP4 antibody titer in an antiserum. That is, examples of the measurement to be used include radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), FIA (fluorescence immunoassay), plaque assay, agglutination reaction method, and the like. Among them, ELISA as shown blew is preferred.

Screening by ELISA

A protein prepared according to the same operation as that for an immunogen is immobilized on the surface of each well of an ELISA plate. Next, BSA, MSA, OVA, KLH, gelatin, skimmed milk, or the like is immobilized

on each well to prevent non-specific adsorption. A supernatant of a hybridoma culture is added to each well and is allowed to stand for a given time so that an immunological reaction proceeds. Each well is washed with
5 a washing solution such as PBS or the like. Preferably, a surfactant is added to this washing solution. An enzyme labeled secondary antibody is added and allowed to stand for a given time. As the enzyme to be used for the label, there can be used β -galactosidase, alkaline phosphatase,
10 peroxidase and the like. After washing each well with the same washing solution, a substrate solution of the labeled enzyme used is added so that an enzymatic reaction proceeds. When the desired antibody is present in the supernatant of a hybridoma culture, the enzymatic reaction proceeds and
15 the color of the substrate solution is changed.

Normally, cloning is carried out by a per se known method such as semi-solid agar method, limiting dilution method and the like. Specifically, after confirming a well in which the desired antibody is produced
20 by the above-described method, cloning is carried out to obtain a single clone. For cloning, it is preferred to employ limiting dilution method wherein hybridoma cells are diluted so that one colony is formed per one well of a culture plate. For cloning by limiting dilution method,
25 feeder cells can be used, or a cell growth factor such as

interleukin 6, etc. can be added to improve colony forming capability. In addition, cloning can be carried out by using FACS and single cell manipulation method. The cloned hybridoma is preferably cultured in a serum-free culture medium and an optimal amount of an antibody is added to its supernatant. The single hybridoma thus obtained can be cultured in a large about by using a flask or a cell culture device, or cultured in the abdominal cavity of an animal (J. Immunol. Meth., 53, 313, 1982) to obtain a monoclonal antibody. When culturing in a flask, there can be used a cell culture medium (e.g., IMDM, DMEM, RPMI1640, etc.) containing 0 to 20% of FCS. When culturing in the abdominal cavity of an animal, the animal to be used is preferably the same species or the same line as that from which the myeloma cells used in the cell fusion are derived, a thymus deficient nude mouse or the like, and the hybridoma is transplanted after administration of a mineral oil such as pristane, etc. After 1 to 2 weeks, myeloma cells are proliferated in the abdominal cavity to obtain ascites containing a monoclonal antibody.

The monoclonal antibody of the present invention which does not cross-react with other proteins can be obtained by selecting a monoclonal antibody which recognizes an epitope specific to hBSSP4 or mBSSP4. In general, an epitope presented by an amino acid sequence

composed of at least 3, preferably 7 to 20 successive amino acid residues in an amino acid sequence which constitutes a particular protein is said to be an inherent epitope of the protein. Then, a monoclonal antibody recognizing an epitope constituted by a peptide having an amino acid sequence composed of at least 3 successive amino acid residue selected from the amino acid residues disclosed in any of SEQ ID NOS: 2 and 4 can be said to be the monoclonal antibody specific for hBSSP4 or mBSSP4 of the present invention. An epitope common to BSSP4 family can be selected by selecting an amino acid sequence conservative among the amino acid sequences described in SEQ ID NOS: 2 and 4. Or, in case of a region containing an amino acid sequence specific for each sequence, a monoclonal antibody which can differentiate respective proteins can be selected.

Separation and purification of the anti-hBSSP4 or mBSSP4 monoclonal antibody, like a conventional polyclonal antibody, can be carried out according to the same manner as those of immunoglobulins. As a known purification method, there can be used a technique, for example, salting out, alcohol precipitation, isoelectric precipitation, electrophoresis, ammonium sulfate precipitation, absorption and desorption with an ion exchange material (e.g., DEAE), ultrafiltration, gel filtration, or specific purification by collecting only an antibody with an antibody-binding

solid phase or an active adsorber such as protein A or protein G, etc., and dissociating the binding to obtain the antibody. For preventing formation of aggregates during purification or decrease in the antibody titer, for example, human serum albumin is added at a concentration of 0.05 to 2%. Alternatively, amino acids such as glycine, α -alanine, etc., in particular, basic amino acids such as lysine, arginine, histidine, etc., saccharides such as glucose, mannitol, etc., or salts such as sodium chloride, etc. can be added. In case of IgM antibody, since it is very liable to be aggregated, it may be treated with β -propiolactone and acetic anhydride.

The polyclonal antibody of the present invention can be produced according to a per se known method or its modification. For example, an immunogen (protein antigen) per se or a complex thereof with a carrier protein is prepared and, according to the same manner as that in the above monoclonal antibody production, a warm-blooded animal is immunized. A material containing an antibody against the protein of the present invention or its fragment is collected from the immunized animal and the antibody is separated and purified to obtain the desired antibody. As for a complex of an immunogen and a carrier protein for immunizing a warm-blooded animal, the kind of a carrier protein and the mixing ratio of a carrier and a hapten are

not specifically limited in so far as an antibody against the hapten immunized by cross-linking with the carrier is efficiently produced. For example, there can be used about 0.1 to 20, preferably about 1 to 5 parts by weight of bovine serum albumin, bovine cycloglobulin, hemocyanin, etc. coupled with one part by weight of a hapten. For coupling a carrier and a hapten, various condensing agents can be used. Examples thereof include glutaraldehyde, carbodiimide or maleimide active ester, active ester agents having thiol group or dithiopyridyl group, and the like. The condensed product is administered as such or together with a carrier or diluent to a site of a warm-blooded animal where an antibody can be produced. For enhancing the antibody production, upon administration, Freund's complete adjuvant or Freund's incomplete adjuvant may be administered. Normally, the administration is carried out once every 2 to 6 weeks, 3 to 10 times in all. The polyclonal antibody can be collected from blood, ascites, or the like, preferably blood of the immunized animal. The polyclonal antibody titer in an antiserum can be measured according to the same manner as measurement of the above monoclonal antibody titer in the antiserum. Separation and purification of the polyclonal antibody, like the above monoclonal antibody, can be carried out according to the same manner as those of immunoglobulins.

The monoclonal antibody and polyclonal antibody against hBSSP4 or mBSSP4 or a fragment thereof can be utilized for diagnosis and treatment of diseases associated with cells expressing hBSSP4 or mBSSP4. By using these antibodies, hBSSP4 or mBSSP4 or a fragment thereof can be determined based on their immunological binding to hBSSP4 or mBSSP4 or a fragment thereof of the present invention. Specifically, examples of a method for determining hBSSP4 or mBSSP4 or a fragment thereof in a specimen by using these antibodies include a sandwich method wherein the antibody attached to an insoluble carrier and the labeled antibody are reacted with hBSSP4 or mBSSP4 or a fragment thereof to form a sandwich complex and the sandwich complex is detected, as well as a competitive method wherein labeled hBSSP4 or mBSSP4, and hBSSP4 or mBSSP4 or a fragment thereof in the specimen are competitively reacted with the antibody and hBSSP4 or mBSSP4 or a fragment thereof in the specimen is determined based on the amount of the labeled antigen reacted with the antibody.

As a sandwich method for determining hBSSP4 or mBSSP4 or a fragment thereof, there can be used two step method, one step method and the like. In two step method, first, the immobilized antibody is reacted with hBSSP4 or mBSSP4 or a fragment thereof and then unreacted materials are completely removed by washing, followed by addition of

the labeled antibody to form immobilized antibody-hBSSP4 or mBSSP4-labeled antibody. In one step method, the immobilized antibody, labeled antibody and hBSSP4 or mBSSP4 or a fragment thereof are added at the same time.

5 Examples of an insoluble carrier used for the determination include synthetic resins such as polystyrene, polyethylene, polypropylene, polyvinyl chloride, polyester, polyacrylate, nylon, polyacetal, fluorine plastic, etc.; polysaccharides such as cellulose, agarose, etc.; glass;
10 metal; and the like. An insoluble carrier may be shaped in various forms, for example, tray, sphere, fiber, rod plate, container, cell, test tube, and the like. The antibody adsorbed by a carrier is stored at a cold place in the presence of an appropriate preservative such as sodium
15 azide or the like.

For immobilization of the antibody, a known chemical bonding method or a physical adsorption can be used. Examples of a chemical bonding method include a method using glutaraldehyde; maleimide method using N-
20 succusinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, N-succusinimidyl-2-maleimide acetate or the like; carbodiimide method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; or the like. In addition, there are maleimidobenzoyl-N-
25 hydroxysuccinimide ester method, N-succinimidyl-3-(2-

pyridylthio)propionic acid method, bisdiazobenzidine method, and dipalmityllysine method. Or, it is possible to capture a complex formed beforehand by reacting a material to be tested with two antibodies, whose epitopes are different, with an immobilized 3rd antibody against the antibody.

For labeling, it is preferred to use enzyme, fluorescent substance, luminous substance, radioactive substance, metal chelate, or the like. Examples of the enzyme include peroxidase, alkaline phosphatase, β -D-galactosidase, malate dehydrogenase, *Staphylococcus* nuclease, δ -5-steroidisomerase, α -glycerol phosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, asparaginase, glucose oxidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase and the like. Examples of the fluorescent substance include fluorescein isothiocyanate, phycobiliprotein, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde, and the like. Examples of the luminous substance include isoluminol, lucigenin, luminol, aromatic acridinium ester, imidazole, acridinium salt and its modified ester, luciferin, luciferase, aequorin and the like. Examples of the radioactive substance include ^{125}I , ^{127}I , ^{131}I , ^{14}C , ^3H , ^{32}P , ^{35}S and the like. The labeling material is not limited to them and any material which can be used for immunological

determination can be used. Further, a low molecular weight hapten such as biotin, dinitrophenyl, pyridoxal or fluorescamine may be attached to the antibody. Preferably, horseradish peroxidase is used as a labeling enzyme. This
5 enzyme can be reacted with various substrates and can readily be attached to the antibody by periodate method.

When an enzyme is used as a labeling material, a substrate and, if necessary, a coloring enzyme is used for measuring its activity. In case of using peroxidase as the
10 enzyme, H_2O_2 is used as a substrate and, as a coloring agent, there can be used 2,2'-azino-di-[3-ethylbenzthiazoline sulfonic acid] ammonium salt (ABTS), 5'-aminosalicylic acid, o-phenylenediamine, 4-aminoantipyrine, 3,3',5,5'-tetramethylbenzidine and the
15 like. In case of using alkaline phosphatase as the enzyme, o-nitrophenylphosphate, p-nitrophenylphosphoric acid, or the like can be used as a substrate. In case of using β -D-galactosidase as the enzyme, fluorescein-d-(β -D-galactopyranoside),
4-methylumbelliphenyl- β -D-galactopyranoside, or the like can be used as a substrate.
20 The present invention also include a kit comprising the above monoclonal antibody, polyclonal antibody and reagents.

As a cross-linking agent, a known cross-linking agent such as N,N'-o-phenylenedimaleimide, 4-(N-maleimidomethyl)cyclohexanoate-N-succinimide ester, 6-
25

maleimidohexanoate-N-succineimide ester, 4,4'-
dithiopyridine or the like can be utilized. The reaction
of these cross-linking agents with enzymes and antibodies
can be carried out by a known method according to
5 properties of a particular cross-linking agent. Further,
as the antibody, a fragment thereof, for example, Fab', Fab,
F(b'2) can be used as the case may be. A labeled enzyme
can be obtained by the same treatment regardless of whether
the antibody is polyclonal or monoclonal. When the above
10 labeled enzyme obtained by using a cross-linking agent is
purified by a known method such as affinity chromatography
or the like, a immunoassay system having more higher
sensitivity can be obtained. The enzyme labeled and
purified antibody is stored at a dark cold place with
15 addition of a stabilizer such as thimerosal, glycerin or
after lyophilization.

An objective to be determined is not specifically
limited in so far as it is a sample containing BSSP4 or a
fragment thereof, or a sample containing a precursor of
20 BSSP4 or a fragment thereof and includes body fluids such
as plasma, serum, blood, serum, urine, tissue fluid,
cerebrospinal fluid and the like.

The following Examples further illustrate the
present invention in detail but are not construed to limit
25 the scope thereof.

Example 1

Cloning of novel serine protease mBSSP4 gene

The cloning was carried out by PCR using a human brain cDNA library (Clontech) as a template and nucleotide sequences corresponding to an amino acid sequence common to serine proteases represented by

Primer 1: GTG CTC ACN GCN GCB CAY TG (SEQ ID NO: 30)

Primer 2: CCV CTR WSD CCN CCN GGC GA (SEQ ID NO: 31)

as primers. Namely, 5 µl of the template, 5 µl of 10 x ExTaq buffer, 5 µl of dNTP, 10 pmol of each of the above primers and 0.5 µl of ExTaq (TAKARA) were added and the total volume was adjusted to 50 µl with sterilized water. PCR was carried out by repeating a cycle of heating at 94°C for 0.5 minute, at 55°C for 0.5 minute and then at 72°C for 1 minutes, 35 times. The PCR product was mixed with pCR II-TOPO vector attached to TOPO TA cloning kit (Invitrogen) and the mixture was allowed to stand at room temperature for 5 minutes. Then, according to a conventional manner, *E. coli* Top 10 attached to the kit was transformed and applied to a LB (Amp^r) plate (containing 100 µg/ml of ampicillin). According to a conventional manner, a plasmid was extracted from each colony obtained and its nucleotide sequence was determined by cycle sequencing method with a fluorescence sequencer (ABI). Homology of the sequence of each clone was examined by means of GenBank. Regarding an unknown

sequence, i.e., BSSP4 gene, the full length cDNA was obtained by 5' RACE and 3' RACE and, according to the same manner as described above, the nucleotide sequence was determined. Namely, BSSP4 clone specific primers, GSP1
5 primers [hBSSP4F1 (SEQ ID NO: 32) or hBSSP4R1 (SEQ ID NO: 36)] and GSP2 primers [hBSSP4F2 (SEQ ID NO: 33) or hBSSP4R2 (SEQ ID NO: 37)] were prepared. PCR was carried out by using human brain Marathon-Ready cDNA (Clontech), AP1 primer attached to this reagent and either of the above
10 GSP1 primers and heating at 94°C for 2 minutes once and repeating a cycle of heating at 94°C for 30 seconds, at 60°C for 30 seconds and then at 72°C for 30 seconds 35 times. Then, 5 µl of the PCR product diluted to 1/100, 5 µl of 10 x buffer, 5 µl of dNTP, 10 pmol of either of 10 µM
15 of the above GSP2 primer, 10 pmol of AP2 primer attached to the above reagent and 0.5 unit of ExTaq were admixed and adjusted to 50 µl with sterilized water. Then, according to the same manner as the above, PCR was carried out. The PCR product was cloned by the above TOPO TA cloning kit and
20 sequenced to obtain the upstream and downstream regions of the above clone. At this time, as for a clone which seemed not to cover the full length of a protein, the specific primers shown hereinafter were prepared based on the newly found nucleotide sequence. Further, based on this sequence,
25 the primers capable of amplifying ORF as shown hereinafter

[hBSSP4F6 (SEQ ID NO: 35) and hBSSP4R3/E (SEQ ID NO: 38) or hBSSP4R4/E (SEQ ID NO: 39)] were prepared and PCR carried out using human brain Marathon-ready cDNA as a template to confirm that these clones were identical. This was cloned
5 into pCR II-TOPO vector attached to TOPO TA cloning kit to obtain the plasmid pCR II/hBSSP4 containing the full length cDNA clone. The nucleotide sequence of DNA contained in this plasmid is shown in SEQ ID NO: 1 and the amino acid sequence of hBSSP4 protein deduced from the nucleotide
10 sequence is shown in SEQ ID NO: 2. Further, two different types of clones were obtained. The amino acid sequence of hBSSP4 represented by SEQ ID NO: 2 (the 1st to 268th amino acids) is hBSSP4 mature or active type protein composed of 268 amino acids. In the amino acid sequence represented by
15 SEQ ID NO: 2, the -49th to -1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of hBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys represented by the 39th to 42nd amino acids and
20 Asp-Ser-Gly-Gly-Pro represented by the 192nd to 196th amino acids and there are one or more Asp's between these consensus sequences.

Further, 8 clones having different nucleotide sequences, perhaps, caused by alternative splicing were
25 obtained. The nucleotide sequences thereof are shown in

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15 and 17. Further, the amino acid sequences thereof deduced from these nucleotide sequences are shown in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16 and 18. As described above, in these sequences, there are those having either or both consensus sequences of serine proteases and those having no consensus sequences of serine proteases. There is a possibility that these gene products (transcription product or translation product) have a function of control factors for serine proteases.

According to the same manner, 5' RACE and 3' RACE were carried out by using the primers as described hereinafter and mouse brain Marathon-Ready cDNA (Clontech) as a template, followed by cloning to obtain mouse homologous gene pCRII/mBSSP4. The nucleotide of DNA containing this plasmid is shown by SEQ ID NO: 19 and the amino acid sequence of mBSSP4 protein deduced from this nucleotide sequence is shown in SEQ ID NO: 20. The amino acid sequence of mBSSP4 represented by SEQ ID NO: 20 (the 1st to 259th amino acids) is mBSSP4 mature or active type protein composed of 259 amino acids. In the amino acid sequence represented by SEQ ID NO: 20, the -49th to 1st amino acids are a prepro or pro part and the -15th to -1st amino acids are a pro part and are considered to be a precursor of mBSSP4. As consensus sequences of serine proteases, there are Ala-Ala-His-Cys (the 39th to 42nd

amino acids) and Asp-Ser-Gly-Gly-Pro (the 192nd to 196th amino acids) and there are one or more Asp's between the consensus sequences.

human BSSP4

5	hBSSP4F1	Forward	AGGTCCTATCATCGACTCG	RACE
				(SEQ ID NO: 32)
	hBSSP4F2	Forward	TGAGGACATGCTGTGTGCCGG	RACE
				(SEQ ID NO: 33)
	hBSSP4F3	Forward	GTGTGGGCGGCGAGGACAG	mature
10				(SEQ ID NO: 34)
	hBSSP4F6	Forward	GCCATGGTGGTTTCTGGAGC	FL*
				(SEQ ID NO: 35)
	hBSSP4R1	Reverse	TATGGTTGTTCAGGTTGTCC	RACE
				(SEQ ID NO: 36)
15	hBSSP4R2	Reverse	AGGGCAATGTCTGCACAGGC	RACE
				(SEQ ID NO: 37)
	hBSSP4R3/E	Reverse	CTGAATTCCTAGGAGCGCGCGGCC	FL*
				(SEQ ID NO: 38)
	hBSSP4R4/E	Reverse	GAGAATTCGATATGTGGGCAGGGTTACA	FL*
20				(SEQ ID NO: 39)
	mouse BSSR4			
	mBSSP4.1	Forward	ACAAACCATCTCTGTTCTCAG	RACE
				(SEQ ID NO: 40)
	mBSSP4F2	Forward	GTCCCAGAAAGTAGGCATTG	RACE
25				(SEQ ID NO: 41)

mBSSP4F3 Forward CTCCACCCATACCAGCAATG FL*
 (SEQ ID NO: 42)

mBSSP4F4 Forward ATTGTGGGAGGTGAGGACAG mature
 (SEQ ID NO: 43)

5 mBSSP4.2 Reverse TGCAGAGTTCGGAGTCGATG RACE
 (SEQ ID NO: 44)

mBSSP4R2 Reverse ATCCAGCAGTCGGTCTTGGG RACE
 (SEQ ID NO: 45)

mBSSP4R3/P Reverse ATTCTGCAGTTCCTTGTTCTCTCGCTCAGG FL*
 10 (SEQ ID NO: 46)

*: for full length

Example 2

Expression hBSSP4 or mBSSP4 gene in human being
 and mouse internal organs

15 According to the protocol of QuickPrep Micro mRNA
 purification Kit (Amersham-Pharmacia), mRNAs were isolated
 from various internal organs of Balb/c mice or their
 fetuses. They were subjected to electrophoresis according
 to a conventional manner and transcribed to a nylon
 20 membrane. A probe was prepared separately by isolating a
 part of a nucleotide sequence encoding the mature protein
 of mBSSP4 from pCR II/mBSSP4, purifying it and labeling it
 with α -³²P dCTP. The probe was diluted with 5 x SSC and
 reacted with the above membrane filter at 65°C for a whole
 25 day and night. Likewise, a probe was prepared by isolating

a part of a nucleotide sequence encoding the mature protein of hBSSP4 from PCR II/hBSSP4, purifying it and labeling it with α -³²P dCTP, and diluted with 5 x SSC and the dilution was reacted with human multiple tissue blot, human multiple tissue blot II and human brain multiple blot II (Clontech) membrane. Then, the filter was washed twice each with 2 x SSC/0.1% SDS at room temperature for 30 minutes, 1 x SSC/0.1% SDS at room temperature for 30 minutes and 0.1 x SSC/0.1% SDS at 65°C for 30 minutes. The filter was exposed to an imaging plate for FLA2000 (Fuji Film) for one day to analyze the expression. The results shown in the drawings are those obtained by using human multiple tissue blot membrane (Fig. 1), human multiple tissue blot II membrane (Fig. 2), human brain multiple blot II membrane (Fig. 3) and mRNAs prepared from various internal organs of 3-month-old mice (Fig. 4) and mRNAs prepared from prostates of 1-month-old, 3-month-old and 12-month-old mice (Fig. 5). In addition, the mRNAs prepared above were subjected to RT-PCR by using Ready To Go RT-PCR Beads (Amersham-Pharmacia) and hBSSP4 and mBSSP4 gene specific primers (human being: SEQ ID NOS: 33 and 38 or 39, mouse: SEQ ID NOS: 40 and 44) according to the protocol attached to the kit.

As seen from Figs. 1 to 3, in case of northern blotting analysis, the expression of hBSSP4 was recognized

in prostate (Fig. 2, the band between 1.35 to 2.4 kb) and cerebellum (Fig. 3, the band between 1.35 and 2.4 kb). The expression of mBSSP4 was recognized in prostate and skeletal muscle (Fig. 4). Further, according to the results of RT-PCR, the expression of hBSSP4 was recognized in brain, placenta, testicle and prostate of from fetuses to adults of human beings and the expression of mBSSP4 was recognized in prostate of newborns to adults of mice. Then, it is considered that the novel serine proteases of the present invention have various roles in brain, prostate, placenta, testicle and skeletal muscle. Further, the presence of the transcribed product (about 1.4 to 1.5 kb) having the nucleotide sequence of SEQ ID NO: 7 has been confirmed by the above northern blotting analysis.

Example 3

Expression of novel serine proteases encoded by hBSSP4 or mBSSP4 gene

(1) Construction of expression plasmid

A cDNA region encoding the mature form of hBSSP4 or mBSSP4 protein was amplified by PCR using the plasmid pCR II/hBSSP4 or pCR II/mBSSP4 as a template (the primers used were those having the sequences of SEQ ID NOS: 34 and 39 for a human being and those having the sequences of SEQ ID NOS: 43 and 46 for mouse). The PCR product was ligated to pTrc-HisB (Invitrogen) which had been digested with

BamHI and blunted with mung bean nuclease. *E. coli* JM109 was transformed by the resultant and colonies formed were analyzed by PCR to obtain *E. coli* containing the desired serine protease expressing plasmid pTrcHis/hBSSP4 or pTrcHis/mBSSP4.

The resultant *E. coli* strains were designated *E. coli* pTrcHis/hBSSP4 and *E. coli* pTrcHis/mBSSP4, respectively, and deposited at National Institute of Bioscience and Human-Technology (NIBH), Agency of Industrial Science & Technology of 1-1-3 Higashi, Tsukubashi, Ibaraki-ken, Japan on October 29, 1998 under the accession numbers of FERM P-17037 and FERM P-17034, respectively.

(2) Expression of protein by *E. coli* containing expression plasmid

A single colony of *E. coli* having the expression plasmid was inoculated in 10 ml of LB (Amp^r) culture medium and incubated at 37°C overnight. This was inoculated in 250 ml of LB (Amp^r) culture medium and incubated at 37°C. When the absorbance at 600 nm became 0.5, 250 μ l of 0.1 M IPTG (isopropyl- β -D-(-)-thiogalactopyranoside) was added and the incubation was continued for additional 5 hours. The *E. coli* was centrifuged and suspended in a cell disruption buffer (10 mM phosphate buffer pH 7.5, 1 mM EDTA) and sonicated on ice to disrupt *E. coli*. This was

centrifuged at 14,000 r.p.m. for 20 minutes to obtain a precipitate. The precipitate was washed twice with a cell disruption buffer containing 0.5% Triton X-100™ and washed with water to remove Triton X-100™. Then, the resultant mixture was dissolved by soaking in a denaturation buffer containing 8 M urea (8M urea, 50 mM Tris pH8.5, 20 mM ME) at 37°C for 1 hour. The solution was passed through TALON metal affinity resin (Clontech), washed with the denaturation buffer containing 10 mM imidazole, and then eluted with the denaturation buffer containing 100 mM imidazole to purify the solution. The purified product was dialyzed against PBS for 3 days with exchanging the buffer every other night to obtain the protein hBSSP4-His or mBSSP4-His.

Example 4

Expression of novel serine protease mature protein encoded by hBSSP4 gene by using pFBTrypSigTag/hBSSP4

(1) Construction of pFBTrypSigTag/hBSSP4

The sequences represented by SEQ ID NOS: 21 and 22 were subjected to annealing and digested with NheI and BamHI. The resultant fragment was inserted into Nhe-I-BamHI digested pSecTag2A (Invitrogen) to obtain pSecTrypHis. Twenty units of BamHI was added to 5 µg of pSecTrypHis vector and the vector was cleaved at 37°C over 4 hours.

Then, 6 units of mung bean nuclease (TAKARA) was added thereto and reacted at room temperature (25°C) for 30 minutes to blunt the terminal ends. Further, the 3'-terminus side of the cloning site was cleaved with 20 units of XhoI, 1 unit of bacterial alkaline phosphatase (TAKARA) was added thereto and the reaction was carried out at 65°C for 30 minutes.

According to the same manner as that described in JP 9-149790 A or Biochim. Biophys. Acta, 1350, 11, 1997, mRNA was prepared from COLO201 cells and cDNA was synthesized to obtain the plasmid pSPORT/neurosin. cDNA of an active region of neurosin was obtained from pSPORT/neurosin by PCR using primers having the sequences represented by SEQ ID NOS: 23 and 24. Ten units of XhoI was reacted with the PCR product at 37°C for 3 hours to cleave XhoI site at the 3'-side thereof. This was inserted into pSecTrypHis by TAKARA ligation kit to obtain pSecTrypHis/neurosin (Fig. 6).

Amplification was carried out by using the primers having the sequences represented by SEQ ID NOS: 25 and 26 so that the peptide of Leu-Val-His-Gly was present at the C-terminus of the part from trypsin signal to the enterokinase recognition site of pSecTrypHis/neurosin. This was inserted between NheI and HindIII sites of pSecTag2A to construct the plasmid pTrypSig.

One μg (0.1 μl) of the plasmid pSecTab2A was treated with the restriction enzymes NheI and BamHI to completely remove a region encoding the leader sequence of IgGk. One hundred pmol portions of DANs represented by SEQ
5 ID NOS: 47 and 48 were added to the resultant solution and the mixture was heated at 70°C for 10 minutes and subjected to annealing by allowing to stand at room temperature for 30 minutes. Two μl of I solution of DNA ligation kit Ver. 2 (TAKARA) was added to 1 μl portions of His secretory
10 signal sequence and pSecTag2A treated by NheI and BamHI and the reaction was carried out at 16°C for 30 minutes.

To the reaction mixture was add 0.1 ml of *E. coli* competent cell XL1-Blue (STRATAGENE) and reacted on ice for 30 minutes. Then, the reaction mixture was subjected to
15 heat shock at 42°C for 60 seconds. After standing on ice for 2 minutes, 0.9 ml of SOC culture medium (Toyo Boseki K.K.) was added thereto and the mixture was shaken with a shaker at 37°C for 1 hour. The mixture was centrifuged at 5,000 r.p.m. for 1 minutes and the supernatant was
20 discarded. The precipitated competent cells were suspended in the liquid remained in the centrifuge tube and the suspension was applied to an ampicillin LB plates containing 100 $\mu\text{g}/\text{ml}$ of ampicillin. The plates were incubated at 37°C overnight. Among the colonies formed, a
25 colony into which DNA of His secretory signal was inserted

was selected by PCR to obtain pTrypHis.

A sequence of about 200 bp containing His Tag region of pTrypHis was amplified by using primers having the sequence represented by SEQ ID NOS: 26 and 27 and a
5 fragment of about 40 bp containing His Tag and enterokinase recognizing site formed by digestion of HindIII and BamHI was inserted into pTrypSig to construct pTrypSigTag (Fig. 7A).

cDNA was prepared by PCR of the sequence from
10 trypsin signal to enterokinase recognizing site of pTrypSigTag using primers having the sequences represented by SEQ ID NOS: 24 and 28 and cut out by digestion with BglII and BamHI. It was inserted into BamHI site of pFastBAC1 (GIBCO). The insertion direction was confirmed
15 by PCR using primers having the sequences represented by SEQ ID NOS 24 and 29. A clone into which the cDNA was inserted in the direction toward transcription and translation by polyhedrin promoter was selected to obtain pFBTrypSigTag.

20 Twenty units of BamHI was added to 5 µg of pFBTrypSigTag vector and the vector was cleaved at 37°C over 4 hours, followed by addition of 6 units of mung bean nuclease (TAKARA) and reaction at room temperature (25°C) for 30 minutes to blunt the terminal ends. Further, the
25 3'-side of the cloning site was cleaved by 20 units of

EcoRI, followed by addition of 1 unit of bacterial alkaline phosphatase (TAKARA). The reaction was carried out at 65°C for 30 minutes.

cDNA of the active region of hBSSP4 was obtained
5 by PCR according to a conventional manner using
pTrcHis/hBSSP4 prepared from *E. coli* pTrcHis/hBSSP4
(accession No. FERM P-17037) or pCRII/hBSSP4. The
resultant cDNA was inserted into pFBTrypSigTag to obtain
pFBTrypSigTag/hBSSP4 (Fig. 7B). At this time, correct
10 insertion of hBSSP4 was confirmed by determining the
sequence.

Bacmid DNA was transformed with
pFBTrypSigTag/hBSSP4 according to a protocol of Gibco BRL
BAC-TO-BAC baculovirus expression system to prepare a
15 recombinant bacmid having chimera hBSSP4 fused with
trypsinogen signal peptide, His tag and enterokinase
recognizing site. When this was expressed in Sf-9 cell
according to a manual of BAC-TO-BAC baculovirus expression
system, it was secreted in the culture supernatant from 2
20 days after infection of the virus.

According to the same manner as described above,
pFETrypSigTag/mBSSP4 can be prepared and secreted by using
pTrcHis/mBSSP4 obtained from *E. coli* pTrcHis/mBSSP4
(accession No. FERM P-17034) or pCRII/mBSSP4 obtained in
25 Example 1.

(2) Determination of enzyme activity

The recombinant fused protein hBSSP4 obtained in the culture supernatant was passed through a chelate column to purify it and, after dialysis, its enzyme activity was determined. First, the culture supernatant was applied to a chelate column (Ni-NTA-Agarose, Qiagen) with PBS buffer and eluted stepwise with a solution of imidazole (Wako Pure Chemical Industries, Ltd.) dissolved in PBS. The resultant imidazole-eluted fraction was applied to a PD-10 column (Pharmacia) to exchange to PBS buffer. Fifty μ l of this sample was mixed with 10 μ l of enterokinase (1 U/1 μ l, Invitrogen) and the reaction was carried out at room temperature for 60 minutes. Each of various synthetic substrates (Peptide Laboratory, Boc-Gln-Ala-Arg-MCA, Boc-Phe-Ser-Arg-MCA, Bz-Arg-MCA, Boc-Val-Leu-Lys-MCA, Pyr-Gly-Arg-MCA, Pro-Phe-Arg-MCA, Boc-Val-Pro-Arg-MCA, Z-Arg-Arg-MCA, Arg-MCA, Z-Phe-Arg-MCA) was dissolved in DMSO and diluted with 1 M Tris-HCl (pH 8.0) to obtain a substrate solution. Fifty μ l of 0.2 M substrate solution was added thereto and further the reaction was carried out at 37°C. After one hour, the fluorescence of AMC (7-amino-4-methylcoumalin) formed by the enzymatic reaction was measured at 380 nm of excitation wavelength and 460 nm of fluorescence wavelength to determine the activity.

As a result, the recombinant fused protein hBSSP4

has been shown to have serine protease activity. Likewise, mBSSP4 derived from a mouse showed the activity.

INDUSTRIAL UTILITY

5 According to the present invention, there are provided isolated human and mouse serine protease (hBSSP4 and mBSSP4) polynucleotides, their homologous forms, mature forms, precursors and polymorphic variants. Further, according to the present invention, there are provided
10 hBSSP4 and mBSSP4 proteins as well as compositions containing hBSSP4 and mBSSP4 polynucleotides and proteins, their production and use.

SEQUENCE LISTING FREE TEXT

15

SEQ ID NO: 21: Designed oligonucleotide to construct plasmid pSecTrypHis

SEQ ID NO: 22: Designed oligonucleotide to construct plasmid pSecTrypHis

20 SEQ ID NO: 23: Designed oligonucleotide primer to amplify neurosin-encoding sequence

SEQ ID NO: 24: Designed oligonucleotide primer to amplify neurosin-encoding sequence

25 SEQ ID NO: 25: Designed oligonucleotide primer to amplify a portion of plasmid pSecTrypHis/Neurosin

SEQ ID NO: 26: Designed oligonucleotide primer to amplify a portion of plasmid pSecTrypHis/Neurosin

SEQ ID NO: 27: Designed oligonucleotide primer to amplify a portion of plasmid pTrypHis

5 SEQ ID NO: 28: Designed oligonucleotide primer to amplify a portion of plasmid pTrypSigTag

SEQ ID NO: 29: Designed oligonucleotide primer to amplify a portion of plasmid pFBTrypSigTag

10 SEQ ID NO: 30: Designed oligonucleotide primer to amplify conserved region of serin proteases-encoding sequence; n is a, c, g or t.

SEQ ID NO: 31: Designed oligonucleotide primer to amplify conserved region of serin proteases-encoding sequence; n is a, c, g or t.

15 SEQ ID NO: 32: Designed oligonucleotide primer designated as hBSSP4F1 for RACE for human BSSP4 (forward)

SEQ ID NO: 33: Designed oligonucleotide primer designated as hBSSP4F2 for RACE for human BSSP4 (forward)

20 SEQ ID NO: 34: Designed oligonucleotide primer designated as hBSSP4F3 to amplify mature human BSSP4-encoding region (forward)

SEQ ID NO: 35: Designed oligonucleotide primer designated as hBSSP4F6 to amplify full-length human BSSP4-encoding mRNA (forward)

25 SEQ ID NO: 36: Designed oligonucleotide primer

designated as hBSSP4R1 for RACE for human BSSP4 (reverse)

SEQ ID NO: 37: Designed oligonucleotide primer
designated as hBSSP4R2 for RACE for human BSSP4 (reverse)

5 SEQ ID NO: 38: Designed oligonucleotide primer
designated as hBSSP4R3/E to amplify full-length human
BSSP4-encoding mRNA (reverse)

SEQ ID NO: 39: Designed oligonucleotide primer
designated as hBSSP4R4/E to amplify full-length human
BSSP4-encoding mRNA (reverse)

10 SEQ ID NO: 40: Designed oligonucleotide primer
designated as mBSSP4.1 for RACE for mouse BSSP4 (forward)

SEQ ID NO: 41: Designed oligonucleotide primer
designated as mBSSP4F2 for RACE for mouse BSSP4 (forward)

15 SEQ ID NO: 42: Designed oligonucleotide primer
designated as mBSSP4F3 to amplify full-length mouse BSSP4-
encoding mRNA (forward)

SEQ ID NO: 43: Designed oligonucleotide primer
designated as mBSSP4F4 to amplify mature mouse BSSP4-
encoding region (forward)

20 SEQ ID NO: 44: Designed oligonucleotide primer
designated as mBSSP4.2 for RACE for mouse BSSP4 (reverse)

SEQ ID NO: 45: Designed oligonucleotide primer
designated as mBSSP4R2 for RACE for mouse BSSP4 (reverse)

25 SEQ ID NO: 46: Designed oligonucleotide primer
designated as mBSSP4R3/P to amplify full-length mouse

BSSP4-encoding mRNA (reverse)

SEQ ID NO: 47: Designed oligonucleotide to
construct plasmid pTrypHis

5 SEQ ID NO: 48: Designed oligonucleotide to
construct plasmid pTrypHis

What is claimed is:

1. A protein having the amino acid sequence composed of 268 amino acids represented by the 1st to 268th amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO: 2; or a modified derivative thereof.

2. A nucleotide sequence represented by the 151st to 954th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 268th amino acids of SEQ ID NO: 2.

3. A protein having the amino acid sequence composed of 270 amino acids represented by the 1st to 270th amino acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO: 4

by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO: 4; or a modified derivative thereof.

4. A nucleotide sequence represented by the 151st to 960th bases of SEQ ID NO: 3; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO: 4; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 270th amino acids of SEQ ID NO: 4.

5. A protein having the amino acid sequence composed of 257 amino acids represented by the 1st to 257th amino acids of SEQ ID NO: 6; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO: 6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO: 6; or a modified derivative thereof.

6. A nucleotide sequence represented by the 151st to 921st bases of SEQ ID NO: 5; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 257th amino acids of SEQ ID NO: 6; or a nucleotide sequence
5 hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 257th amino acids of SEQ
10 ID NO: 6.

7. A protein having the amino acid sequence composed of 97 amino acids represented by the 1st to 97th amino acids of SEQ ID NO: 8; or a protein having an amino acid sequence derived from the amino acid sequence
15 represented by the 1st to 97th amino acids of SEQ ID NO: 8 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO: 8; or a modified
20 derivative thereof.

8. A nucleotide sequence represented by the 151st to 441st bases of SEQ ID NO: 7; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 97th amino acids of SEQ ID NO: 8; or a nucleotide sequence
25 hybridizable with a nucleotide sequence which is

complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 97th amino acids of SEQ

5 ID NO: 8.

9. A protein having the amino acid sequence composed of 158 amino acids represented by the 1st to 158th amino acids of SEQ ID NO: 10; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO: 10 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO: 10; or a modified
10
15 derivative thereof.

10. A nucleotide sequence represented by the 151st to 624th bases of SEQ ID NO: 9; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 158th amino acids of SEQ ID NO: 10; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 158th amino acids of SEQ
20
25 ID NO: 10.

11. A protein having the amino acid sequence composed of 82 amino acids represented by the 1st to 82nd amino acids of SEQ ID NO: 12; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO: 12 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO: 12; or a modified derivative thereof.

12. A nucleotide sequence represented by the 151th to 396th bases of SEQ ID NO: 11; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 82nd amino acids of SEQ ID NO: 12; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 82th amino acids of SEQ ID NO: 12.

13. A protein having the amino acid sequence composed of 185 amino acids represented by the 1st to 185th amino acids of SEQ ID NO: 14; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO:

14 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO: 14; or a modified derivative thereof.

14. A nucleotide sequence represented by the 151st to 705th bases of SEQ ID NO: 13; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO: 14; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 185th amino acids of SEQ ID NO: 14.

15. A protein having the amino acid sequence composed of 80 amino acids represented by the 1st to 80th amino acids of SEQ ID NO: 16; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO: 16 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO: 16; or a modified derivative thereof.

16. A nucleotide sequence represented by the 151st to 390th bases of SEQ ID NO: 15; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 80th amino acids of SEQ ID NO: 16; or a
5 nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 80th amino acids of
10 SEQ ID NO: 16.

17. A protein having the amino acid sequence composed of 253 amino acids represented by the 1st to 253rd amino acids of SEQ ID NO: 18; or a protein having an amino acid sequence derived from the amino acid sequence
15 represented by the 1st to 253rd amino acids of SEQ ID NO: 18 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO: 18; or a modified
20 derivative thereof.

18. A nucleotide sequence represented by the 151st to 909th bases of SEQ ID NO: 17; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO: 18; or a
25 nucleotide sequence hybridizable with a nucleotide sequence

which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 253rd amino acids of SEQ ID NO: 18.

19. A protein having the amino acid sequence composed of 34 amino acids represented by the -49th to -16th amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 2; or a modified derivative or fragment thereof.

20. A nucleotide sequence represented by the 4th to 105th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 2; or a fragment thereof.

21. A protein having the amino acid sequence composed of 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 2; or a modified derivative or fragment thereof.

22. A nucleotide sequence represented by the 106th to 150th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 2; or a fragment thereof.

23. A protein having the amino acid sequence composed of 259 amino acids represented by the 1st to 259th amino acids of SEQ ID NO: 20; or a protein having an amino acid sequence derived from the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO:

20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO: 20; or a modified derivative thereof.

24. A nucleotide sequence represented by the 227th to 1003rd bases of SEQ ID NO: 19; a nucleotide sequence encoding the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO: 20; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the 1st to 259th amino acids of SEQ ID NO: 20.

25. A protein having the amino acid sequence composed of 34 amino acids represented by the -49th to -16th amino acids of SEQ ID NO: 20; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 20; or a modified derivative or fragment thereof.

26. A nucleotide sequence represented by the 80th to 181st bases of SEQ ID NO: 19; a nucleotide sequence encoding the amino acid sequence represented by the -49th to -16th amino acids of SEQ ID NO: 20; or a nucleotide
5 sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to -16th amino acids of
10 SEQ ID NO: 20; or a fragment thereof.

27. A protein having the amino acid sequence composed of 15 amino acids represented by the -15th to -1st amino acids of SEQ ID NO: 20; or a protein having an amino acid sequence derived from the amino acid sequence
15 represented by the -15th to -1st amino acids of SEQ ID NO: 20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 20; or a modified
20 derivative or fragment thereof.

28. A nucleotide sequence represented by the 182th to 226th bases of SEQ ID NO: 19; a nucleotide sequence encoding the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 20; or a
25 nucleotide sequence hybridizable with a nucleotide sequence

which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to -1st amino acids of SEQ ID NO: 20; or a fragment thereof.

29. A protein having the amino acid sequence composed of 317 amino acids represented by the -49th to 268th amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO: 2; or a modified derivative thereof.

30. A nucleotide sequence represented by the 4th to 954th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 268th amino acids of SEQ ID NO: 2.

31. A protein having the amino acid sequence composed of 283 amino acids represented by the -15th to 268th amino acids of SEQ ID NO: 2; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO: 2 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO: 2; or a modified derivative thereof.

32. A nucleotide sequence represented by the 106th to 954th bases of SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO: 2; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 268th amino acids of SEQ ID NO: 2.

33. A protein having the amino acid sequence composed of 319 amino acids represented by the -49th to 270th amino acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO:

4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO: 4; or a modified
5 derivative thereof.

34. A nucleotide sequence represented by the 4th to 960th bases of SEQ ID NO: 3; a nucleotide sequence encoding the amino acid sequence represented by the -49th to 270th amino acids of SEQ ID NO: 4; or a nucleotide
10 sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 270th amino acids of
15 SEQ ID NO: 4.

35. A protein having the amino acid sequence composed of 285 amino acids represented by the -15th to 270th amino acids of SEQ ID NO: 4; or a protein having an amino acid sequence derived from the amino acid sequence
20 represented by the -15th to 270th amino acids of SEQ ID NO: 4 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO: 4; or a modified
25 derivative thereof.

36. A nucleotide sequence represented by the 106th to 960th bases of SEQ ID NO: 3; a nucleotide sequence encoding the amino acid sequence represented by the -15th to 270th amino acids of SEQ ID NO: 4; or a nucleotide
5 sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 270th amino acids of
10 SEQ ID NO: 4.

37. A protein having the amino acid sequence composed of 306 amino acids represented by the -49th to 257th amino acids of SEQ ID NO: 6; or a protein having an amino acid sequence derived from the amino acid sequence
15 represented by the -49th to 257th amino acids of SEQ ID NO: 6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO: 6; or a modified
20 derivative thereof.

38. A nucleotide sequence represented by the 4th to 921th bases of SEQ ID NO: 5; a nucleotide sequence encoding the amino acid sequence represented by the -49th to 257th amino acids of SEQ ID NO: 6; or a nucleotide
25 sequence hybridizable with a nucleotide sequence which is

complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 257th amino acids of
5 SEQ ID NO: 6.

39. A protein having the amino acid sequence composed of 272 amino acids represented by the -15th to 257th amino acids of SEQ ID NO: 6; or a protein having an amino acid sequence derived from the amino acid sequence
10 represented by the -15th to 257th amino acids of SEQ ID NO: 6 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO: 6; or a modified
15 derivative thereof.

40. A nucleotide sequence represented by the 106th to 921th bases of SEQ ID NO: 5; a nucleotide sequence encoding the amino acid sequence represented by the -15th to 257th amino acids of SEQ ID NO: 6; or a nucleotide
20 sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 257th amino acids of
25 SEQ ID NO: 6.

41. A protein having the amino acid sequence composed of 308 amino acids represented by the -49th to 259th amino acids of SEQ ID NO: 20; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO: 20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO: 20; or a modified derivative thereof.

42. A nucleotide sequence represented by the 80th to 1003rd bases of SEQ ID NO: 19; a nucleotide sequence encoding the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO: 20; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -49th to 259th amino acids of SEQ ID NO: 20.

43. A protein having the amino acid sequence composed of 274 amino acids represented by the -15th to 259th amino acids of SEQ ID NO: 20; or a protein having an amino acid sequence derived from the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO:

20 by deletion, substitution or addition of one to several amino acids and having the same property as that of the protein having the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO: 20; or a modified derivative thereof.

44. A nucleotide sequence represented by the 182nd to 1003rd bases of SEQ ID NO: 19; a nucleotide sequence encoding the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO: 20; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein having the amino acid sequence represented by the -15th to 259th amino acids of SEQ ID NO: 20.

45. A nucleotide sequence represented by SEQ ID NO: 1; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 1.

46. A nucleotide sequence represented by SEQ ID NO: 3; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above

nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 3.

5 47. A nucleotide sequence represented by SEQ ID NO: 5; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein
10 encoded by the nucleotide sequence represented by SEQ ID NO: 5.

 48. A nucleotide sequence represented by SEQ ID NO: 7; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above
15 nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID
NO: 7.

 49. A nucleotide sequence represented by SEQ ID
20 NO: 9; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID
25 NO: 9.

50. A nucleotide sequence represented by SEQ ID NO: 11; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding
5 a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 11.

51. A nucleotide sequence represented by SEQ ID NO: 13; or a nucleotide sequence hybridizable with a
10 nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 13.

52. A nucleotide sequence represented by SEQ ID NO: 15; or a nucleotide sequence hybridizable with a
15 nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein
20 encoded by the nucleotide sequence represented by SEQ ID NO: 15.

53. A nucleotide sequence represented by SEQ ID NO: 17; or a nucleotide sequence hybridizable with a
25 nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding

a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 17.

54. A nucleotide sequence represented by SEQ ID NO: 19; or a nucleotide sequence hybridizable with a nucleotide sequence which is complementary to the above nucleotide sequence under stringent conditions and encoding a protein having the same property as that of the protein encoded by the nucleotide sequence represented by SEQ ID NO: 19.

55. A vector comprising the nucleotide sequence according to any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 44-54.

56. Transformed cells having the nucleotide sequence according to any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42 and 44-54 in an expressible state.

57. A process for producing a protein which comprises culturing cells transformed with the nucleotide sequence according to any one of claims 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 30, 32, 34, 36, 38, 40 and 45-53, and collecting hBSSP4 produced.

58. A process for producing a protein which comprises culturing cells transformed with the nucleotide

sequence according to any one of claims 24, 26, 28, 42, 44 or 54, and collecting mBSSP4 produced.

59. The process according to claim 57 or 58, wherein the cells are *E. coli* cells, animal cells or insect cells.

60. A non-human transgenic animal whose expression level of BSSP4 gene has been altered.

61. The non-human transgenic animal according to claim 60, wherein BSSP4 gene is cDNA, genomic DNA or synthetic DNA encoding BSSP4.

62. The non-human transgenic animal according to claim 60, wherein the expression level has been altered by mutating a gene expression regulatory site.

63. A knockout mouse whose mBSSP4 gene function is deficient.

64. An antibody against the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43 or a fragment thereof.

65. The antibody according to claim 64 which is a polyclonal antibody, a monoclonal antibody or a peptide antibody.

66. A process for producing a monoclonal antibody against the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31,

33, 35, 37, 39, 41 and 43 or a fragment thereof which comprises administering the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43 or a fragment thereof to a warm-blooded animal other than a human being, selecting the animal whose antibody titer is recognized, collecting its spleen or lymph node, fusing the antibody producing cells contained therein with myeloma cells to prepare a monoclonal antibody producing hybridoma.

67. A method for determining the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43 or a fragment thereof in a specimen which is based on immunological binding of an antibody against the protein or a fragment thereof to the protein or a fragment thereof.

68. A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a monoclonal antibody or a polyclonal antibody against the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35, 37 and 39 or a fragment thereof and a labeled antibody with hBSSP4 or a fragment thereof in the specimen to detect a sandwich complex produced.

69. A method for determining hBSSP4 or a fragment thereof in a specimen which comprises reacting a

monoclonal antibody or a polyclonal antibody against the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35, 37 and 39 or a fragment thereof with labeled hBBSP4 and hBSSP4 or a fragment thereof in the specimen competitively to detect an amount of hBSSP4 or a fragment thereof in the specimen based on an amount of the labeled hBBSP4 reacted with the antibody.

70. The method according to any one of claims 67-69, wherein the specimen is a body fluid.

71. A diagnostic marker for diseases in tissues comprising the protein according to any one of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41 and 43.

72. The marker according to claim 71 to be used for diagnosis of Alzheimer's disease or epilepsy in brain.

73. The marker according to claim 71 to be used for diagnosis of cancer or inflammation of brain, prostate or testicle.

74. The marker according to claim 71 to be used for diagnosis of sterility in semen or sperms


75. The marker according to claim 71 to be used for diagnosis of prostatic hypertrophy in prostate.

Abstract of the disclosure:

There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences encoding the same; transgenic non-human animals with altered expression level of a serine protease BSSP4; an antibody against BSSP4; and a method for detecting BSSP4 in a specimen by using the antibody.

1/7


Fig. 1



2/7

Fig. 2


hBSSP-4



3/7


Fig. 3

hBSSP-4



4 / 7


Fig. 4



5/7


Fig. 5

mBSSP-4




6 / 7

Fig. 6



7/7

Fig. 7



Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL SERINE PROTEASE BSSP4

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appl. No. _____; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an
 international (PCT) application, PCT/JP99/06472; filed 19/11/1999, entry requested on
 _____; national stage application received U.S. Appl. No. _____; §371/§102(c)
 date _____ (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 and 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority is claimed:

347813/1998	Japan	20/11/1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or prior PCT application(s) designating the U.S. listed below, or under §119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

_____	_____	_____
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444; i.e.,

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from AOYAMA & PARTNERS as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

Page 2 of 2 Pages

Atty. Docket:

Title: NOVEL SERINE PROTEASE BSSP4
 U.S. Application filed _____ Serial No. _____
 PCT Application filed Nov. 19, 1999 Serial No. PCT/JP99/06472

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR <u>Hidetoshi UEMURA</u>		INVENTOR'S SIGNATURE <u>Hidetoshi Uemura</u>	DATE <u>Apr. 17, 2001</u>
RESIDENT <u>Itami-shi, Hyogo Japan</u>		CITIZENSHIP <u>Japan</u>	
POST OFFICE ADDRESS <u>133, Minamisuzuhara 3-chome, Itami-shi, Hyogo Japan</u>			
FULL NAME OF SECOND JOINT INVENTOR <u>Akira OKUI</u>		INVENTOR'S SIGNATURE <u>Akira Okui</u>	DATE <u>Apr. 17, 2001</u>
RESIDENT <u>Yamatokoriyama-shi, Nara Japan</u>		CITIZENSHIP <u>Japan</u>	
POST OFFICE ADDRESS <u>275-3, 603-0000 Tsutsui-cho, Yamatokoriyama-shi, Nara Japan</u>			
FULL NAME OF THIRD JOINT INVENTOR <u>Katsuya KOMINAMI</u>		INVENTOR'S SIGNATURE <u>Katsuya Kominami</u>	DATE <u>Apr. 17, 2001</u>
RESIDENT <u>Hannan-shi, Osaka Japan</u>		CITIZENSHIP <u>Japan</u>	
POST OFFICE ADDRESS <u>786-2, Jinenda, Hannan-shi, Osaka Japan</u>			
FULL NAME OF FOURTH JOINT INVENTOR <u>Nozomi YAMAGUCHI</u>		INVENTOR'S SIGNATURE <u>Nozomi Yamaguchi</u>	DATE <u>Apr. 17, 2001</u>
RESIDENT <u>Kyoto-shi, Kyoto Japan</u>		CITIZENSHIP <u>Japan</u>	
POST OFFICE ADDRESS <u>285-79, Shingoryoguchi-cho, Teramachinishi-iru, Kuramaguchi-dori, Kita-ku, Kyoto-shi, Kyoto Japan</u>			
FULL NAME OF FIFTH JOINT INVENTOR <u>Shinichi MITSUI</u>		INVENTOR'S SIGNATURE <u>Shinichi Mitsui</u>	DATE <u>Apr. 17, 2001</u>
RESIDENT <u>Kyoto-shi, Kyoto Japan</u>		CITIZENSHIP <u>Japan</u>	
POST OFFICE ADDRESS <u>202, Kitashirakawa-koporasu, 86, Kitashirakawanishi-machi, Sakyo-ku, Kyoto-shi, Kyoto Japan</u>			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENT		CITIZENSHIP	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THIS DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

SEQUENCE LISTING

5 <110> Fuso Pharmaceutical Industries Ltd.

<120> Novel serine protease BSSP4

<130> 661639

10

<150> JP 10-347813

<151> 1998-11-20

<160> 48

15

<210> 1

<211> 1282

<212> DNA

<213> human

20

<400> 1

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc ggc 51

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45

-40

-35

acc ttc acc tcc ctg ctg ctg ctg gcg tgc aca gcc atc ctc aat gcg gcc 102

25

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

	-30	-25	-20	
	agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt	153		
	Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val			
	-15	-10	-5	-1 1
5	gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc	204		
	Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile			
	5	10	15	
	cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg	255		
	Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp			
10	20	25	30	35
	gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg	306		
	Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu			
	40	45	50	
	ttc tct gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tct cgg tcc	357		
15	Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser			
	55	60	65	
	cag aag gtg ggt gtt gcc tgg gtg gag ccc cac cct gtg tat tcc tgg aag	408		
	Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys			
	70	75	80	85
20	gaa ggt gcc tgt gca gac att gcc ctg gtg cgt ctc gag cgc tcc ata cag	459		
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln			
	90	95	100	
	ttc tca gag cgg gtc ctg ccc atc tgc cta cct gat gcc tct atc cac ctc	510		
	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu			
25	105	110	115	120

cct cca aac acc cac tgc tgg atc tca ggc tgg ggg agc atc caa gat gga 561
 Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly
 125 130 135
 gtt ccc ttg ccc cac cct cag acc ctg cag aag ctg aag gtt cct atc atc 612
 5 Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile
 140 145 150
 gac tcg gaa gtc tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc 663
 Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro
 155 160 165 170
 10 atc act gag gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct 714
 Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala
 175 180 185
 tgt ctg ggc gac tcc ggg ggc ccc ctc atg tgc cag gtg gac ggc gcc tgg 765
 Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp
 15 190 195 200 205
 ctg ctg gcc ggc atc atc agc tgg ggc gag ggc tgt gcc gag cgc aac agg 816
 Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg
 210 215 220
 ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg ttg gag aag atc 867
 20 Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile
 225 230 235
 gtg caa ggg ttg cag ctc cgc ggg cgc gct cag ggg ggt ggg gcc ctc agg 918
 Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu Arg
 240 245 250 255
 25 gca ccg agc cag ggc tct ggg gcc gcc gcg cgc tcc tagggcgag cgggacgcgg974

Ala Pro Ser Gln Gly Ser Gly Ala Ala Ala Arg Ser

260

265

ggctcggatc tgaaggcgg ccagatccac atctggatct ggatctgcgg cggcctcggg 1034

cggtttcccc cgccgtaaat aggetcatct acctctacct ctggggggccc ggacggctgc 1094

5 tgcggaaagg aaacccctc ccgaccgc ccgacggcct caggcccgcc cctccaaggc 1154

atcaggcccc gccaacggc ctcattgtcc cgccccacg acttcggcc cgccccggg 1214

gccccagcgc ttttgttat ataatgtta atgattttta taggtatttg taacctgcc 1274

cacatatac 1282

10 <210> 2

<211> 317

<212> PRT

<213> human

15 <400> 2

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys leu Gly

-45

-40

-35

Thr Phe Thr Ser Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

20

-30

-25

-20

Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

-15

-10

-5

-1 1

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

5

10

15

25 Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp

	20	25	30	35
	Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu			
	40	45	50	
	Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser			
5	55	60	65	
	Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys			
	70	75	80	85
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln			
	90	95	100	
10	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu			
	105	110	115	120
	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly			
	125	130	135	
	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile			
15	140	145	150	
	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro			
	155	160	165	170
	Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala			
	175	180	185	
20	Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp			
	190	195	200	205
	Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg			
	210	215	220	
	Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile			
25	225	230	235	

Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu Arg

240 245 250 255

Ala Pro Ser Gln Gly Ser Gly Ala Ala Ala Arg Ser

260 265

5

<210> 3

<211> 1007

<212> DNA

<213> human

10

<400> 3

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc gcc 51

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45 -40 -35

15 acc ttc acc tcc ctg ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc 102

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30 -25 -20

agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153

Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

20 -15 -10 -5 -1 1

gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

5 10 15

cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg 255

25 Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp

	20	25	30	35	
	gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg	306			
	Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu				
	40	45	50		
5	ttc tct gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tct cgg tcc	357			
	Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser				
	55	60	65		
	cag aag gtg ggt gtt gcc tgg gtg gag ccc cac cct gtg tat tcc tgg aag	408			
	Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys				
10	70	75	80	85	
	gaa ggt gcc tgt gca gac att gcc ctg gtg cgt ctc gag cgc tcc ata cag	459			
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln				
	90	95	100		
	ttc tca gag cgg gtc ctg ccc atc tgc cta cct gat gcc tct atc cac ctc	510			
15	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu				
	105	110	115	120	
	cct cca aac acc cac tgc tgg atc tca ggc tgg ggg agc atc caa gat gga	561			
	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly				
	125	130	135		
20	gtt ccc ttg ccc cac cct cag acc ctg cag aag ctg aag gtt cct atc atc	612			
	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile				
	140	145	150		
	gac tcg gaa gtc tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc	663			
	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro				
25	155	160	165	170	

atc act gag gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct 714
 Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala
 175 180 185
 tgt ctg ggc gac tcc ggg ggc ccc ctc atg tgc cag gtg gac ggc gcc tgg 765
 5 Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp
 190 195 200 205
 ctg ctg gcc ggc atc atc agc tgg ggc gag ggc tgt gcc gag cgc aac agg 816
 Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg
 210 215 220
 10 ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg gtg gag aag atc 867
 Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile
 225 230 235
 gtg caa ggg gtg cag ctc cgc ggg cgc gct cag ggg ggt ggg gcc ctc agg 918
 Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu Arg
 15 240 245 250 255
 gca ccg agc cag ggc tct ggg gcc cca gcg ctt ttg tgt ata taaatgttaa 970
 Ala Pro Ser Gln Gly Ser Gly Ala Pro Ala Leu Leu Cys Ile
 260 265 270
 tgatttttat aggtatttgt aaccctgcc acatatc 1007
 20
 <210> 4
 <211> 319
 <212> PRT
 <213> human

<400> 4

	Met	Val	Val	Ser	Gly	Ala	Pro	Pro	Ala	Leu	Gly	Gly	Gly	Cys	Leu	Gly	
					-45					-40						-35	
	Thr	Phe	Thr	Ser	Leu	Leu	Leu	Leu	Ala	Ser	Thr	Ala	Ile	Leu	Asn	Ala	Ala
5				-30					-25				-20				
	Arg	Ile	Pro	Val	Pro	Pro	Ala	Cys	Gly	Lys	Pro	Gln	Gln	Leu	Asn	Arg	Val
				-15			-10					-5				-1	1
	Val	Gly	Gly	Glu	Asp	Ser	Thr	Asp	Ser	Glu	Trp	Pro	Trp	Ile	Val	Ser	Ile
				5					10					15			
10	Gln	Lys	Asn	Gly	Thr	His	His	Cys	Ala	Gly	Ser	Leu	Leu	Thr	Ser	Arg	Trp
				20				25					30				35
	Val	Ile	Thr	Ala	Ala	His	Cys	Phe	Lys	Asp	Asn	Leu	Asn	Lys	Pro	Tyr	Leu
					40					45					50		
	Phe	Ser	Val	Leu	Leu	Gly	Ala	Trp	Gln	Leu	Gly	Asn	Pro	Gly	Ser	Arg	Ser
15			55					60					65				
	Gln	Lys	Val	Gly	Val	Ala	Trp	Val	Glu	Pro	His	Pro	Val	Tyr	Ser	Trp	Lys
	70					75						80					85
	Glu	Gly	Ala	Cys	Ala	Asp	Ile	Ala	Leu	Val	Arg	Leu	Glu	Arg	Ser	Ile	Gln
					90					95					100		
20	Phe	Ser	Glu	Arg	Val	Leu	Pro	Ile	Cys	Leu	Pro	Asp	Ala	Ser	Ile	His	Leu
			105					110					115				120
	Pro	Pro	Asn	Thr	His	Cys	Trp	Ile	Ser	Gly	Trp	Gly	Ser	Ile	Gln	Asp	Gly
					125					130					135		
	Val	Pro	Leu	Pro	His	Pro	Gln	Thr	Leu	Gln	Lys	Leu	Lys	Val	Pro	Ile	Ile
25			140							145				150			

10

Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro

155

160

165

170

Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala

175

180

185

5

Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp

190

195

200

205

Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg

210

215

220

Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile

10

225

230

235

Val Gln Gly Val Gln Leu Arg Gly Arg Ala Gln Gly Gly Gly Ala Leu Arg

240

245

250

255

Ala Pro Ser Gln Gly Ser Gly Ala Pro Ala Leu Leu Cys Ile

260

265

270

15

<210> 5

<211> 1036

<212> DNA

<213> human

20

<400> 5

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc gcc 51

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45

-40

-35

25

acc ttc acc tcc ctg ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc 102

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
 -30 -25 -20
 agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153
 Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
 5 -15 -10 -5 -1 1
 gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204
 Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
 5 10 15
 cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg 255
 10 Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
 20 25 30 35
 gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg 306
 Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu
 40 45 50
 15 ttc tet gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tet cgg tcc 357
 Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser
 55 60 65
 cag aag gtg ggt gtt gcc tgg gtg gag ccc cac cct gtg tat tcc tgg aag 408
 Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys
 20 70 75 80 85
 gaa ggt gcc tgt gca gac att gcc ctg gtg cgt ctc gag cgc tcc ata cag 459
 Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln
 90 95 100
 ttc tca gag cgg gtc ctg ccc atc tgc cta cct gat gcc tet atc cac ctc 510
 25 Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu

	105	110	115	120	
	cct cca aac acc cac tgc tgg atc tca ggc tgg ggg agc atc caa gat gga	561			
	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly				
	125	130	135		
5	gtt ccc ttg ccc cac cct cag acc ctg cag aag ctg aag gtt cct atc atc	612			
	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile				
	140	145	150		
	gac tgc gaa gtc tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc	663			
	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro				
10	155	160	165	170	
	atc act gag gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct	714			
	Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala				
	175	180	185		
	tgt ctg ggc gac tcc ggg ggc ccc ctc atg tgc cag gtg gac ggc gcc tgg	765			
15	Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp				
	190	195	200	205	
	ctg ctg gcc ggc atc atc agc tgg ggc gag ggc tgt gcc gag cgc aac agg	816			
	Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg				
	210	215	220		
20	ccc ggg gtc tac atc agc ctc tct gcg cac cgc tcc tgg gtg gag aag atc	867			
	Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile				
	225	230	235		
	gtg caa ggg gtg cag ctc cgc ggg cgc ccc cgg gcc cca gcg ctt ttg tgt	918			
	Val Gln Gly Val Gln Leu Arg Gly Arg Pro Arg Ala Pro Ala Leu Leu Cys				
25	240	245	250	255	

ata taaatgttaa tgatttttat aggtatttgt aacctgccc acatatctta 971

Ile

ttttattecte caatttcaat aaattattta tttccagaa aaaaaaaaa aaaaaaaaa 1031

5 aaaaa 1036

<210> 6

<211> 306

<212> PRT

10 <213> human

<400> 6

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45 -40 -35

15 Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30 -25 -20

Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

-15 -10 -5 -1 1

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

20 5 10 15

Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp

20 25 30 35

Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu

40 45 50

25 Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser

14

	55	60	65	
	Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys			
	70	75	80	85
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln			
5	90	95	100	
	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu			
	105	110	115	120
	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly			
	125	130	135	
10	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile			
	140	145	150	
	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro			
	155	160	165	170
	Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala			
15	175	180	185	
	Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln Val Asp Gly Ala Trp			
	190	195	200	205
	Leu Leu Ala Gly Ile Ile Ser Trp Gly Glu Gly Cys Ala Glu Arg Asn Arg			
	210	215	220	
20	Pro Gly Val Tyr Ile Ser Leu Ser Ala His Arg Ser Trp Val Glu Lys Ile			
	225	230	235	
	Val Gln Gly Val Gln Leu Arg Gly Arg Pro Arg Ala Pro Ile Leu Leu Cys			
	240	245	250	255
	Ile			

25

15

<210> 7

<211> 1232

<212> DNA

<213> human

5

<400> 7

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc ggc 51

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45

-40

-35

10 acc ttc acc tcc ctg ctg ctg ctg gcg tgc aca gcc atc ctc aat gcg gcc 102

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30

-25

-20

agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153

Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

15

-15

-10

-5

-1 1

gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

5

10

15

cag aag aat ggg acc cac cac tgc gca gga caa cct gaa caa acc ata cct 255

20 Gln Lys Asn Gly Thr His His Cys Ala Gly Gln Pro Glu Gln Thr Ile Pro

20

25

30

35

gtt ctc tgt gct gct ggg ggc ctg gca gct ggg gaa ccc tgg ctc tgc gtc 306

Val Leu Cys Ala Ala Gly Gly Leu Ala Ala Gly Glu Pro Trp Leu Ser Val

40

45

50

25 cca gaa ggt ggg tgt tgc ctg ggt gga gcc cca ccc tgt gta ttc ctg gaa 357

Pro Glu Gly Gly Cys Cys Leu Gly Gly Ala Pro Pro Cys Val Phe Leu Glu

55

60

65

gga agg tgc ctg tgc aga cat tgc cct ggt gcg tct cga gcg ctc cat aca 408

Gly Arg Cys Leu Cys Arg His Cys Pro Gly Ala Ser Arg Ala Leu His Thr

5

70

75

80

85

gtt ctc aga gcg ggt cct gcc cat ctg cct acc tgaatcctct atccacctcc 461

Val Leu Arg Ala Gly Pro Ala His Leu Pro Thr

90

95

ctccaaacac ccactgctgg atctcaggct gggggagcat ccaagatgga gttcccttgc 521

10

cccaccctca gaccctgcag aagctgaagg ttctatcat cgactcgaa gtctgcagcc 581

atctgtactg gcggggagca ggacagggaac ccactactga ggacatgctg tgtccggct 641

acttgagggg ggagcgggat gcttgtcttg gcgactccgg gggccccctc atgtgccagg 701

tggacggcgc ctggctgctg gccggcatca tcagctgggg cgagggtgt gccgagcgca 761

acaggccccg ggtctacatc agcctctctg cgcaccgctc ctgggtggag aagatcgtgc 821

15

aagggggtgca gctccggggg cgcgctcagg ggggtggggc cctcaggcca ccgagccagg 881

gctctggggc cgcgcgcgcg tcttagggcg cagcgggacg cggggctcgg atctgaaagg 941

cggccagatc cacatctgga tctggatctg cggcggcctc ggcggtttc ccccgccgta 1001

aataggctca tctacctcta cctctggggg cccggacggc tgcctcgaa aggaaccccc 1061

ctccccgacc cgcgccagcg cctcaggccc cgccctccaa ggcatcagge ccgcccacac 1121

20

ggcctcatgt ccccgcccc acgactccg gcccccccc cgggccccag cgtttttgtg 1181

tataataatg ttaatgattt ttataggtag ttgtaaccct gccacatat c 1232

<210> 8

<211> 146

25

<212> PRT

<213> human

<400> 8

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
5 -45 -40 -35
Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
 -30 -25 -20
Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
 -15 -10 -5 -1 1
10 Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
 5 10 15
Gln Lys Asn Gly Thr His His Cys Ala Gly Gln Pro Glu Gln Thr Ile Pro
 20 25 30 35
Val Leu Cys Ala Ala Gly Gly Leu Ala Ala Gly Glu Pro Trp Leu Ser Val
15 40 45 50
Pro Glu Gly Gly Cys Cys Leu Gly Gly Ala Pro Pro Cys Val Phe Leu Glu
 55 60 65
Gly Arg Cys Leu Cys Arg His Cys Pro Gly Ala Ser Arg Ala Leu His Thr
 70 75 80 85
20 Val Leu Arg Ala Gly Pro Ala His Leu Pro Thr
 90 95

<210> 9

<211> 952

25 <212> DNA

<213> human

<400> 9

```

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc ggc 51
5      Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
          -45          -40          -35
acc ttc acc tcc ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc 102
      Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
          -30          -25          -20
10     agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153
      Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
          -15          -10          -5          -1  1
gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204
      Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
15          5          10          15
cag aag aat ggg acc cac cac tgc gca gtt ccc ttg ccc cac cct cag acc 255
      Gln Lys Asn Gly Thr His His Cys Ala Val Pro Leu Pro His Pro Gln Thr
          20          25          30          35
ctg cag aag ctg aag gtt cct atc atc gac tcg gaa gtc tgc agc cat ctg 306
20     Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys Ser His Leu
          40          45          50
tac tgg cgg gga gca gga cag gga ccc atc act gag gac atg ctg tgt gcc 357
      Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp Met Leu Cys Ala
          55          60          65
25     ggc tac ttg gag ggg gag cgg gat gct tgt ctg ggc gac tcc ggg ggc ccc 408

```

Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly Asp Ser Gly Gly Pro
 70 75 80 85
 ctc atg tgc cag gtg gac ggc gcc tgg ctg ctg gcc ggc atc atc agc tgg 459
 Leu Met Cys Gln Val Asp Gly Ala Trp Leu Leu Ala Gly Ile Ile Ser Trp
 5 90 95 100
 ggc gag ggc tgt gcc gag cgc aac agg ccc ggg gtc tac atc agc ctc tct 510
 Gly Glu Gly Cys Ala Glu Arg Asn Arg Pro Gly Val Tyr Ile Ser Leu Ser
 105 110 115 120
 gcg cac cgc tcc tgg gtg gag aag atc gtg caa ggg gtg cag ctc cgc ggg 561
 10 Ala His Arg Ser Trp Val Glu Lys Ile Val Gln Gly Val Gln Leu Arg Gly
 125 130 135
 cgc gct cag ggg ggt ggg gcc ctc agg gca ccg agc cag ggc tct ggg gcc 612
 Arg Ala Gln Gly Gly Gly Ala Leu Arg Ala Pro Ser Gln Gly Ser Gly Ala
 140 145 150
 15 gcc gcg cgc tcc tagggcgag cgggacgcgg ggctcggatc tgaaaggcgg 664
 Ala Ala Arg Ser
 155
 ccagatccac atctggatct ggatctgcgg cggcctcggg cggtttcccc cgccgtaaat 724
 aggtcatct acctctacct ctggggggccc ggacgggtgc tgcggaaagg aaaccacctc 784
 20 ccgacccgc ccgacggcct caggccccgc cctccaaggc atcaggcccc gcccaacggc 844
 etcatgtccc cgccccacg acttcgggcc ccgccccgg gccccagcgc ttttgttat 904
 ataaatgtta atgattttta taggtatttg taacctgcc cacatata 952

 <210> 10
 25 <211> 207

20

<212> PRT

<213> human

<400> 10

5 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35
 Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
 -30 -25 -20
 Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
 10 -15 -10 -5 -1 1
 Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
 5 10 15
 Gln Lys Asn Gly Thr His His Cys Ala Val Pro Leu Pro His Pro Gln Thr
 20 25 30 35
 15 Leu Gln Lys Leu Lys Val Pro Ile Ile Asp Ser Glu Val Cys Ser His Leu
 40 45 50
 Tyr Trp Arg Gly Ala Gly Gln Gly Pro Ile Thr Glu Asp Met Leu Cys Ala
 55 60 65
 Gly Tyr Leu Glu Gly Glu Arg Asp Ala Cys Leu Gly Asp Ser Gly Gly Pro
 20 70 75 80 85
 Leu Met Cys Gln Val Asp Gly Ala Trp Leu Leu Ala Gly Ile Ile Ser Trp
 90 95 100
 Gly Glu Gly Cys Ala Glu Arg Asn Arg Pro Gly Val Tyr Ile Ser Leu Ser
 105 110 115 120
 25 Ala His Arg Ser Trp Val Glu Lys Ile Val Gln Gly Val Gln Leu Arg Gly

21

	125	130	135	
	Arg Ala Gln Gly Gly Gly Ala Leu Arg Ala Pro Ser Gln Gly Ser Gly Ala			
	140	145	150	
	Ala Ala Arg Ser			
5	155			
	<210> 11			
	<211> 1083			
	<212> DNA			
10	<213> human			
	<400> 11			
	gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc ggc			51
	Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly			
15	-45	-40	-35	
	acc ttc acc tcc ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc			102
	Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala			
	-30	-25	-20	
	agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt			153
20	Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val			
	-15	-10	-5	-1 1
	gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc			204
	Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile			
	5	10	15	
25	cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg			255

Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
 20 25 30 35
 gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg 306
 Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu
 5 40 45 50
 ttc tct gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tct cgg tcc 357
 Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser
 55 60 65
 cag aag ttc cct tgc ccc acc etc aga ccc tgc aga agc tgaaggttcc 406
 10 Gln Lys Phe Pro Cys Pro Thr Leu Arg Pro Cys Arg Ser
 70 75 80
 tatcatcgac tcggaagtct gcagccatct gtactggcgg ggagcaggac agggacccat 466
 cactgaggac atgctgtgtg ccggctactt ggagggggag cgggatgctt gtctggcgga 526
 ctccgggggc cccctcatgt gccaggtgga cggcgccctgg ctgctggccg gcatcatcag 586
 15 ctggggcgag ggctgtgccg agcgcaacag gccgggggtc tacatcagcc tctctgcgca 646
 ccgctcctgg gtggagaaga tcgtgcaagg ggtgcagctc cgcgggcgcg ctgagggggg 706
 tggggccctc agggcaccca gccagggtc tggggccgcc gcgcgctcct agggcgcagc 766
 ggagacgggg gctcggtatc gaaaggcggc cagatccaca tctggtatctg gatctgcggc 826
 ggccctcgggc ggtttccccc gccgtaaata ggctcatcta cctctacctc tggggggccc 886
 20 gacggctgct gcggaaagga aacccctcc ccgaccgcc cgagggcctc agggccccgcc 946
 ctccaaggca tcaggccccc cccaacggcc tcatgtccc gccccaaga ctccggcccc 1006
 cgccccggg cccagcgct tttgtgtata taaatgttaa tgatttttat aggtatttgt 1066
 aaccctgcc acatatac 1083
 25 <210> 12

<211> 131

<212> PRT

<213> human

5 <400> 12

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45 -40 -35

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30 -25 -20

10 Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

-15 -10 -5 -1 1

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

5 10 15

Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp

15 20 25 30 35

Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu

40 45 50

Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser

55 60 65

20 Gln Lys Phe Pro Cys Pro Thr Leu Arg Pro Cys Arg Ser

70 75 80

<210> 13

<211> 723

25 <212> DNA

<213> human

<400> 13

```

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc gcc 51
5      Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
          -45          -40          -35
acc ttc acc tcc ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc 102
Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
          -30          -25          -20
10     agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153
Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
          -15          -10          -5          -1  1
gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204
Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
15          5          10          15
cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg 255
Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
          20          25          30          35
gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg 306
20     Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu
          40          45          50
ttc tct gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tct cgg tcc 357
Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser
          55          60          65
25     cag aag gtg ggt gtt gcc tgg gtg gag ccc cac cct gtg tat tcc tgg aag 408

```

Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys
 70 75 80 85
 gaa ggt gcc tgt gca gac att gcc ctg gtg cgt ctc gag cgc tcc ata cag 459
 Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln
 5 90 95 100
 ttc tca gag cgg gtc ctg ccc atc tgc cta cct gat gcc tct atc cac ctc 510
 Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu
 105 110 115 120
 cct cca aac acc cac tgc tgg atc tca ggc tgg ggg agc atc caa gat gga 561
 10 Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly
 125 130 135
 gtt ccc ttg ccc cac cct cag acc ctc tcc aag gca tca ggc ccc gcc caa 612
 Val Pro Leu Pro His Pro Gln Thr Leu Ser Lys Ala Ser Gly Pro Ala Gln
 140 145 150
 15 cgg cct cat gtc ccc gcc ccc acg act tcc ggc ccc gcc ccg ggc ccc agc 663
 Arg Pro His Val Pro Ala Pro Thr Thr Ser Gly Pro Ala Pro Gly Pro Ser
 155 160 165 170
 gct ttt gtg tat ata aat gtt aat gat ttt tat agg tat ttg taacctgcc 715
 Ala Phe Val Tyr Ile Asn Val Asn Asp Phe Tyr Arg Tyr Leu
 20 175 180 185
 cacatatc 723

 <210> 14
 <211> 234
 25 <212> PRT

<213> human

<400> 14

```

      Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
5      -45      -40      -35
      Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
      -30      -25      -20
      Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
      -15      -10      -5      -1  1
10     Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
      5      10      15
      Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
      20      25      30      35
      Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu
15      40      45      50
      Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser
      55      60      65
      Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys
      70      75      80      85
20     Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln
      90      95      100
      Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu
      105      110      115      120
      Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly
25      125      130      135

```

Val Pro Leu Pro His Pro Gln Thr Leu Ser Lys Ala Ser Gly Pro Ala Gln

140

145

150

Arg Pro His Val Pro Ala Pro Thr Thr Ser Gly Pro Ala Pro Gly Pro Ser

155

160

165

170

5 Ala Phe Val Tyr Ile Asn Val Asn Asp Phe Tyr Arg Tyr Leu

175

180

185

<210> 15

<211> 1004

10 <212> DNA

<213> human

<400> 15

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc ggc 51

15 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

-45

-40

-35

acc ttc acc tcc ctg ctg ctg ctg gcg tcg aca gcc atc ctc aat gcg gcc 102

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30

-25

-20

20 agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153

Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

-15

-10

-5

-1 1

gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

25

5

10

15

cag aag aat ggg acc cac cac tgc gca ggt tct ctg etc acc agc cgc tgg 255
 Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
 20 25 30 35
 gtg atc act gct gcc cac tgt ttc aag gat tcc ett gcc cca ccc tca gac 306
 5 Val Ile Thr Ala Ala His Cys Phe Lys Asp Ser Leu Ala Pro Pro Ser Asp
 40 45 50
 cct gca gaa gct gaa ggt tcc tat cat cga ctc gga agt ctg cag cca tct 357
 Pro Ala Glu Ala Glu Gly Ser Tyr His Arg Leu Gly Ser Leu Gln Pro Ser
 55 60 65
 10 gta ctg gcg ggg agc agg aca ggg acc cat cac tgaagacatg ctgtgtgccg 410
 Val Leu Ala Gly Ser Arg Thr Gly Thr His His
 70 75 80
 gctacttgga gggggagcgg gatgtttgtc tgggcgactc cgggggcccc ctcatgtgcc 470
 aggtggacgg cgcctggctg ctggccggca tcatcagctg gggcgagggc tgtgccgagc 530
 15 gcaacaggcc cggggtctac atcagcctct ctgcgcacgc ctccctgggtg gagaagatcg 590
 tgcaaggggt gcagctccgc gggcgcgcctc aggggggtgg ggcctcagg gcaccgagcc 650
 agggctctgg ggcgcgcgcg cgctcctagg gcgcagcggg acgcggggct cggatctgaa 710
 agggcgccag atccacatct ggatctggat ctgcggcggc ctccggcggt ttccccgcc 770
 gtaaataggc tcacttaect ctactctgg gggeccggac ggctgctgcg gaaaggaac 830
 20 cccctcccc accgcgcga cggeectcagg cccgcctc caaggcata ggcgccgcc 890
 aacggcctca tgtccccgc ccaacgactt ccggcccccc cccggggccc cagcgctttt 950
 gtgtataata atgttaatga tttttatagg tatttgaac cctgccaca taic 1004

<210> 16

25 <211> 129

<212> PRT

<213> human

<400> 16

5 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
 -45 -40 -35
 Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
 -30 -25 -20
 Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
 10 -15 -10 -5 -1 1
 Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
 5 10 15
 Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
 20 25 30 35
 15 Val Ile Thr Ala Ala His Cys Phe Lys Asp Ser Leu Ala Pro Pro Ser Asp
 40 45 50
 Pro Ala Glu Ala Glu Gly Ser Tyr His Arg Leu Gly Ser Leu Gln Pro Ser
 55 60 65
 Val Leu Ala Gly Ser Arg Thr Gly Thr His His
 20 70 75 80

<210> 17

<211> 948

<212> DNA

25 <213> human

<400> 17

gcc atg gtg gtt tct gga gcg ccc cca gcc ctg ggt ggg ggc tgt ctc gcc 51

Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly

5 -45 -40 -35

acc ttc acc tcc ctg ctg ctg ctg gcg tgg aca gcc atc ctc aat gcg gcc 102

Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala

-30 -25 -20

agg ata cct gtt ccc cca gcc tgt ggg aag ccc cag cag ctg aac cgg gtt 153

10 Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val

-15 -10 -5 -1 1

gtg ggc ggc gag gac agc act gac agc gag tgg ccc tgg atc gtg agc atc 204

Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile

5 10 15

15 cag aag aat ggg acc cac cac tgc gca ggt tct ctg ctc acc agc cgc tgg 255

Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp

20 25 30 35

gtg atc act gct gcc cac tgt ttc aag gac aac ctg aac aaa cca tac ctg 306

Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu

20 40 45 50

ttc tct gtg ctg ctg ggg gcc tgg cag ctg ggg aac cct ggc tct cgg tcc 357

Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser

55 60 65

cag aaa gtg ggt gtt gcc tgg gtg gag ccc cac cct gtg tat tcc tgg aag 408

25 Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys

	70	75	80	85	
	gaa ggt gcc tgt gca gac att gcc ctg gtg cgt ctc gag cgc tcc ata cag				459
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln				
	90	95	100		
5	ttc tca gag cgg gtc ctg ccc atc tgc cta cct gat gcc tct atc cac etc				510
	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu				
	105	110	115	120	
	cct cca aac acc cac tgc tgg atc tca ggc tgg ggg agc atc caa gat gga				561
	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly				
10	125	130	135		
	gtt ecc ttg ccc cac cct cag acc ctg cag aag ctg aag gtt cct atc atc				612
	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile				
	140	145	150		
	gac tgc gaa gtc tgc agc cat ctg tac tgg cgg gga gca gga cag gga ccc				663
15	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro				
	155	160	165	170	
	atc act gag gac atg ctg tgt gcc ggc tac ttg gag ggg gag cgg gat gct				714
	Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala				
	175	180	185		
20	tgt ctg gtg agc tcc etc gag ccc ecc acc cct ggc cag gag ggc etc ggg				765
	Cys Leu Val Ser Ser Leu Glu Pro Pro Thr Pro Gly Gln Glu Gly Leu Gly				
	190	195	200	205	
	aag gag cca gcg tca gtc ctg tcc cca ctg agc ccc aca acc tct ccc tgg				816
	Lys Glu Pro Ala Ser Val Leu Ser Pro Leu Ser Pro Thr Thr Ser Pro Trp				
25	210	215	220		

```

cct cct ccc cag aac tgg ctg tgc ctg aca gtc cgg ggt ccc cat aga acc 867
Pro Pro Pro Gln Asn Trp Leu Cys Leu Thr Val Pro Gly Pro His Arg Thr
      225              230              235
agc ctc agc ctg gct cag cca ctc act tat ttg ttc aga cat taaactgggc 919
5  Ser Leu Ser Leu Ala Gln Pro Leu Thr Tyr Leu Phe Arg His
      240              245              250
atcccagctg caaaaaaaaa aaaaaaaaaa 948

<210> 18
10 <211> 302
    <212> PRT
    <213> human

<400> 18
15 Met Val Val Ser Gly Ala Pro Pro Ala Leu Gly Gly Gly Cys Leu Gly
      -45              -40              -35
Thr Phe Thr Ser Leu Leu Leu Leu Ala Ser Thr Ala Ile Leu Asn Ala Ala
      -30              -25              -20
Arg Ile Pro Val Pro Pro Ala Cys Gly Lys Pro Gln Gln Leu Asn Arg Val
20 -15              -10              -5              -1 1
Val Gly Gly Glu Asp Ser Thr Asp Ser Glu Trp Pro Trp Ile Val Ser Ile
      5              10              15
Gln Lys Asn Gly Thr His His Cys Ala Gly Ser Leu Leu Thr Ser Arg Trp
      20              25              30              35
25 Val Ile Thr Ala Ala His Cys Phe Lys Asp Asn Leu Asn Lys Pro Tyr Leu

```

	40	45	50
	Phe Ser Val Leu Leu Gly Ala Trp Gln Leu Gly Asn Pro Gly Ser Arg Ser		
	55	60	65
	Gln Lys Val Gly Val Ala Trp Val Glu Pro His Pro Val Tyr Ser Trp Lys		
5	70	75	80
	Glu Gly Ala Cys Ala Asp Ile Ala Leu Val Arg Leu Glu Arg Ser Ile Gln		
	90	95	100
	Phe Ser Glu Arg Val Leu Pro Ile Cys Leu Pro Asp Ala Ser Ile His Leu		
	105	110	115
10	Pro Pro Asn Thr His Cys Trp Ile Ser Gly Trp Gly Ser Ile Gln Asp Gly		
	125	130	135
	Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu Lys Val Pro Ile Ile		
	140	145	150
	Asp Ser Glu Val Cys Ser His Leu Tyr Trp Arg Gly Ala Gly Gln Gly Pro		
15	155	160	165
	Ile Thr Glu Asp Met Leu Cys Ala Gly Tyr Leu Glu Gly Glu Arg Asp Ala		
	175	180	185
	Cys Leu Val Ser Ser Leu Glu Pro Pro Thr Pro Gly Gln Glu Gly Leu Gly		
	190	195	200
20	Lys Glu Pro Ala Ser Val Leu Ser Pro Leu Ser Pro Thr Thr Ser Pro Trp		
	210	215	220
	Pro Pro Pro Gln Asn Trp Leu Cys Leu Thr Val Pro Gly Pro His Arg Thr		
	225	230	235
	Ser Leu Ser Leu Ala Gln Pro Leu Thr Tyr Leu Phe Arg His		
25	240	245	250

<210> 19

<211> 1322

<212> DNA

5 <213> mouse

<400> 19

cctgccagtc tcaagcaaca cagcccttag gtcttttgag cgggccagca gccttgctgg 60

gtctccacc ataccagca atg atg atc tcc aga cct ccc cca gca ctg ggt 112

10 Met Met Ile Ser Arg Pro Pro Pro Ala Leu Gly

-45

-40

ggg gac cag ttc agc atc tta atc ctt ctg gtg ctg ctg act tcc aca gct 163

Gly Asp Gln Phe Ser Ile Leu Ile Leu Leu Val Leu Leu Thr Ser Thr Ala

-35

-30

-25

15 ccc atc agt gct gcc acc atc cga gtg tcc cca gac tgt ggg aag cct cag 214

Pro Ile Ser Ala Ala Thr Ile Arg Val Ser Pro Asp Cys Gly Lys Pro Gln

-20

-15

-10

-5

cag ctg aac cgg att gtg gga ggt gag gac agc atg gat gcc cag tgg ecc 265

Gln Leu Asn Arg Ile Val Gly Gly Glu Asp Ser Met Asp Ala Gln Trp Pro

20 -1 1 5 10

tgg att gtt agc atc ctc aag aat ggc tcc cac cac tgt gca ggc tcc ctg 316

Trp Ile Val Ser Ile Leu Lys Asn Gly Ser His His Cys Ala Gly Ser Leu

15

20

25

30

ctc acc aac cgc tgg gtg gtc aca gcc ggc cac tgc ttt aag agc aat atg 367

25 Leu Thr Asn Arg Trp Val Val Thr Ala Ala His Cys Phe Lys Ser Asn Met

	35	40	45	
	gac aaa cca tct ctg ttc tca gta ttg ttg ggg gcc tgg aag ctg ggg agc			418
	Asp Lys Pro Ser Leu Phe Ser Val Leu Leu Gly Ala Trp Lys Leu Gly Ser			
	50	55	60	
5	cca ggc cca agg tcc cag aaa gta ggc att gct tgg gtg ctg cct cac ccc			469
	Pro Gly Pro Arg Ser Gln Lys Val Gly Ile Ala Trp Val Leu Pro His Pro			
	65	70	75	80
	agg tat tct tgg aag gag gga acc cat gca gac att gcc ctg gtg cgc ctg			520
	Arg Tyr Ser Trp Lys Glu Gly Thr His Ala Asp Ile Ala Leu Val Arg Leu			
10	85	90	95	
	gaa cac tcc atc cag ttc tct gag cgg atc ctg ccc atc tgc cta cct gac			571
	Glu His Ser Ile Gln Phe Ser Glu Arg Ile Leu Pro Ile Cys Leu Pro Asp			
	100	105	110	115
	tcc tct gtc cgt ctc cct ccc aag acc gac tgc tgg att gcc ggc tgg gga			622
15	Ser Ser Val Arg Leu Pro Pro Lys Thr Asp Cys Trp Ile Ala Gly Trp Gly			
	120	125	130	
	agc atc cag gat gga gtg ccc ctg ccc cac cct cag acc ctt cag aag ctg			673
	Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu			
	135	140	145	
20	aag gtg ccc atc atc gac tcc gaa ctc tgc aaa agc ttg tac tgg cgg gga			724
	Lys Val Pro Ile Ile Asp Ser Glu Leu Cys Lys Ser Leu Tyr Trp Arg Gly			
	150	155	160	165
	gcc ggt cag gaa gcc atc acg gag ggc atg ctg tgt gct ggt tac ctg gaa			775
	Ala Gly Gln Glu Ala Ile Thr Glu Gly Met Leu Cys Ala Gly Tyr Leu Glu			
25	170	175	180	

ggg gag cgg gat gct tgt ctg ggc gac tct ggg ggt ccc ctg atg tgc cag 826
 Gly Glu Arg Asp Ala Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln
 185 190 195 200
 gtg gat gac cac tgg cta ctg act ggc ata atc agc tgg gga gag ggc tgc 877
 5 Val Asp Asp His Trp Leu Leu Thr Gly Ile Ile Ser Trp Gly Glu Gly Cys
 205 210 215
 gga ggc caa cgg gcc cgg tgt gta cac cag cct cct agc tca ccg ctc ctg 928
 Gly Ala Gln Pro Ala Arg Cys Val His Gln Pro Pro Ser Ser Pro Leu Leu
 220 225 230
 10 ggt gca aag gat cgt tca agg ggt gca gct gcg cgg gta ctt ggc gga cag 979
 Gly Ala Lys Asp Arg Ser Arg Gly Ala Ala Ala Arg Val Leu Gly Gly Gln
 235 240 245 250
 tgg gga cac agg aag ctc cta atc taggatctga agatgagcag cctcctgcaa 1033
 Trp Gly His Arg Lys Leu Leu Ile
 15 255
 ttctctctgc tgtaaatatg tcttctacct ccggggggcg cccgcggcct gaggcagaga 1093
 acaaggaagt tctggaaccg cccacataga ggatccgccc ctcaatcgag gactctgtgt 1153
 gtgtgtgtgt gtgtgtgtgt gtgtgtgect ctgtgtgcgt gtgtatgcgc gcgcacgtgc 1213
 gcgcgagagc aatgattttt ttttttacag ttatacgtaa ccattgccac atatattatc 1273
 20 cagtttcaat aaattattta ttcttaaaaa aaaaaaaaaa aaaaaaaaaa 1322

 <210> 20
 <211> 308
 <212> PRT
 25 <213> mouse

<400> 20

Met Met Ile Ser Arg Pro Pro Pro Ala Leu Gly

-45

-40

5 Gly Asp Gln Phe Ser Ile Leu Ile Leu Leu Val Leu Leu Thr Ser Thr Ala

-35

-30

-25

Pro Ile Ser Ala Ala Thr Ile Arg Val Ser Pro Asp Cys Gly Lys Pro Gln

-20

-15

-10

-5

Gln Leu Asn Arg Ile Val Gly Gly Glu Asp Ser Met Asp Ala Gln Trp Pro

10

-1 1

5

10

Trp Ile Val Ser Ile Leu Lys Asn Gly Ser His His Cys Ala Gly Ser Leu

15

20

25

30

Leu Thr Asn Arg Trp Val Val Thr Ala Ala His Cys Phe Lys Ser Asn Met

35

40

45

15 Asp Lys Pro Ser Leu Phe Ser Val Leu Leu Gly Ala Trp Lys Leu Gly Ser

50

55

60

Pro Gly Pro Arg Ser Gln Lys Val Gly Ile Ala Trp Val Leu Pro His Pro

65

70

75

80

Arg Tyr Ser Trp Lys Glu Gly Thr His Ala Asp Ile Ala Leu Val Arg Leu

20

85

90

95

Glu His Ser Ile Gln Phe Ser Glu Arg Ile Leu Pro Ile Cys Leu Pro Asp

100

105

110

115

Ser Ser Val Arg Leu Pro Pro Lys Thr Asp Cys Trp Ile Ala Gly Trp Gly

120

125

130

25 Ser Ile Gln Asp Gly Val Pro Leu Pro His Pro Gln Thr Leu Gln Lys Leu

135 140 145
 Lys Val Pro Ile Ile Asp Ser Glu Leu Cys Lys Ser Leu Tyr Trp Arg Gly
 150 155 160 165
 Ala Gly Gln Glu Ala Ile Thr Glu Gly Met Leu Cys Ala Gly Tyr Leu Glu
 5 170 175 180
 Gly Glu Arg Asp Ala Cys Leu Gly Asp Ser Gly Gly Pro Leu Met Cys Gln
 185 190 195 200
 Val Asp Asp His Trp Leu Leu Thr Gly Ile Ile Ser Trp Gly Glu Gly Cys
 205 210 215
 10 Gly Ala Gln Pro Ala Arg Cys Val His Gln Pro Pro Ser Ser Pro Leu Leu
 220 225 230
 Gly Ala Lys Asp Arg Ser Arg Gly Ala Ala Ala Arg Val Leu Gly Gly Gln
 235 240 245 250
 Trp Gly His Arg Lys Leu Leu Ile
 15 255

 <210> 21
 <211> 99
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Designed oligonucleotide to construct plasmid pSecTrypHis

 <400> 21
 25 aagcttggct agcaacacca tgaatctact cctgatacctt acctttgttg ctgctgctgt 60

tgctgceccc ttgacgacg atgacaagga tccgaattc

99

<210> 22

<211> 99

5 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide to construct plasmid pSecTrypHis

10 <400> 22

gaattcggat ccttgctatc gtcgtcaaag ggggcagcaa cagcagcagc aacaaaggta 60

aggatcagga gtagattcat ggtgttgcta gccaaagctt 99

<210> 23

15 <211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify neurosin-encoding sequence

20

<400> 23

ttgggtgcatg gcgga

15

<210> 24

25 <211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify neurosin-encoding sequence

5

<400> 24

tcctcgagac ttggcctgaa tggtttt

27

<210> 25

10

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify a portion of plasmid

15

pSecTrypHis/Neurosin

<400> 25

gcgctagcag atctccatga atctactcct gatcc

35

20

<210> 26

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

25

<223> Designed oligonucleotide primer to amplify a portion of plasmid

pSecTrypHis/Neurosin

<400> 26

tgaagcttgc catggaccaa ctgtcatc

29

5

<210> 27

<211> 26

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Designed oligonucleotide primer to amplify a portion of plasmid pTrypHis

<400> 27

ccaagcttca ccataccat caccat

26

15

<210> 28

<211> 17

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Designed oligonucleotide primer to amplify a portion of plasmid

pTrypSigTag

<400> 28

25

gcacagtcga ggetgat

17

<210> 29

<211> 17

<212> DNA

5 <213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify a portion of plasmid
pFBTrypSigTag

10 <400> 29

caaatgtggt atggctg

17

<210> 30

<211> 20

15 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify conserved region of serin
proteases-encoding sequence

20 <220>

<221> UNSURE

<222> 9, 12

<223> n is a, c, g or t.

25 <400> 30

gtgctcacng cngcbcaytg

20

<210> 31

<211> 20

5 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer to amplify conserved region of serin
proteases-encoding sequence

10 <220>

<221> UNSURE

<222> 12, 15

<223> n is a, c, g or t.

15 <400> 31

ccvctrwsdc cncenggcga

20

<210> 32

<211> 20

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as hBSSP4F1 for RACE for human
BSSP4 (forward)

25

<400> 32

aggttcttat catcgactcg

20

<210> 33

5

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as hBSSP4F2 for RACE for human

10

BSSP4 (forward)

<400> 33

tgaggacatg ctgtgtgccg g

21

15

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

20

<223> Designed oligonucleotide primer designated as hBSSP4F3 to amplify mature human BSSP4-encoding region (forward)

<400> 34

gttgtgggcg gcgaggacag

20

25

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

5 <220>

<223> Designed oligonucleotide primer designated as hBSSP4F6 to amplify full-length human BSSP4-encoding mRNA (forward)

<400> 35

10 gccatggtgg ttctggagc

20

<210> 36

<211> 21

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as hBSSP4R1 for RACE for human BSSP4 (reverse)

<400> 36

20 tatggtttgt tcaggtgtgc c

21

<210> 37

<211> 20

25 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as hBSSP4R2 for RACE for human
BSSP4 (reverse)

5

<400> 37

aggggcaatgt ctgcacaggc

20

<210> 38

10

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as hBSSP4R3/E to amplify full-
length human BSSP4-encoding mRNA (reverse)

15

<400> 38

ctgaattcct aggagcgcgc ggcggcc

27

20

<210> 39

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

25

<223> Designed oligonucleotide primer designated as hBSSP4R4/E to amplify full-

length human BSSP4-encoding mRNA (reverse)

<400> 39

gagaattcga tatgtgggca gggttaca

28

5

<210> 40

<211> 21

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Designed oligonucleotide primer designated as mBSSP4.1 for RACE for mouse
BSSP4 (forward)

<400> 40

15

acaaaccatc tctgttctca g

21

<210> 41

<211> 20

<212> DNA

20

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as mBSSP4F2 for RACE for mouse
BSSP4 (forward)

25

<400> 41

gtccagaaa gtaggcattg

20

<210> 42

<211> 20

5 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as mBSP4F3 to amplify full-length mouse BSP4-encoding mRNA (forward)

10

<400> 42

ctccacccat accagcaatg

20

<210> 43

15 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as mBSP4F4 to amplify mature mouse BSP4-encoding region (forward)

20

<400> 43

attgtgggag gtgaggacag

20

25 <210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

5 <223> Designed oligonucleotide primer designated as mBSSP4.2 for RACE for mouse
BSSP4 (reverse)

<400> 44

tgcagagttc ggagtcgatg

20

10

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

15 <220>

<223> Designed oligonucleotide primer designated as mBSSP4R2 for RACE for mouse
BSSP4 (reverse)

<400> 45

20 atccagcagt cggctcttggg

20

<210> 46

<211> 30

<212> DNA

25 <213> Artificial Sequence

<220>

<223> Designed oligonucleotide primer designated as mBSSP4R3/P to amplify full-length mouse BSSP4-encoding mRNA (reverse)

5 <400> 46

attctgcagt tcttgttct ctcgtcagg

30

<210> 47

<211> 117

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide to construct plasmid pTrypHis

15 <400> 47

AAGCTTGGCT AGCAACACCA TGAATCTACT CCTGATCCTT ACCTTTGTTG CTGCTGCTGT 60
TGCTGCCCCC TTTCACCATC ACCATCACCA TGACGACGAT GACAAGGATC CGAATTC 117

<210> 48

20 <211> 117

<212> DNA

<213> Artificial Sequence

<220>

<223> Designed oligonucleotide to construct plasmid pTrypHis

25

<400> 48

GAATTCGGAT CCTTGCATC GTCGTCATGG TGATGGTGAT GGTGAAAGGG GGCAGCAACA 60

GCAGCAGCAA CAAAGGTAAG GATCAGGAGT AGATTCATGG TGTGCTAGC CAAGCTT 117

5

10